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ABSTRACT
Antiviral drug resistance is a major problem in the treatment of viral
infections, including influenza and hepatitis C virus (HCV). Influenza
neuraminidase (NA) is a viral sialidase on the surface of the influenza virion and
a primary antiviral target in influenza. Two subtypes of NA predominate in
humans, N1 and N2, but different patterns of drug resistance have emerged in
each subtype. To provide a framework for understanding the structural basis of
subtype specific drug resistance mutations in NA, we used molecular dynamics
simulations to define dynamic substrate envelopes for NA to determine how
different patterns of drug resistance have emerged in N1 and N2 NA.
Furthermore, we used the substrate envelope to analyze HCV NS3/4A protease
inhibitors in clinical development. In addition, influenza hemagglutinin (HA) is a
primary target of neutralizing antibodies against influenza. Novel broadly
neutralizing antibodies (BnAbs) against the stem region of HA have been
described and inhibit several influenza viral subtypes, but antibody neutralization
escape mutations have emerged. We identified potential escape mutations in
broadly neutralizing antibody F10 that may impact protein dynamics in HA that
are critical for function. We also solved crystal structures of antibody fragments
that are important for understanding the structural basis of antibody binding for
influenza BnAbs. These studies can inform the design of improved therapeutic
strategies against viruses by incorporating an understanding of structural
elements that are critical for function, such as substrate processing and protein
viii
dynamics, into the development of novel therapeutics that are robust against
resistance.
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1CHAPTER I
1 INTRODUCTION
1.1 Therapeutic Strategies Against Viruses
Vaccines and antiviral drugs are two major classes of agents for fighting
viruses. Vaccines have eradicated smallpox and have also significantly
decreased rates of measles, mumps, rubella, and polio infections (1d3). However,
vaccines still need to be developed for many diseasedcausing viruses, such as
human immunodeficiency virus (HIV) and hepatitis C virus (HCV). In influenza,
seasonal vaccines are available, but a universal vaccine has not yet been
developed and antiviral drugs are still needed for combating infection (4, 5). For
example, oseltamivir, a direct acting influenza neuraminidase inhibitor, was the
most prescribed antiviral drug and 34th most prescribed drug overall in 2014 (6).
However, many antiviral drugs have flaws, such as low efficacy, toxicity, side
effect profiles, and high susceptibility to resistance. Viruses use host cell
mechanisms to replicate and many viruses mutate rapidly and have natural
variation, so designing effective antiviral drugs and vaccines is challenging.
Nevertheless, there are still many opportunities to develop and improve
therapeutic strategies against viruses.
In contrast to antibiotics, there are not as many broaddspectrum antiviral
drugs to fight infection, but there are several specific drugs that target individual
viruses, including influenza, herpesviruses, HBV, HCV, and HIV. In general,
2antiviral drugs combat viral infection by targeting a specific stage of the viral life
cycle to inhibit viral replication as is the case for direct acting antivirals (DAAs) or
by improving the immune response to infection (7). For example, in influenza,
antiviral drugs target several stages of the viral life cycle (Figure 1.1).
Amantadine inhibits fusion by blocking the M2 ion channel and preventing the
acidification of the endosome, which is required for the conformational changes
in hemagglutinin that are necessary for viral and endosomal membrane fusion
(8). Ribavirin interferes with replication of the viral genome, and oseltamivir and
zanamivir inhibit influenza neuraminidase, which is a sialidase on the surface of
the influenza virion that facilitates viral budding (9). Ribavirin is also used to treat
viral hemorrhagic fevers, chronic hepatitis C virus infection, and severe acute
respiratory syndrome (SARS) (10). In addition, seasonal vaccines prevent
influenza binding to a cell by eliciting the development of antibodies that target
the head region of influenza hemagglutinin. Recently, broadly neutralizing
antibodies (BnAbs) against influenza hemagglutinin and neuraminidase have
been discovered that also interfere with the viral life cycle by neutralizing these
proteins in locations that are important for function, such as sialic acid binding,
membrane fusion, and viral release from an infected cell (11d13). Many BnAbs
target the conserved sialic acid binding site on the head of hemagglutinin or the
conserved stem region that is important for fusion. In the HCV viral life cycle,
there are also multiple points of intervention by antiviral drugs: viral entry, viral
translation, polyprotein processing, HCV RNA replication, and viral assembly
3(Figure 1.2). In addition, some peptides with antidvirucidal activity have been
reported for HCV, but these are still in early development (14).
4Figure 1.1 Influenza virus life cycle and targets for therapeutic strategies
against influenza (9).
5Figure 1.2 Hepatitis C virus life cycle and points of intervention for
therapeutic strategies (14).
6Antiviral drugs can also be broad spectrum and nondspecific. One welld
known class of these types of antiviral drugs are interferons, which were a main
treatment for HCV until recently and are also a treatment for chronic active HBV
infection (15d17). Antiviral drugs have host or viral targets, and drugs that target
host mechanisms may be broad spectrum, but they also have a greater likelihood
of toxicity and side effects. For instance, interferons are cytokines with broad
antiviral activity that activate the immune system through various pathways and
also activate other immune cells, including natural killer cells and macrophages
(18). As a treatment, however, interferon has many undesirable side effects and
is administered intravenously, increasing patient burden (19). Antiviral DAAs that
inhibit specific viral targets, in contrast, are in general less toxic and more
selective. For instance, influenza neuraminidase inhibitors have a reasonable
sidedeffect profile, and longdterm administration for prophylaxis is well tolerated in
adults and children (20).
Antiviral drugs can be designed as small molecules or larger biological
medical products (biologics) that are active against viruses through a variety of
mechanisms. Examples of biologics include interferon, immunoglobulin therapy,
vaccines, and monoclonal antibody therapy. The mechanisms of action for
antiviral drugs include competitive and nondcompetitive antagonism and
agonism. For example, Tolldlike receptor agonists are being studied for their
potential antiviral applications (21). Nondnucleoside reversedtranscriptase
inhibitors (NNRTI) are an example of a class of nondcompetitive allosteric
7antagonist antiviral drugs (22). There are also several examples of directdacting
antivirals that act as competitive antagonists, such as influenza neuraminidase
inhibitors and HIV and HCV protease inhibitors.
1.2 Structure Based Drug Design in Antivirals
Structure based drug design is an important tool for improving the activity,
selectivity, and pharmacokinetic profile of antiviral drugs. For instance, to
increase activity and selectivity, HIV and HCV protease inhibitors were designed
through extensive structure activity relationship (SAR) studies as substrate
peptidomimetics with modifications to reduce peptide character and improve
bioavailability while increasing favorable active site interactions (23d28). Influenza
neuraminidase inhibitors were also designed to mimic substrates while optimizing
interactions in the active site (9, 29d31). In addition, various strategies are used
to improve the pharmacokinetics of drugs by altering properties such as
absorption, distribution, metabolism, and excretion (ADME).
Although these strategies have increased specificity and potency of drugs,
losses in efficacy still occur as a result of antiviral resistance, which is a major
challenge in developing antiviral drugs (8, 32). Often, antiviral drug targets are
not evolutionarily conserved, and these targets can acquire mutations that result
in a loss of antiviral drug efficacy while still maintaining function. Understanding
the structural basis of interactions between antiviral drugs and their targets is
8critical for improving potency and specificity while also avoiding a loss of efficacy
due to resistance.
1.3 Drug Resistance and Antibody Neutralization Escape in Antivirals
Drug resistance and antibody neutralization escape occur when drugs and
antibodies lose the ability to treat or prevent infection through their usual
mechanism of action. Drug resistance is a major health problem that impacts not
only antivirals but also antimicrobial and antineoplastic drugs. Loss of efficacy
from resistance can result through a variety of direct and indirect mechanisms. In
the main type of direct drug resistance mechanism, primary drug resistance
mutations or antibody neutralization escape mutations prevent binding by directly
altering the binding site of the drug or antibody. Various indirect mechanisms of
resistance have also been observed. Permissive compensatory mutations, also
known as secondary resistance mutations, reduce the fitness cost of primary
resistance mutations and can occur in various locations throughout a disease
system. For instance, in HIV protease, primary drug resistance mutations have
occurred in the protease active site and secondary mutations have developed in
different locations outside of the active site (33, 34). Substrate codevolution has
also been observed where substrates mutate to become better substrates in the
presence of HIV protease resistance mutations (35, 36). In influenza,
hemagglutinin can also evolve to weaken binding affinity for the substrate sialic
acid to compensate for reduced cleavage activity in neuraminidase (37). In
9influenza neuraminidase and HIV and HCV proteases, there are also examples
of drug resistant targets with multiple resistance mutations, and changes in
protein dynamics can also confer resistance (34, 38d42).
Resistance mutations against antivirals have emerged as a result of
selective pressures in the environment. Many viruses have a high rate of errord
prone replication, creating heterogeneous populations of viruses with drug
resistant variants at low frequency in the absence of selective pressure. In fact,
many viruses exist as quasispecies, which is a population of viruses with mutant
genomes. When these viruses are exposed to selective pressure from antiviral
drugs, the fitness of drug resistant variants increases, allowing them to dominate
in the population, while the growth of drug susceptible variants is inhibited. This
process also occurs when antiviral drug doses are sufficiently low (suboptimal)
and administered over long periods of time, encouraging the development of
drug resistant variants. In addition, reservoirs of virus also exist in other species
besides humans for some viruses, such as in birds, pigs, horses, and sea
mammals for influenza, and these reservoirs allow new viral variants in humans
to emerge periodically (12). If antiviral drug targets are not evolutionarily
constrained and can accommodate resistance mutations while still maintaining
function, resistance mutations can develop.
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1.3.1 Resistance to Competitive Small Molecule Antivirals and the
Substrate Envelope
Drug resistance is a change in molecular recognition such that drug
resistant variants no longer bind inhibitors while maintaining biological function.
Understanding the salient molecular features of a drug target necessary for
maintaining function is critical for designing antiviral drugs that are less
susceptible to drug resistance. Through our work studying HIV and HCV
proteases, we established the substrate envelope hypothesis, which predicts that
substrates fill a conserved enzymedspecific volume when bound to the active site
even though substrates vary in amino acid sequence, and primary drug
resistance mutations occur where inhibitors protrude beyond the substrate
envelope (Figure 1.3) (43, 44). The substrate envelope has been established for
HIV and HCV proteases, but should also be applicable to understanding primary
drug resistance mutations in other enzymes that process substrates. In fact, the
substrate envelope hypothesis has been applied prospectively to a set of drug
targets including Abl kinase, thymidylate synthase, chitinase, dihydrofolate
reductase, and influenza neuraminidase, and the protrusion of inhibitors outside
of the substrate envelope correlates with different patterns of drug resistance
(45). In addition, the substrate envelope has been used in the development of a
reverse transcriptase inhibitor, tenofovir (46, 47). Recently, crystal structures of
inactive influenza NA in complex with uncleaved substrates were reported, and
the substrate envelope hypothesis should be applicable to understanding drug
resistance in NA in different subtypes using these crystal structures (48). In HCV,
11
there are also several protease inhibitors in clinical development, and comparing
how these inhibitors fit within the substrate envelope may also help elucidate how
different patterns of drug resistance have emerged for these inhibitors.
12
Figure 1.3 Substrate and inhibitor envelopes in HIV protease (33, 49).
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Figure 1.3 Substrate and inhibitor envelopes in HIV protease (33, 49). A)
The overlapping van der Waals volumes of substrates fill a conserved shape
known as the substrate envelope, shown in blue. Each substrate moiety is
labeled. B) The overlapping van der Waals volumes of inhibitors fill a conserved
shape known as the inhibitor envelope, shown in red. C) Superposition of the
inhibitor and substrate envelopes shows that where inhibitors protrude outside of
the substrate envelope is where primary drug resistance mutations occur.
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1.3.2 Resistance to Antibodies as Therapeutics: Antibody Neutralization
Escape
Neutralizing antibodies are also an important element of an immune
response to viruses, and antibody neutralization escape resistance mutations
occur when antibodies that were once capable of neutralizing antigens are no
longer effective. Antibodies can develop over the course of an infection naturally
without treatment, and vaccines can also actively stimulate the immune system
to develop antibodies that protect against viral infection. Antibodies can also be
administered as passive immunotherapy before or during infection.
There are three main types of viral vaccines: live attenuated, inactivated,
and recombinant vaccines (50). In general, these antiviral vaccines are effective
for long periods of time but influenza vaccines are a major exception. Seasonal
influenza vaccines are very effective against specific strains, but they lose
efficacy regularly against new dominating circulating strains as a result of viral
evolution and variation, and new vaccines must continually be developed (12).
Therefore influenza vaccines should be improved so that they provide broader
and longer acting protection against more influenza strains.
Seasonal influenza vaccines become less effective over time due to
several factors. Current influenza vaccines mount an immune response against
the highly variable immunodominant globular head region of influenza
hemagglutinin (HA), and since this region is highly variable, vaccines become a
mismatch to circulating strains as this region evolves. The influenza viral RNAd
dependent RNA polymerase is highly error prone and does not contain a
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proofreading mechanism (51, 52). Consequently, new mutations accumulate
rapidly over time in evolutionarily unconstrained regions of the genome, such as
the globular head region of HA, in a process known as antigenic shift (53). In
addition, the genome of the influenza virus is segmented, so that if an organism
or a cell is infected by at least two different influenza viruses simultaneously, the
segmented strands of the genome can reassort and create new viruses with
strands of RNA from each parental virus, in a process known as antigenic shift.
These changes also contribute to influenza virus diversity.
Reservoirs of influenza viruses exist in different species, and viruses from
these sources periodically emerge in humans. These viruses can mutate to
sustain humandtodhuman transmission, which occurred with the 2009 swine flu
(54). When influenza strains emerge to which a population lacks immunity,
epidemics and pandemics can occur. However, vaccines that can be designed to
mount an immune response to antigens that are highly conserved between
multiple strains of influenza may provide broader and longer acting protection.
In addition to vaccines, there are nearly a dozen specific monoclonal
antibody immunotherapies against different viruses (55, 56). However, antibody
neutralization escape resistance mutations have also been reported with these
therapies. For instance, in vivo and in vitro resistance mutations have developed
in respiratory syncytial virus (RSV) in response to palivizumab, an antiviral
monoclonal antibody therapy and the first commercially available antibody
approved by the FDA for use against an infectious disease (57).
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Recently, crossdreactive broadly neutralizing antibodies (BnAbs) in
influenza have been discovered that neutralize a wide spectrum of influenza
strains, and these antibodies are currently in development as passive or active
immunotherapy (12, 58d63). These antibodies target highly conserved regions on
hemagglutinin, such as the stem region, which is important for the conformational
changes that occur during fusion, and the sialic acid binding region on the
globular head domain of HA (12). BnAbs have reactivity across subtypes,
groups, and even types of influenza, and there is widespread interest in
developing them into therapies (12). For instance, Diridavumab, or CR6261, is a
monoclonal antibody therapy against influenza A HA based on a BnAb that is
being developed by Crucell, a Johnson & Johnson subsidiary (60). However,
resistance mutations have emerged with some of these BnAbs. Two antibody
neutralization escape mutations, D19N and G33E, were discovered against the
stemddirected BnAb CR8020 after four viral passages in the presence of CR8020
as a selective pressure (61, 64). These mutations are both located at the binding
interface of CR8020 with HA. Two escape mutations were also discovered
against stemddirected BnAb C179 at positions 318 in HA1 and 52 in HA2 (58, 65).
CR6261, which also binds the stem, was initially refractory to developing
resistance, but still developed the resistance mutation H111L after 10 passages
(12, 66, 67). Therefore, revealing the effect of such mutations on antibody–target
interaction is needed to design BnAbs that are less susceptible to resistance.
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1.4 Protein Dynamics in Molecular Recognition
Proteins undergo conformational changes on various time scales, which
are essential in molecular recognition and biological function. Therefore,
understanding protein dynamics is critical for understanding biological functions
of proteins, including target binding and substrate turnover. Several experimental
and computational methods are available for studying protein dynamics,
including nuclear magnetic resonance spectroscopy (NMR), hydrogenddeuterium
exchange mass spectrometry, small angle Xdray scattering (SAXS), spin label
electron paramagnetic resonance (EPR) spectroscopy, fluorescence
spectroscopy, and timedresolved xdray crystallography. In addition, molecular
dynamics (MD) simulations are a computational method for studying protein
dynamics with detailed atomic resolution. Some important considerations for
deciding which experimental and computational methods to use for studying
protein dynamics include the time scale of the motion, the size and properties of
the biological system being studied, and the specific limitations of each method.
However, recent technological advances have greatly improved many of these
methods. For instance, advances in xdray sources, data collection, and data
analysis methods have also increased the accessibility of timedresolved xdray
crystallography (68). The speed with which MD simulations can be calculated
today has greatly increased based on the availability of supercomputing clusters
and increased parallelization of calculations using powerful graphics processing
unit (GPU) technology. Thus, MD simulations can be run on much longer time
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scales, and they are very valuable as a complementary method to experiments in
revealing the underlying molecular details of experimentally observed data on
protein dynamics.
1.4.1 Role of Protein Dynamics in Antiviral Resistance
Protein dynamics can contribute to antiviral drug resistance (42, 69d71).
For example, secondary permissive mutations can improve enzyme fitness in the
presence of primary drug resistance mutations by altering protein dynamics to
enhance biological function. Differences in the conformation of loops and other
structures in an enzyme active site can affect catalytic activity. For example, in
certain subtypes of influenza neuraminidase, the 150dloop in the active site
closes down on ligands after binding (72, 73). This loop contains a catalytic
residue D151, and therefore, the motion of this loop may impact substrate
processing. In HIV protease, the flaps close down on the substrate, which
requires an extensive rearrangement of hydrophobic residues in the core of the
enzyme, known as hydrophobic sliding, and changes in these protein dynamics
can alter the balance between inhibitor binding and substrate processing (69).
Mutations outside of the active site in HIV protease can change the dynamic
ensemble of the protease, and the effect of such distal mutations are propagated
to critical active site residues, suggesting that a network of interactions is
involved in how distal drug resistance mutations impact the active site (34).
Furthermore, in the HIV gp41/gp120 envelope fusion protein, gp120 variants that
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have faster fusion kinetics are more resistant to the fusion inhibitor enfuvirtide
(74, 75). Overall, changes in protein dynamics can alter the balance between
biological function versus inhibitor binding, and this balance can be tipped in
favor of biological function while limiting inhibitor binding and conferring drug
resistance.
1.4.2 Role of Protein Dynamics in Antibody Neutralization Escape
Alterations in protein dynamics can also be involved in antibody
neutralization escape. With the HIV gp41/gp120 envelope protein, antibody
potency is related to the ability of the antibody to bind to the predfusion closed
form of the HIV envelope protein, and therefore changes in dynamics can impact
the binding affinity of antibodies. In addition, conformational diversity can inhibit
antibodydmediated neutralization (76, 77). In human T cell leukemia
transmembrane protein, which is a class I fusion protein like HIV gp41/gp120
envelope and influenza HA, binding of antibodies to the coileddcoil predhairpin
fusion intermediate is highly conformation dependent, and this mechanism
appears to be applicable to other retroviruses, providing additional examples of
how protein dynamics can impact antibody binding to its target (78).
1.5 Scope of Thesis
In this thesis, I attempt to fill gaps in our understanding of antiviral drug
resistance in influenza NA and HCV NS3/4A protease, and broadly neutralizing
antibodies against influenza HA. First, I use molecular dynamics simulations to
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define the dynamic substrate envelope in influenza neuraminidase to understand
how different patterns of drug resistance have emerged in N1 and N2 NA
subtypes. I demonstrate that differences in van der Waals contact potential
energies and hydrogen bonding with the enzyme between substrates and
inhibitors in the two subtypes can explain the different patterns of drug resistance
for mutations that are in the active site. Although highly homologous, the
differences between N1 and N2 NA are sufficient to define distinct substrate
envelopes in these subtypes, leading to selection of different drug resistance
mutations. Then, I use a similar approach for HCV NS3/4A protease, and use the
substrate envelope hypothesis to understand different patterns of drug resistance
that have emerged with various inhibitors in clinical development. Next, I
examine potential antibody neutralization escape mutations that emerged in
influenza HA during viral passaging in the presence of the broadly neutralizing
antibody F10 as a selective pressure. The antibody neutralization escape
mutations in HA occur outside of the F10 binding epitope and may impact the
conformational changes in HA that are important for fusion. Finally, I solved novel
crystal structures of an influenza broadly neutralizing antibody fragment D80
alone and in complex with an antididiotypic antibody G6. I show that the most
important interactions for binding to D80 occur in the CDR2 and CDR3 loops of
the heavy chain of D80, and an extensive pi stacking interaction is conserved
between the CDR loops in the heavy chain of the bound and unbound structures
of D80, suggesting a predarranged binding interface.
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CHAPTER II
2 THE SUBSTRATE ENVELOPE HYPOTHESIS DESCRIBES
DIFFERENTIAL PATTERNS OF DRUG RESISTANCE IN N1 AND N2
NEURAMINIDASE
2.1 Abstract
Currently, the main antiviral drugs against influenza are neuraminidase
(NA) inhibitors, but drug resistance is widespread and highly prevalent, such as
during the 2007d2008 influenza season. Two subtypes of NA predominate in
humans, N1 and N2, but different patterns of drug resistance have emerged in
each subtype despite highly homologous active sites. To understand the
molecular basis for the alternative patterns of drug resistance, structural and
dynamic analysis on N1 and N2 in complex with substrates and inhibitors were
performed. Comparing dynamic substrate and inhibitor envelopes and
interactions at the active site during MD simulations revealed how different
patterns of drug resistance have emerged for specific drug resistance mutations,
including residues I222, N246, and H274 in N1 and E119 in N2. This work
provides guidelines for predicting and understanding mutations that decrease
susceptibility to NA inhibitors in different subtypes, insights toward development
of novel inhibitors to avoid drug resistance by better mimicking the dynamic
binding features and molecular interactions of substrates in the active site.
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2.2 Introduction
Seasonal influenza infects over 24 million people annually in the United
States, causing over 200,000 hospitalizations and 40,000 deaths (79). Vaccines
prevent influenza infection, but are not always effective because of antigenic drift,
a high mutation rate, and mismatches between vaccine and circulating strains
(51, 53). Therefore, direct acting antiviral medications are needed as another
strategy for combating influenza infection.
Currently, the main antiviral drugs against influenza are neuraminidase
(NA) inhibitors (5). Influenza NA is a viral sialidase necessary for viral maturation,
and cleaves terminal sialic acid residues from glycoproteins to release the
budding virus from the surface of infected cells (80d82). NA may also increase
viral motility in mucus (83). In 1999, the U.S. Food and Drug Administration
(FDA) approved two competitive active site NA inhibitors, oral oseltamivir (OST)
and inhaled zanamivir (ZMR), and in 2014 peramivir for intravenous
administration (5, 29d31).
Subtype specific patterns of drug resistance have developed against NA
inhibitors even though sialic acid binding sites between subtypes are highly
homologous (Table 2.1) (41, 84d93). Type A influenza is most prevalent and is
divided into subtypes based on two surface proteins, hemagglutinin (HA) and NA,
and two subtypes predominate in human infection, N1 and N2. In addition to drug
resistance mutations observed clinically in N1 and N2, additional resistance
mutations have been identified experimentally through in vitro and in vivo
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experiments, and more residues have been associated with decreased NA
inhibitor susceptibility (Tables 2.2 and 2.3)(41). Double mutations and secondary
permissive mutations have also been observed(40). Between N1 and N2, the
residues in the active site are 94% identical, but overall, N1 and N2 share
approximately 45% amino acid sequence identity and 60% similarity. The
particular viral genetic background and differences in protein dynamics between
N1 and N2 may contribute to different patterns of drug resistance, but the
mechanisms underlying these differences are still not well understood (87).
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Table 2.1 Drug resistance mutations in NA subtypes N1 and N2 that
have been observed in viruses clinically or during influenza surveillance.
Specific inhibitors that are susceptible to each mutation are noted in the superscript for each
mutation by the letters O, Z, and P for oseltamivir, zanamivir, and peramivir, respectively.
Residues in bold make direct van der Waals contacts with the ligands analyzed in this study.
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Table 2.2 Drug resistance mutations in NA subtypes N1 and N2 that
have been observed experimentally.
Specific inhibitors that are susceptible to each mutation are noted in the superscript for each
mutation by the letters O, Z, and P for oseltamivir, zanamivir, and peramivir, respectively.
Residues in bold make direct van der Waals contacts with the ligands analyzed in this study.
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Table 2.3 Additional residue positions in NA associated with decreased
neuraminidase inhibitor susceptibility (41).
Residues in bold make direct van der Waals contacts with the ligands in this study.
Residues in italics are considered outside of the active site.
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Drug resistance in enzyme targets is a change in molecular recognition
such that drug resistant variants no longer bind inhibitors while processing
substrates effectively. Understanding substrate recognition is critical because
biological function constrains NA under the selective pressure of inhibitors.
Interestingly, NA inhibitors were rationally designed based on the molecular
features of substrates and to optimize binding interactions in the active site,
however resistant variants that avoid inhibition but still process substrates have
emerged (29d31, 41).
Through our work studying HIV and Hepatitis C virus (HCV) NS3/4A
proteases, we established the substrate envelope hypothesis, which predicts that
substrates fill a conserved enzymedspecific volume when bound to the active
site, and primary drug resistance mutations occur where inhibitors protrude
beyond the substrate envelope (43, 44). We also incorporated protein dynamics
into a dynamic substrate envelope using molecular dynamics (MD) simulations to
determine how conformational fluctuations of inhibitors compared to substrates
contribute to drug resistance (94, 95). Differences in dynamic interaction profiles
between substrates and inhibitors at the active site illustrate how primary drug
resistance mutations occur at residues that interact more extensively with
inhibitors than substrates.
How influenza N1 and N2 interact with substrates versus inhibitors at the
molecular level and how specific mutations alter the balance between inhibitor
binding versus substrate processing to lead to different patterns of drug
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resistance in the two subtypes is not clear. In this study, we performed molecular
dynamics simulations on representative N1 and N2 NA structures in complex
with substrates and inhibitors, and calculated dynamic substrate envelopes for
these NAs. These dynamic substrate envelopes reveal how different patterns of
drug resistance have emerged in N1 and N2 NA for specific drug resistance
mutations, including those at residues I222, N246, and H274 in N1 and E119 in
N2. These data are predictive for mutations that decrease susceptibility to NA
inhibitors in different subtypes, and insights from this work can guide the
development of novel inhibitors to avoid drug resistance by better mimicking the
dynamic binding features and molecular interactions of substrates in the active
site.
2.3 Results
2.3.1 Description of Molecular Dynamics Simulations
Eight 100 ns molecular dynamics (MD) simulations on prototypic N1 and
N2 tetrameric NAs in complex with substrates and inhibitors were performed
(Table 2.4). All MD simulations were performed on the full tetramer to simulate
the biological unit with the added benefit of multiple copy simulation sampling
(72). The root mean squared deviation (RMSD) calculations converge and
indicate that the systems are stable (Figure 2.1). In addition, experimental and
simulation derived Bdfactors and alpha carbon root mean squared fluctuation
(RMSF) values agree well (Figure 2.2).
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Table 2.4 Table of NA ligand complexes that were analyzed.
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Figure 2.1 Overall root mean squared deviation (RMSD) calculations for
each MD simulation were performed over 100 ns.
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Figure 2.1 Overall root mean squared (RMSD) calculations for each MD
simulation were performed over 100 ns. A) and C) RMSD calculations for N1
and N2 NA, respectively, for all simulations over all alpha carbons and B) and D)
over all alpha carbons except five flexible Ndterminal and Cdterminal residues that
were omitted from the calculation.
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Figure 2.2 Experimental average B factors and RMSF values for
simulations.
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Figure 2.2 Experimental average temperature factors (B factors) and
alpha carbon root mean squared fluctuation (RMSF) values for simulations.
Values were compared for all simulations in N1 (A) and N2 (B) NA.
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Influenza neuraminidase is a homotetrameric transmembrane protein
(Figure 2.3A), and sites of drug resistance are located both in and outside of the
active site (Figure 2.3B). Influenza NA also cleaves two types of substrates
(Figure 2.4A) (48, 96). One substrate has alphad2,3 glycosidic linkages between
the terminal sialic acid and the neighboring galactose, and these substrates are
present in avian gastrointestinal epithelium, human respiratory tract mucin, and
human lower airway epithelium (96). The other type of substrate has alphad2,6
glycosidic linkages, and these substrates are present in human upper airway
epithelium (96). Neuraminidase inhibitors, such as oseltamivir and zanamivir are
also very similar in structure to each other and the substrate cleavage product
sialic acid (Figure 2.4B).
2.3.2 Static and Dynamic Substrate and Inhibitor Envelopes
We incorporated dynamics into a dynamic substrate envelope by mapping
the van der Waals (vdW) volumes of substrates in the active site over time on a
threeddimensional grid (Figure 2.5). This calculation produces a probabilistic
distribution of conformers in the active site, providing more detail compared to
static substrate envelopes. We also calculated dynamic inhibitor envelopes for
N1 and N2 NA for both oseltamivir and zanamivir individually (Figure 2.5).
Carbohydrate moieties galactose and Ndacetyldglucosamine that extend from
sialic acid in the substrates contribute additional flexibility, which is also evident
in the high rootdmeandsquareddfluctuation (RMSF) for these atoms (Figure 2.6).
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The dynamic substrate envelopes also reflect this flexibility, where the more
solvent exposed carbohydrate moieties have a broader probabilistic volume
distribution (Figure 2.5). The movement in the galactose and Nd
acetylglucosamine moieties may also propagate additional flexibility to sialic acid.
In contrast, the inhibitors oseltamivir and zanamivir are smaller and more rigid
than the substrate (Figure 2.5). However, the glycerol moiety in zanamivir better
mimics the flexibility of the glycerol moiety in sialic acid (Figure 2.6).
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Figure 2.3 Influenza NA structure and sites of drug resistance.
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Figure 2.3 Influenza NA structure and sites of drug resistance. (A)
Ectodomain of an NA tetramer. Each chain is a different color, calcium ions are
dark blue, and glycosylation is gold. Zanamivir is in violet sticks bound to each
subunit. B) The active site in one monomer. Zanamivir is in violet sticks bound in
the active site. Drug resistance residues from Table 1 that form direct van der
Waals contacts with inhibitors are shown in yellow sticks, and additional drug
resistance residues from Table 1 are shown in green sticks.
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Figure 2.4 Two;dimensional structures of substrates and inhibitors of
NA.
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Figure 2.4 Two;dimensional structures of substrates and inhibitors of
NA. A) An αJ2,3 substrate, 3’JsialylJNJacetyllactosamine, and an αJ2,6 substrate,
6’JsialylJNJacetyllactosamine, are shown. Scissors indicate the location of the
scissile bond. The R group is an NJacetyl group. B) Two dimensional structures
of two NA inhibitors, zanamivir and oseltamivir, and the substrate cleavage
product sialic acid.
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Figure 2.5 Dynamic substrate and inhibitor envelopes for NA.
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Figure 2.5 Dynamic substrate and inhibitor envelopes for NA.
Corresponding ligands are shown in the active site in gray sticks. (A) The
combined dynamic substrate envelope of αJ2,3 and αJ2,6 substrates is shown in
N1 NA, and in (B) N2 NA. (C) and (D) The individual substrate envelopes of αJ2,3
and αJ2,6 substrates are shown in N1 NA, respectively, and also in (G) and (H)
for N2 NA. (E) and (F) The individual inhibitor envelopes of oseltamivir and
zanamivir are shown in N1 NA, respectively, and also in (I) and (J) for N2 NA.
The probabilistic volume distribution is represented using a rainbow color
spectrum from red to blue to indicate more or less occupied regions, respectively.
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Figure 2.6 Average ligand root mean squared fluctuation (RMSF) in NA.
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Figure 2.6 Average ligand root mean squared fluctuation (RMSF) in NA.
The average RMSF over 400 ns is mapped onto the structures of substrate and
inhibitor atoms for each system.
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2.3.3 Differences in Van der Waals Contacts Correlate with Differential
Patterns of Drug Resistance in N1 and N2
The average vdW contact energies were calculated over the course of MD
simulations and mapped onto the active site for each system (Figure 2.7).
Comparing the vdW energies between substrate versus inhibitor binding reveals
what residues are more critical for inhibitor binding than substrate recognition.
Specific drug resistance mutations occur at these sites as they are less
determinant in substrate binding, such as E119 in N2 and I222 and S246 in N1.
Residue E119 is primarily a drug resistance residue in N2 NA, which can
be explained by differences in van der Waals interactions and hydrogen bonds in
N1 versus N2 NA (Figure 2.8A and 2.9). E119 interacts with both substrate and
inhibitor to a similar extent in N1, and therefore, a mutation to decrease inhibitor’s
contacts at this residue would also impact substrate processing. Resistance
mutations at this residue in N1 has not yet been observed clinically or though
influenza surveillance (41), although mutations at 119 have been observed
experimentally in vitro through reverse genetics and other in vitro mutagenesis
studies. E119 is interacts with the C4Jguanidinium group on zanamivir and
peramivir and with the corresponding amino group on oseltamivir. Since E119
makes more extensive contact in substrate binding in N1, mutations at this site
confer strong fitness penalties that cannot be overcome even in the presence of
inhibitor. Experimental results support the in silico observations that E119 is
critical for substrate binding and fitness in N1, and therefore, E119 is not a
prevalent drug resistance site in N1 (97).
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In contrast in N2, both oseltamivir and zanamivir have greater vdW
contacts than substrates, especially the αJ2,6 substrate, indicating that a drug
resistance mutation would be well tolerated at this location in N2 NA. Drug
resistance mutations in N2 E119V and E119I likely cause a loss of inhibitor
contacts. Hydrogen bonds with inhibitors are also more prevalent at E119
compared to substrates (Figure 2.9) in N2 making E119 an optimal site for drug
resistance in N2 NA.
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Figure 2.7 Van der Waals interactions in NA.
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Figure 2.7 Van der Waals interactions in NA. In A) through D), NA residues
that contact inhibitors are colored on the surface of NA according to differences
in average van der Waals contact potential energies during MD simulations
between substrates and the inhibitor. This calculation was performed for A) N1
NA in complex with oseltamivir, B) N1 NA in complex with zanamivir, C) N2 NA in
complex with oseltamivir, and D) N2 NA in complex with zanamivir. Oseltamivir
and zanamivir are shown in cyan and violet sticks, respectively, and the surface
of NA is shown in gray surface representation. E) Average van der Waals contact
potential energies for NA residues that contact substrates and inhibitors. Drug
resistance residues in N1 NA, N2 NA, and in both subtypes are indicated with red
stars, green triangles, and blue circles, respectively.
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Figure 2.8 Van der Waals interactions for drug resistance residues in NA.
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Figure 2.8 Van der Waals interactions for drug resistance residues in NA.
Each figure panel corresponds to either a clinically observed drug resistance
residue or a residue directly involved in drug resistance: A) E119, B) I222, C)
S/A246, and D) E276. For panel C), residue 246 is S in N1 and A in N2. In each
panel, histograms of average intermolecular van der Waals contact energies
during MD simulations are shown for N1 NA on the top and for N2 NA on the
bottom. Substrates are in light gray and inhibitors are in dark gray. On the right of
each figure panel, the structure of NA is shown in gray cartoon representation,
the indicated residue is shown in yellow sticks, and oseltamivir is shown in cyan
sticks. Dots show van der Waals radii of atoms. Significant difference in the
average van der Waals contact energies (p < 0.05) between the αT2,3 and αT2,6
substrates and inhibitors is indicated by an asterisk (*) and a cross (†),
respectively.
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Figure 2.9 Intermolecular hydrogen bonding interactions during MD
simulations.
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Figure 2.9 Intermolecular hydrogen bonding interactions during MD
simulations. A) Tables of the percentage of time that intermolecular hydrogen
bonds are present during MD simulations in N1 and N2 NA. Drug resistance
residues are in italics and catalytic residues are in bold. B) The residues involved
in each intermolecular hydrogen bond to the four ligands are shown in yellow
sticks, and hydrogen bonds are shown with black dotted lines. The αT2,3
substrate, αT2,6 substrate, oseltamivir, and zanamivir are shown in green, gray,
cyan, and violet sticks, respectively.
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Figure 2.10 Increased van der Waals contact potential energies of
inhibitors compared to substrates.
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Figure 2.10 Increased van der Waals contact potential energies of
inhibitors compared to substrates. Each figure panel A) through H)
corresponds to a residue that has been associated with decreased
neuraminidase inhibitor susceptibility. In each panel, histograms of average
intermolecular van der Waals contact energies during MD simulations are shown
for N1 NA on the top and for N2 NA on the bottom. Substrates are in light gray
and inhibitors are in dark gray. Significant difference in the average van der
Waals contact energies (p < 0.05) between the αT2,3 and αT2,6 substrates and
inhibitors is indicated by an asterisk (*) and a cross (†), respectively.
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Residue I222 is a primary drug resistance residue in N1 NA and a
secondary permissive mutation in N2 NA, and differences in vdW contacts also
explain this pattern (Figure 2.8B) (84). I222 contacts the NTacetyl group and the
glycerol/pentylTether hydrophobic moieties in ligands. When comparing the vdW
contacts for residue I222 in N1 and N2, I222 is makes extensive vdW contact
with both substrate and inhibitor binding in N2, and therefore I222 is not an
optimal site for drug resistance in N2. However, in N1, I222 is makes much more
extensive vdW contact with inhibitors compared to substrates. A drug resistance
mutation would be well tolerated at this site, as both oseltamivir and zanamivir
have greater vdW contacts with N1 compared to substrates. Since I222 does not
appear to be necessary for substrate binding in N1, mutations at this site confer
strong fitness advantages in the presence of inhibitor, as shown experimentally in
fitness experiments (97). In fact, I222 appears to be a “hotspot” location for drug
resistance mutations in N1, where many drug resistance mutations are well
tolerated and provide wild type like fitness for N1 in the presence of oseltamivir
(97).
S246N is a primary drug resistance mutation in N1 NA, but not N2, in both
in vitro experiments and clinical samples (90). When comparing vdW contacts in
N1 and N2, residue 246 is interacts more extensively in substrate recognition
than inhibitor binding in N2, and therefore this location is not an optimal site for
drug resistance (Figure 2.8C). However, in N1, N246 is more important for
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inhibitor binding compared to substrate recognition, especially for the αT2,6
substrate, indicating that a drug resistance mutation may be tolerated at this site
in N1. Thus, the differences in vdW contacts in comparison to substrates
correlate well with S246N being a resistance mutation in N1 only.
vdW contacts with residue E276 also explain the differential patterns of
drug resistance observed for mutation H274Y. Binding of oseltamivir to NA
requires that residue E276 rotate to create a larger pocket in the active site that
can accommodate the pentylTether hydrophobic moiety on oseltamivir (98).
Previous studies have shown that the drug resistance mutation H274Y in N1 NA
prevents rotation of E276 so that the active site can no longer accommodate
oseltamivir, but can still bind substrates and zanamivir. Since oseltamivir and
peramivir both contain the pentylTether hydrophobic moiety, both inhibitors are
impacted by the mutation H274Y. Although residue H274 does not directly
contact ligands, H274 mediates the interaction of residue E276 with ligands that
contain a bulky hydrophobic group at this position. When comparing vdW
contacts for residue E276 in N1 and N2 N, hydrophobic interactions of E276 are
much more important for oseltamivir binding in N1 NA than substrate or
zanamivir binding. This result indicates that a residue that may impact the
orientation of E276, such as drug resistance mutation H274Y, may prevent
inhibitors with a bulky hydrophobic group, such as oseltamivir and peramivir,
from binding (Figure 2.8D). In corresponding experimental fitness experiments in
N1 NA in the presence or absence of oseltamivir as a selective pressure,
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mutations at position E276 cause nullTlike fitness (97). However, mutation H274Y
confers wild type like fitness in the presence of oseltamivir.
For remaining residues that make increased vdW contacts with inhibitors
compared to substrates, these residues have been associated with either in vitro
drug resistance or decreased NA inhibitor susceptibility (Figure 2.10 and Tables
2.2G2.3) (41, 99, 100). These residues are active site and framework residues
that are well conserved, and mutations at these locations do not seem to be
tolerated in experimental fitness measurements in N1 (97). The differential
behavior of these residues for inhibitor versus substrate binding may explain
some of the decreased NA inhibitor susceptibility that has been observed with
mutations at these residues.
2.3.4 Hydrogen Bond Interactions
NA inhibitors were designed to optimize interactions in the active site,
such as hydrogen bonds and electrostatic interactions, and therefore there are
larger numbers of specific hydrogen bonds with NA active site residues
compared to the substrates (Figure 2.9) (101). Substrates form the most
prevalent hydrogen bonds with residues R371, R292, and R118 (Figure 2.9A).
These residues form hydrogen bonds to the carboxylic acid adjacent to the
scissile bond in the substrates, and may help stabilize the substrate in the active
site during the cleavage reaction (Figure 2.9B) (102). These residues are also
conserved evolutionarily in both N1 and N2 sequencesd R118, R292, and R371
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are 99% conserved. Inhibitors form additional hydrogen bonds with additional NA
residues. Oseltamivir makes hydrogen bonds with R152 and E119. E119 is a
drug resistance mutation in N1 NA, and R152 is a drug resistance mutation in
type B influenza NA. Mutations at R152 have been associated with decreased
NA inhibitor susceptibility (84). Zanamivir forms hydrogen bonds with E119 in
both N1 and N2, R152 in N2, and E227 and E277 in both N1 and N2. E227 and
E277 have been associated with decreased NA inhibitor susceptibility but not
reported as major drug resistance sites (41). Oseltamivir makes significant
hydrogen bonds with D151 in both N1 and N2 (93% and 94% of the simulation
time, respectively), and these hydrogen bonds are also present in zanamivir
(40% and 24% of the simulation time, respectively). These hydrogen bonds are
not as prevalent with substrates even though D151 is a catalytic residue (less
than 20% and 10% of the simulation time in N1 and N2, respectively). Thus, in
addition to increased vdW contacts, additional hydrogen bonds to nonTconserved
NA active site residues beyond those of substrates correlate with sites of drug
resistance mutations in the two subtypes.
2.4 Discussion
In this study, we used the dynamic substrate envelope to explain
differential patterns of drug resistance between N1 and N2 subtypes. This
method is useful for understanding drug resistance where vdW interactions play
a significant role in the drug resistance mechanism. However, for understanding
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more complex drug resistance mechanisms, such as those related to mutations
that primarily involve electrostatic interactions, like mutations R292K and N294S,
and for understanding double mutations and secondary permissive mutations,
more inTdepth study is required. Another mechanism of NA inhibitor drug
resistance, which is even more complex, occurs when hemagglutinin binding to
sialic acid is weakened, thereby decreasing the dependence of the virus on NA
cleavage activity.
D151E is another complex resistance mutation involving a catalytic
residue (102). However, hydrogen bonds between inhibitors and D151 may be
more stabilizing for inhibitor binding than substrate binding (Figure 2.9), and the
mutation D151E may be able to prevent inhibitor binding while still maintaining
catalytic activity. The mutation D151G allows unhydrolyzed substrate to bind and
be visualized in the active site through crystallography, which supports the
concept that while D151 is necessary for catalysis, this side chain is not required
for recognition (48). However, mixed populations of virus with drug resistance
mutations D151D/E and D151V/D have also been observed clinically and during
influenza surveillance, so further study is needed to fully understand the drug
resistance mechanism of this residue (41, 85, 86).
This study examined models and crystal structures of influenza
neuraminidase in complex with ligands that are similar to naturally occurring
substrates, such as 3’TsialylTNTacetyllactosamine and 6’TsialylTNT
acetyllactosamine. However, the solvent exposed GlcNac termini of these
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ligands may be more flexible than naturally occurring glycans because sialic
acids are tethered to polysaccharide chains that are longer than three sugar
residues and can be found as terminating branches of NTglycans, OTglycans,
glycosphingolipids (gangliosides), and side chains on glycophosphatidylinositol
(GPI) anchors, which are glycolipids on the surface of cell membranes often
associated with CTtermini of proteins during postTtranslational modification (103T
105). During the molecular dynamics simulations examined in this study,
extensive motion in the GlcNac termini of substrates was observed, but this
motion is likely to be reduced biologically because sialic acid is tethered to
polysaccharides on glycoproteins and polysaccharides attached to glycolipids in
the cell membrane. Although the motion of the GlcNac would likely be reduced
as a result of being tethered, the motion from the tethering object, whether it is a
glycoprotein or glycolipid, likely still contributes to the increased flexibility that is
seen in sialic acid compared to the inhibitors oseltamivir and zanamivir, which
are not tethered and have a tight subnanomolar binding affinity. Future analysis
of this motion in tethered substrates may more accurately identify which
molecular interactions in the active site are critical for substrate recognition.
The dynamic substrate envelope of NA can be incorporated into the
design of novel NA inhibitors to prevent the development of drug resistance.
Inhibitors can be designed to target evolutionarily conserved residues important
for substrate binding and to fill the substrate envelope more optimally to take
advantage of the remaining volume in the substrate envelope that is unfilled by
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inhibitors. In addition, inhibitor rigidity may promote susceptibility to drug
resistance mutations in the active site. Substrates can accommodate binding to
an active site with drug resistance mutations because they are more flexible, so
inhibitors can be designed to better mimic these substrate dynamics. However,
the high rigidity in inhibitors may also be important for tight binding interactions in
the active site. Inhibitors must be optimized to balance tight binding interactions
that contribute to high potency while sharing critical features of substrates, such
as substrate flexibility. Following these guidelines may heighten the barrier to the
development of drug resistance.
2.5 Methods
2.5.1 Influenza Neuraminidase Substrate and Inhibitor Complex
Structures
We chose prototypic N1 and N2 sequences for this study based on three
criteria: 1) existence of high quality high resolution crystal structures for MD
simulations 2) presence of a “typical” 150Tloop in the active site based on
previous reports for N1 and N2, and 3) high percent identity to N1 and N2
consensus sequences based on multiple sequence alignments (72, 106). All of
the crystal structures used in this study are of the globular head domain.
Alignments were performed using the multiple sequence alignment tools
available on the Influenza Research Database (www.fludb.org) and accessed on
February 18, 2016. The strain of N2 NA used is A/Tanzania/205/2010 H3N2 NA.
This strain has 94% sequence identity and 96% sequence similarity to a
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consensus sequence determined from an alignment of 8,745 complete and
unique sequences. The strain of N1 NA used is A/Brevig Mission/1/1918 H1N1
NA. This strain has 92% sequence identity and 96% sequence similarity to a
consensus sequence determined from an alignment of 7,370 complete and
unique N1 NA sequences
For N2 NA, crystal structures were available in complex with αT2,6 and αT
2,3 substrates (PDB ID: 4GZX and 4GZW, respectively) (48). A crystal structure
of the same strain of N2 NA was also available in complex with oseltamivir (PDB
ID: 4GZP). For N1 NA, the highest quality crystal structure available of N1 NA is
in complex with zanamivir (PDB ID: 3B7E) (107). Additional models were created
using these four structures for coTcomplex crystal structures that were
unavailable (Table 2.4).
2.5.2 Structure Preparation
Crystallographic waters and calcium ions were retained, and all buffer
salts were removed. The substrate coTcrystal structures have a D151G
substitution in the active site to prevent catalytic activity and allow substrates to
be captured in the active site. To more accurately model the interactions of
ligands with this residue, the backTmutation G151D was modeled in silico using
the software Maestro and Prime from Schrodinger (108, 109). Crystal structures
were prepared using the Protein Preparation Wizard from Schrodinger (110).
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2.5.3 Molecular Dynamics Simulation Protocol
We performed 100 nanosecond MD simulations for each tetrameric
complex using Desmond and the OPLS2005 force field (111, 112). Each system
was solvated with a 10 Å pad of TIP3P waters in a truncated octahedron solvent
box. Sodium (Na+) or chloride (Cl ) counterions were added to neutralize the
overall charge of the system. Each system was energy minimized using a
relaxation protocol to relieve steric clashes before initiating production stage MD
calculations. After minimization, each system was equilibrated using a sequence
of four short MD stages, following the default relaxation process for an NPT
ensemble published in the Desmond User Manual with modifications (113). For
the production stage, MD simulations were performed for 100 ns and 1 atm in the
NPT ensemble using a NoseTHoover thermostat and a MartynaTTuckermanTKlein
(MTK) barostat. LongTrange electrostatics were calculated using the Particle
Mesh Ewald method with a cutoff radius of 9 Å. For each system, the trajectories
of each monomer were concatenated to provide 400 ns of sampling.
2.5.4 Root Mean Squared Deviation (RMSD)
For each system, trajectories were sampled at intervals of 200 ps. Root
mean squared deviation (RMSD) calculations were performed using a custom
TCLTTK script in the Visual Molecular Dynamics software package (VMD) (114).
Before RMSD values were calculated, the frames from each interval were
aligned to the first frame of the trajectory, and RMSD values were calculated
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using all backbone alpha carbon atoms. In addition, five NTterminal and CT
terminal residues were omitted from the additional RMSD calculations to show
that the approximately 375 central amino acids of each monomer were highly
stable and equilibrated rapidly.
2.5.5 Root Mean Squared Fluctuation (RMSF) and SimulationGDerived
Temperature Factors
Root mean squared fluctuations (RMSF) and simulationTderived
temperature factors (B factors) were calculated for all alpha carbons in the
trajectory and averaged over 400 ns using VMD. RMSF was calculated using the
built in rmsf command in VMD, and simulationTderived B factors were calculated
using a TCLTTK script on the VMD website (115). For crystal structures with
more than one molecule in the asymmetric unit, temperature factors were
averaged over all molecules for comparison.
2.5.6 Dynamic Substrate Envelope
All trajectories were aligned based on the alpha carbons of a subset of
structurally rigid residues using VMD. The van der Waals (vdW) volumes of
ligand conformers in the active site of each monomer from each trajectory were
mapped onto a threeTdimensional grid, and a probability distribution was
calculated for each grid point and plotted using inThouse Fortran scripts. The
vdW radii were defined by the OPLS2005 force field. The mathematical details
have been reported previously (94).
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2.5.7 Van der Waals Contact Potential
The van der Waals contact potential energies between ligands and NA
were calculated over an MD trajectory and averaged using a simplified LennardT
Jones potential function defined by the following equation, where rij is the
distance between NA atom i and ligand atom j, ! is the energy well depth, and σ
is the collision diameter: " #$% = 4![ ( +#$% )-. − ( +#$% )0]
Van der Waals contact energies were calculated for all intermolecular
atom pairs within a 6 Å cutoff of the binding interface using an inThouse Fortran
script. The nonbonded parameters were determined using the OPLS2005 force
field, and values were averaged over 400 ns. Further details of this computation
have been described previously (94).
2.5.8 Hydrogen Bond Calculations
The percentage of time that a hydrogen bond exists during a trajectory
was calculated using the HBonds Plugin from VMD and averaged over 400 ns. A
hydrogen bond was defined as having a donorTacceptor distance of a maximum
of 3.5 Å and involving only polar atoms nitrogen, oxygen, sulfur, and fluorine. The
donorThydrogenTacceptor angle was also defined as being less than the cutoff of
30 degrees. Hydrogen bonds were summed over each residue and ligand except
as indicated.
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2.5.9 Plots and Figures
Microsoft Excel, Matlab, GraphPad Prism, PyMOL, and Geneious version
8.0.5 were used to create all plots and figures (116T119).
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CHAPTER III
3 COMPARATIVE ANALYSIS OF HEPATITIS C NS3/4A INHIBITOR
STRUCTURES
3.1 Abstract
Direct acting antivirals are increasing the efficacy and tolerability of
hepatitis C virus treatment, but drug resistance has emerged with some of these
inhibitors, including nonTstructural protein 3/4A protease inhibitors. Although
many structures of PIs in complex with the NS3/4A protease have been reported,
a systematic review of these crystal structures in the context of the substrate
envelope hypothesis has not been performed. To provide a framework for
designing better NS3/4A protease inhibitors with a higher barrier to resistance,
we performed a quantitative structural analysis of PIs in clinical use or
development using coTcrystal structures and models of NS3/4A protease in
complex with natural substrates and inhibitors. By comparing substrate structural
motifs and active site interactions with inhibitor recognition, we observed that the
development of drug resistance mutations correlates with how inhibitors deviate
from viral substrates in molecular recognition.
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3.2 Introduction
Hepatitis C is a bloodTborne liver disease caused by the hepatitis C virus
(HCV), that infects 3T4 million people each year (120). According to the WHO,
approximately 150 million people are infected with HCV chronically, which is one
of the most common reasons for liver transplants and can cause liver cirrhosis
and hepatocellular carcinoma (120, 121). HCV is a genetically heterogeneous
RNA virus, with six major genotypes and several subtypes within each genotype.
HCV is also a member of the Flaviviridae virus family, which also includes West
Nile Virus, dengue virus, and zika virus (122). Genotypes differ in sequence by
approximately 30%, and genotype 1 is the most prevalent and until recently, was
the most difficult to treat (123, 124). The errorTprone RNATdependent RNA
polymerase generates high sequence variation, in addition to a high viral
replication rate, making HCV a difficult target for designing effective antiviral
drugs (125, 126). Although many direct acting antivirals (DAAs) against HCV
have been developed, genetic diversity is a challenge for designing DAAs that
effectively inhibit multiple genotypes and drug resistant variants of HCV (123,
125, 126).
While DAAs are increasing the efficacy and tolerability of HCV treatment,
drug resistance has emerged with some of these inhibitors, including nonT
structural protein 3/4A protease inhibitors (NS3/4A PIs) (127). Although current
PIs are effective against genotype 1 HCV, some PIs have less activity against
other genotypes. In addition, first generation PIs, such as telaprevir (now
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withdrawn (128)) and boceprevir, are limited in use due to their burdensome
administration, considerable side effect profiles, drugTdrug interactions, and low
barriers to resistance (127). Second generation PIs, such as simeprevir, offer
more benefits over first generation PIs, such as better side effect profiles and
fewer drugTdrug interactions, but the barrier to resistance is still low (123, 127).
By studying drug resistance in HIVT1 PIs and HCV NS3/4A PIs, we
learned that the key to designing robust inhibitors with high barriers to resistance
is to incorporate details of molecular recognition in substrate and inhibitor binding
into drug design (33, 43, 129). Inhibitors that structurally mimic viral substrates
are more likely to retain binding against drug resistant variants because these
variant proteases must retain the ability to cleave viral substrates for survival.
Inhibitors that mimic the dynamics of natural substrates are also more likely to
maintain potency against drug resistant variants, and in general, additional
flexibility allows inhibitors to better accommodate drug resistance mutations. To
provide a framework for designing better NS3/4A PIs with a higher barrier to
resistance, we performed a quantitative structural analysis of PIs in clinical use or
development using coTcrystal structures and models of NS3/4A protease in
complex with natural substrates and inhibitors. By comparing substrate structural
motifs and active site interactions with inhibitor recognition, we observed that the
development of drug resistance mutations correlates with how inhibitors deviate
from viral substrates in molecular recognition.
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3.2.1 HCV NS3/4A Protease and Current Inhibitors
HCV NS3/4A helicaseTprotease is a 631 aminoTacid protein with two
domains, a NTterminal NTPase/helicase domain and a CTterminal serine
protease domain, which is the target of NS3/4A PIs (Figure 3.1). The protease
domain contains two betaTbarrel subdomains and a zinc binding site, sharing a
fold similar to chymotrypsin. To activate, HCV NS3 forms a heterodimer with the
cofactor NS4A (123). The protease cleaves the HCV viral polyprotein, releasing
proteins essential for viral maturation and infectivity. HCV protease also impairs
hostTmediated viral elimination by cleaving host proteins, including TRIF, which is
involved in TRIFTmediated TollTlike receptor 3 (TLR3) signaling, and MAVS,
which is involved in CardiffTmediated retinoic acidTinducible gene 1 (RIGT1)
signaling (130T133). The catalytic triad His 57, Asp 81, and Ser 139 in the active
site of the protease domain hydrolyzes substrates and is located between the
two betaTbarrel subdomains. The protease active site is very shallow, which is
another challenge for designing tight binding low molecular weight inhibitors (46).
71
Figure 3.1 Cartoon representation of the hepatitis C NS3/4A helicaseG
protease structure.
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Figure 3.1 Cartoon representation of the hepatitis C NS3/4A helicase
protease structure. The NTterminal protease domain is green, the CTterminal
helicase domain is pink, the last six amino acids in the CTterminus are in
magenta, and the NS4A cofactor is blue. The catalytic triad H57, D81, and S139
is in yellow sticks.
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Figure 3.2 Hepatitis C NS3/4A protease inhibitors in clinical use or
development.
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Figure 3.2 Hepatitis C NS3/4A protease inhibitors in clinical use or
development. A) Linear covalent ketoamide inhibitors, B) P2TP4 macrocyclic
inhibitors, C) P1TP3 macrocylic inhibitors, and D) linear nonTcovalent inhibitors
that have been FDA approved or are in Phase II or III clinical trials.
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Five HCV PIs, telaprevir, boceprivir, simeprevir, paritaprevir, and
grazoprevir, are FDATapproved, and several more PIs are in clinical development
(Figure 3.2) (134). Faldaprevir, asunaprevir, vaniprevir, narlaprevir, glecaprevir,
and GST9857, are currently in Phase III clinical trials, while danoprevir,
sovaprevir, and vedroprevir are in Phase II clinical trials (135). The structures of
these inhibitors have been disclosed except for GST9857. GST9256 was also in
Phase II clinical trials however inhibition of bilirubin transport and metabolism is
preventing development (136, 137). Additional PIs with disclosed and
undisclosed structures are in Phase I trials or preTclinical development, such as
ACHT2684 (deldeprevir), MKT2748, MKT6325, and GST9857 (138T140). TGT2349
is in Phase II clinical trials in Taiwan and Phase I clinical trials in the United
States (135).
NS3/4A PIs are prescribed in combination with other classes of DAAs and
nonspecific antivirals, such as pegylated interferonTalpha and ribavirin (123).
With many of the newly developed DAAs on the market, several interferonTfree
and ribavirinTfree regimens are available, but many of these newer regimens are
costly, so treatment choices are often limited by what is covered by an insurance
provider.
NS3/4A PIs are peptidomimetics and competitive active site inhibitors, and
they were designed based on the structure of natural substrates, whose cleavage
products are weak inhibitors (141T143). Many of these inhibitors were coT
crystallized with the protease domain and the cofactor NS4A. Similar to substrate
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positions in the active site, inhibitor moieties are named based on the analogous
substrate residue in the active site. For instance, an inhibitor moiety in a position
analogous to the P1 substrate residue is called a P1 inhibitor moiety.
The FDA approved the first NS3/4A PIs, boceprevir and telaprevir, in
2011, two potent acyclic peptidomimetic ketoamide inhibitors (28, 144T146).
These PIs contain an alphaTketoamide group that reversibly covalently bonds
with the catalytic residue Ser 139. In addition, these inhibitors form shortTrange
electrostatic and van der Waals interactions with the binding site (46). Designed
to target the active site of genotype 1 NS3/4A proteases, these inhibitors are
most effective against genotype 1 and also inhibit genotypes 2, 5, and 6 in vitro,
but they are least effective against genotype 3 (147, 148). Narlaprevir is another
linear ketoamide inhibitor in Phase III clinical trials, which has improved potency,
pharmacokinetic profile, and physicochemical properties (147, 149).
In addition to the linear covalent ketoamide PIs, there are linear nonT
covalent peptidomimetics, including faldaprevir, asunaprevir, sovaprevir and
vedroprevir (26, 150T154). Faldaprevir and asunaprevir are in Phase III clinical
trials, while sovaprevir and vedroprevir are in phase II clinical trials (135). All four
of these inhibitors have a quinoline or isoquinoline moiety in the P2 position.
Asunaprevir and sovaprevir are related linear acylsulfonamide inhibitors that only
differ in structure at the P4 capping group and the P2 extension. In addition,
sovaprevir demonstrates high potency against all HCV genotypes except
genotype 3 and has a low side effect profile (139, 147). Asunaprevir is a highly
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potent inhibitor with in vitro activity against genotypes 1 and 4, but drug
resistance mutations have emerged in patients infected with HCV genotype 1b
as well as associated with hepatotoxicity, limiting its use in combination with
pegylated interferon alpha and ribavirin (123, 155, 156).
Faldaprevir and vedroprevir are related linear CTterminal carboxylic acid
inhibitors that span the P4TP1 substrate sites, and they also only differ in
structure at the P4 capping group and the P2 extension. These inhibitors were
designed based on the observation that the C8 substituent (bromide in
faldaprevir and chloride in vedroprevir) on the P2 quinoline BTring improved the
cellTbased potency and pharmacokinetic profile of these inhibitors (147, 150). In
particular, faldaprevir is a onceTdaily selective inhibitor with a good absorption,
distribution, metabolism, and excretion (ADME) profile and favorable
pharmacokinetics (123, 147).
The other group of nonTcovalent NS3/4A PIs is the acylsulfonamide
macrocyclic inhibitors, which include vaniprevir, danoprevir, glecaprevir,
grazoprevir, paritaprevir, and simeprevir (25, 147, 157T159). Grazoprevir,
paritaprevir, and simeprevir are FDATapproved inhibitors. Vaniprevir and
glecaprevir are in Phase III clinical trials, and danoprevir is in Phase II clinical
trials (135). These inhibitors contain a macrocycle that connects either the P1
and P3 moieties (simeprevir, paritaprevir, and danoprevir) or the P2 and P4
moieties (grazoprevir, glecaprevir, and vaniprevir). In general, macrocyclic PIs
demonstrate higher subnanomolar affinities compared to linear inhibitors, but
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drug resistance mutations have also emerged. However, macrocyclic inhibitors
are better able to accommodate drug resistance mutations compared to linear
inhibitors. Some of these inhibitors have been designed for increased panT
genotypic efficacy, such as grazoprevir, paritaprevir, and glecaprevir (123, 160,
161).
Many of these macrocyclic inhibitors are related compounds with
differences in specific substituents or moiety positions. Vaniprevir and danoprevir
are related compounds with similar isoindoline P2 moieties, P4 capping groups,
and carbamate linkages between the P4 and P3 moieties, but they differ in
macrocyclization. Vaniprevir demonstrates excellent selectivity against a panel of
169 pharmacologically relevant receptors, enzymes, and ion channels (IC50 > 10
µM) except for chymotrypsin (IC50 = 520 nM), and danoprevir is unique with a low
incidence of viral rebound after combined treatment with PEG interferon alphaT2a
(162, 163). Grazoprevir and glecaprevir are related compounds that have similar
quinoxiline P2 moieties and carbamate linkages between the P4 and P3
moieties, but they differ in macrocyclization, P4 capping groups, and P2
quinoxiline substituents. Grazoprevir is active against genotypes 1, 2, and 3,
whereas many NS3/4A PIs lose potency against genotype 3 (164). Paritaprevir,
which is an inhibitor developed by Abbvie, has a phenanthridine P2 moiety, and it
was recently FDA approved in December 2014 in a combination medication with
ombitasvir and ritonavir (165). Simeprevir is smaller than other macrocyclic
inhibitors, has a P1TP3 macrocycle, and has a quinoline P2 group. Simeprevir
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spans the P3TP1’ sites compared to the other macrocyclic inhibitors, which span
the P4TP1’ sites, and has a high selectivity ratio of 5,785 in vitro, which is the
ratio of the 50% cytotoxic concentration and the 50% effective concentration in
cellTbased assays (166). Over the past few years, panTgenotypic inhibitors have
also emerged. Glecaprevir is a P2TP4 macrocylic inhibitor in Phase III clinical
trials that is highly potent against many genotypes (EC50 = 0.85T2.7 nM), and in
particular, it has high activity against genotype 3a (EC50 = 1.6 nM) (167). It is
currently being investigated as an oral, ribavirin free, oneTaTday combination
therapy with NS5A inhibitor ABTT530 for patients with genotype 1T6 HCV
infection (167).
3.2.2 Drug Resistance to HCV NS3/4A Protease Inhibitors
Drug resistance mutations have emerged against NS3/4A protease
inhibitors both experimentally and clinically in 5T15% of patients (124, 160, 168T
174). These mutations occur both inside and outside the protease active site
(Table 3.1). Drug resistance mutations at residues R155, A156, and D168 impact
the most inhibitors. These residues are located directly in the active site, and
they are also the main sources of drug resistance clinically (124). In addition to
drug resistant variants with single mutations, variants with multiple mutations
have also been reported, such as V36M and R155K. Boceprevir and telaprevir
are the oldest inhibitors and are most susceptible to drug resistance, with main
drug resistance mutations at residues V36, T54, R155, and A156 (124, 168).
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These resistance mutations cause three orders of magnitude changes in Ki and
IC50 values (175). Macrocylic PIs are less susceptible to resistance, but are still
impacted by mutations at residues R155, A156, and D168. Grazoprevir has
increased activity against multiple genotypes compared to other PIs and a more
favorable and flatter drug resistance profile. Grazoprevir is still susceptible to
resistance mutations at R155, A156, and D168, but the fold changes in Ki and
IC50 vary widely. For instance, the resistance mutation R155K increases the Ki
for grazoprevir by 6 fold, but the resulting Ki and IC50 measurements are still
subnanomolar. However, for the resistance mutations A156T and D168A, the
fold changes in Ki and IC50 are much greater.
Using the substrate envelope hypothesis to understand drug resistance in
HIV and HCV protease inhibitors, we discovered that substrates fill a conserved
volume within the active site known as the substrate envelope, and primary drug
resistance mutations occur where inhibitors protrude outside of the substrate
envelope and contact residues that are not evolutionarily conserved or are not
necessary for biological function (43, 44). Although many structures of PIs in
complex with the NS3/4A protease have been reported, a systematic review of
these crystal structures in the context of the substrate envelope hypothesis has
not been performed. This type of a study would provide insight into how different
patterns of resistance have emerged for different classes of NS3/4A PIs and may
also help us predict resistance for inhibitors that are still in development. We
used the substrate envelope hypothesis to analyze crystal structures of NS3/4A
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protease in complex with inhibitors that have been FDA approved or are in Phase
II or III clinical trials. We also modeled four additional PIs that have not yet been
crystallized. Understanding how different patterns of drug resistance have
emerged for different classes of NS3/4A PIs and applying this information to
predict resistance would be useful for designing inhibitors that are less
susceptible to resistance.
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Table 3.1 Sites of drug resistance mutations to HCV NS3/4A protease
inhibitors.
The top row lists residues where resistance mutations have occurred. Colored boxes indicate that
a drug resistance mutation was observed. Green boxes are for residues outside of the active site,
and yellow boxes for are for residues that contact inhibitors.
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3.3 Results
3.3.1 Substrate Envelope and VIN and VOUT
High resolution crystal structures of the protease domain in complex with
cleavage products of four viral polyprotein substrates demonstrate that viral
substrates fill a conserved volume in the active site, known as the
crystallographic substrate envelope (Figure 3.3) (43). Even though substrates
are nonThomologous, they adopt a conserved shape in the active site. Previous
studies established that the most severe drug resistance mutations occur where
inhibitors protrude beyond the substrate envelope and contact binding site
residues more important for inhibitor binding compared to substrate binding.
Three sites of highly prevalent drug resistance mutations, Arg 155, Ala 156, and
Asp 168, do not contact natural substrates but are more critical for inhibitor
binding.
The fit of inhibitors within the substrate envelope, represented by VIN and
VOUT, also correlates with loss of binding affinity to NS3/4A protease drug
resistant variants (Figures 3.4 and 3.5). VIN and VOUT are the volumes of
inhibitors that are contained within and protrude outside of the substrate
envelope, respectively. The linear ketoamide inhibitors telaprevir, boceprevir, and
narlaprevir do not protrude outside of the substrate envelope in the P2 moiety as
much as the macrocylic inhibitors, and consequently they have lower VOUT
volumes. However, the macrocylic inhibitors have higher potency, with better Ki
and IC50 values (175). For linear ketoamide inhibitors in the presence of drug
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resistance mutations, fold changes in Ki and IC50 values range from 2T20 fold,
whereas these same changes in macrocyclic inhibitors are 10T1000 fold (175).
However, since macrocyclic inhibitors have much stronger subnanomolar or
nanomolar binding affinity in wildTtype protease, losses of affinity in drug resistant
variants still result in relatively tight binding inhibitors. For instance, vaniprevir
and grazoprevir have subnanomolar activity against wildTtype NS3/4A protease,
and these inhibitors still retain nanomolar activity in the presence of drug
resistance mutations. (175)
However, many inhibitors do not take advantage of the remaining space
within the substrate envelope to make additional contacts with the protease. Only
narlaprevir and telaprevir extend into the P5 position and none of the inhibitors
extend into the P6 position. Most inhibitors also fill the P1’ volume. Full unT
cleaved substrates in the active site have not yet been crystallized, so this
portion of the substrate envelope remains undefined but is likely still useful for
designing compounds that are less susceptible to drug resistance. Optimizing the
balance between staying within and filling the substrate envelope, minimizing
protrusions from the substrate envelope, and maintaining a high level of activity
are important for designing potent inhibitors with flat resistance profiles.
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B)
Figure 3.3 Viral substrates of HCV NS3/4A protease share a conserved
binding mode in the active site.
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Figure 3.3 Viral substrates of HCV NS3/4A protease share a conserved
binding mode in the active site. (A) Amino acid cleavage site sequences of
four HCV NS3/4A protease viral substrates. (B) Viral substrates fill a conserved
volume in the active site known as the crystallographic substrate envelope. The
NS3/4A protease domain is in gray surface representation. Substrate 3T4A is in
red sticks, substrate 4AT4B is in green sticks, substrate 4BT5A is in blue sticks,
substrate 5AT5B is in yellow sticks, and the substrate envelope is in blue surface
representation. The catalytic triad D81, H57, and S139 is in yellow sticks, and
sites of three reported drug resistance mutations are in burgundy sticks.
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Figure 3.4 Inhibitors protruding outside of the substrate envelope in HCV
NS3/4A protease.
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Figure 3.4 Inhibitors protruding outside of the substrate envelope in HCV
NS3/4A protease. Drug resistance mutations occur where inhibitors protrude
beyond the substrate envelope and contact residues that are not important for
substrate binding. The NS3/4A protease domain is in gray surface
representation, and the substrate envelope is in blue surface representation. The
catalytic triad D81, H57, and S139 is in yellow sticks, and sites of drug resistance
residues R155, A156, and D168 are in burgundy sticks. Inhibitors are in stick
representation with carbon atoms in gray and other atoms in standard CPK
colors. The volume of each inhibitor inside (V n) and outside (Vout) the substrate
envelope is reported in Å3. MKT5172 is grazoprevir.
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Figure 3.5 Volume of substrates and inhibitors inside (VIN) and outside
(VOUT) of the substrate envelope by substrate moiety.
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Figure 3.5 Volume of substrates and inhibitors inside (VIN) and outside
(VOUT) of the substrate envelope by substrate moiety. VIN is blue and VOUT is
in red. If inhibitors did not occupy a particular substrate moiety, VIN and VOUT
were not calculated (such as with the P6 moiety). Ligands are listed on the xT
axis, and volume is on the yTaxis in Å3. MKT5172 is grazoprevir.
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3.3.2 InhibitorGProtease Contacts at the Active Site
Van der Waals contact energies of substrates and inhibitors with the
protease were calculated and mapped onto the surface of the active site
(Figures 3.6 and 3.7). These calculations were also performed for four inhibitors
without available crystal structures that were modeled: glecaprevir, paritaprevir,
sovaprevir, and vedroprevir (Figure 3.8). All surface van der Waals figures were
colored on the same energy scale from 0 to a maximum of approximately T7.4
kcal/mol according to the per residue van der Waals contact energies (Figure
3.9).
Overall, inhibitors demonstrate different distributions of van der Waals
contacts based on the type of moiety that extends from the P2 position and which
types of macrocycles are present in inhibitors. These different patterns of van der
Waals contacts also correspond to the different patterns of drug resistance that
have emerged for these inhibitors. In addition, all inhibitors generally make
increased contacts with catalytic residues H57, D80, and S139 compared to
substrates, and these interactions are ideal because these residues are
evolutionarily conserved and required for biological function, so they are less
likely to mutate without compromising catalysis and they are less likely to confer
drug resistance.
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Figure 3.6 Substrate van der Waals contacts mapped on the surface of
the NS3/4A protease active site for each substrate.
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Figure 3.6 Substrate van der Waals contacts mapped on the surface of
the NS3/4A protease active site for each substrate. The protease domain is in
gray surface representation, and the contact surface is in rainbow spectrum
colors where tangential contacts are in blue and warmer colors indicate stronger
van der Waals contact interactions. Substrates are in stick representation with
carbon atoms in gray and other atoms in standard CPK colors. Residues in bold
are drug resistance residues R155, A156, and D168. Underlined italicized
residues are the catalytic residues H57, D81, and S139.
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Figure 3.7 Inhibitor van der Waals contacts mapped on the surface of the
NS3/4A protease active site.
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Figure 3.7 Inhibitor van der Waals contacts mapped on the surface of the
NS3/4A protease active site. The protease domain is in gray surface
representation, and the contact surface is in rainbow spectrum colors where
tangential contacts are in blue and warmer colors indicate stronger van der
Waals contacts interactions. Inhibitors are in stick representation with carbon
atoms in gray and other atoms in standard CPK colors. Residues in bold are drug
resistance residues R155, A156, and D168. Underlined italicized residues are
the catalytic residues H57, D81, and S139.
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Figure 3.8 Substrate envelope and van der Waals surface representations
for modeled HCV NS3/4A protease inhibitors.
97
Figure 3.8 Substrate envelope and van der Waals surface representations
for modeled HCV NS3/4A protease inhibitors. A) The NS3/4A protease
domain is in gray surface representation, and the substrate envelope is in blue
surface representation. The catalytic triad D81, H57, and S139 is in yellow sticks,
and sites of drug resistance residues R155, A156, and D168 are in burgundy
sticks. B) Inhibitor van der Waals contacts mapped on the surface of the NS3/4A
protease active site. Residues in bold are drug resistance residues R155, A156,
and D168. Underlined italicized residues are the catalytic residues H57, D81, and
S139.
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Figure 3.9 Differential van der Waals interactions on the binding surface of HCV NS3/4A protease.
99
Figure 3.9 Differential van der Waals interactions on the binding surface
of HCV NS3/4A protease. (A) Per residue van der Waals contacts interactions
for each viral substrate. (B) Per residue van der Waals contacts for inhibitors.
Red stars indicate catalytic residues, and yellow circles indicate drug resistance
residues.
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Grazoprevir has the best activity and also is able to accommodate drug
resistance mutations at residues R155 and D168. The quinoxiline group in
grazoprevir stacks most favorably on the catalytic triad H57, D80, and S139. Out
of all the macrocyclic inhibitors with extended P2 moieties, grazoprevir appears
to make the least contacts with R155 and D168. None of the other inhibitors that
have been crystallized have a quinoxiline group, but glecaprevir has a quinoxiline
group that would also be predicted to stack against the catalytic triad. However,
the P2TP4 macrocycle in glecaprevir has two additional fluorine atoms, and the
P4 moiety has a five membered ring instead of a three membered ring, so these
differences may impact how glecaprevir behaves in the presence of resistance
mutations at residues R155 and D168. Paritaprevir has a phenanthridine group in
the extended P2 position, and this moiety also seems to stack well on the
catalytic triad. Paritaprevir also has a P1TP3 macrocycle instead of a P2TP4
macrocycle, and this difference may allow paritaprevir to better accommodate
resistance mutations at A156. It also appears that paritaprevir makes slightly less
contacts with A156 compared to glecaprevir and grazoprevir. In addition,
compounds without a P2TP4 macrocycle are better able to accommodate
resistance mutations at R155 and D168 (46, 176).
Compounds with quinoline, isoquinoline, and isoindoline at the P2
extended position have worse antiviral profiles against main drug resistance
residues R155, A156, and D168 compared to compounds like grazoprevir with a
quinoxiline at this position. These inhibitors include asunaprevir, danoprevir, and
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vaniprevir, and the moieties at the P2 extended position make increased contacts
with drug resistance residues R155, A156, and D168 (175, 176). Rather than
stacking on the catalytic triad, these moieties stack on these primary drug
resistance residues, which increases the susceptibility of these inhibitors to
resistance mutations at these locations.
Inhibitors with a P1TP3 macrocycle, such as simeprevir and danoprevir,
are slightly more susceptible to resistance mutations at S138, which is located
underneath the P1TP3 macrocycle binding site. Drug resistance at S138 has also
been reported for simeprevir and danoprevir. Based on the van der Waals
analysis, other inhibitors with a P1TP3 macrocycle may also be susceptible to
resistance at this location, such as paritaprevir.
Simeprevir and faldaprevir have P2 moieties that extend very broadly into
the active site in both the direction of the catalytic triad and also the direction of
drug resistance residues. Simeprevir is susceptible to mutations as S122, but
faldaprevir is not susceptible to this drug resistance mutation even though both
inhibitors are similar at this position. However, faldaprevir has additional contacts
in the S4 pocket whereas simeprevir only extends to the S3 pocket. These
additional interactions in S4 may help stabilize faldaprevir in the presence of
mutations at S122 even though S122 is located distal from the S4 pocket.
Sovaprevir is similar to faldaprevir and simeprevir at this location, with increased
contacts in the S4 pocket, so it may be able to accommodate resistance
mutations at S122. Vedroprevir has the largest P2 moiety of all the inhibitors
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analyzed in this study, and it makes many contacts with R155, D168, and S122,
so vedroprevir may also be susceptible to drug resistance mutations at these
locations.
Boceprevir, telaprevir, simeprevir, danoprevir, asunaprevir, and faldaprevir
are susceptible to mutations at Q80. Q80K is a polymorphism that impacts the
activity of PIs. The mechanism of resistance as a result of this polymorphism is
not clear, especially for inhibitors that do not directly contact this residue, such as
boceprevir and telaprevir, but the change in charge at this residue likely impacts
the electrostatic network of residues around residue 80. Residue 80 is located at
the edge of the active site, and it makes tangential contacts with inhibitors that
have a P2Tmoiety that extends in the direction of this residue, such as simeprevir,
danoprevir, asunaprevir, and faldaprevir. Therefore, mutations at residue 80 may
have some direct impact on binding of these inhibitors. In addition, sovaprevir
and vedroprevir make tangential contacts with residue 80 and may also be
susceptible to resistance mutations at this location.
3.3.3 Hydrogen Bond Interactions
Hydrogen bonds were calculated for inhibitors and substrates in complex
with the protease for backbone and side chain atoms (Figures 3.10 and 3.11).
Overall, inhibitors have similar hydrogen bonds as substrates to backbone atoms
in the protease. Inhibitors have increased hydrogen bonds to side chain atoms of
the conserved catalytic residues H57 and S139 compared to substrates.
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Substrates make hydrogen bonds with residues K165 and K136, and hydrogen
bonds to these residues are not as common in inhibitors. In a comparison of the
crystal structures analyzed in this study, K136 appears to occupy different
conformations in the active site. In addition, acidic residues at P6 in the substrate
interact with K165, but this interaction has been shown to be highly dynamic (46),
so designing inhibitors to maintain these hydrogen bonds may be challenging.
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Figure 3.10 Hydrogen bond interactions between ligands and backbone
atoms in the HCV NS3/4A protease active site.
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Figure 3.10 Hydrogen bond interactions between ligands and backbone
atoms in the HCV NS3/4A protease active site. Backbone atoms are listed on
the top row with the residue name and number and the name of the backbone
atom. Backbone atoms listed twice make more than one hydrogen bond with
ligand atoms. Crystal structures with more than one ligandTprotease complex in
the asymmetric unit are listed by chain letter. Distances less than or equal to 2.5
Å are red, distances greater than 2.5 Å and less than or equal to 3.0 Å are
yellow, and distances greater than 3.0 Å and less than or equal to 3.5 Å are
green. MKT5172 is grazoprevir.
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Figure 3.11 Hydrogen bond interactions between ligands and side chain
atoms in the HCV NS3/4A protease active site.
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Figure 3.11 Hydrogen bond interactions between ligands and side chain
atoms in the HCV NS3/4A protease active site. Side chain atoms are listed on
the top row with the residue name and number and the name of the backbone
atom. Side chain atoms listed twice make more than one hydrogen bond with
ligand atoms. Crystal structures with more than one ligandTprotease complex in
the asymmetric unit are listed by chain letter. Distances less than or equal to 2.5
Å are red, distances greater than 2.5 Å and less than or equal to 3.0 Å are
yellow, and distances greater than 3.0 Å and less than or equal to 3.5 Å are
green. MKT5172 is grazoprevir. MS is a missing side chain.
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3.4 Discussion
In general, inhibitors with a P2TP4 macrocycle and a quinoxilineTrelated P2
moiety have greater activity and stack well against the conserved catalytic triad in
the active site, but inhibitors with a P1TP3 macrocycle may maintain a better
balance between high potency and increased flexibility to accommodate
resistance mutations and have a flatter resistance profile. Therefore, an inhibitor
with a P1TP3 macrocycle and a flexible quinoxilineTrelated P2 moiety may be an
optimal strategy, and QSAR studies are underway to develop compounds with
flexible P2 quinoxilines.
In addition, extending inhibitors in the P1’ and P4TP6 regions to make
increased contacts with conserved residues in the S1’ and S4TS6 pockets rather
than extending outside of the S2 pocket may increase inhibitor potency while
decreasing susceptibility to drug resistance mutations (46, 95). For instance,
simeprevir does not have any contacts in the S4 pocket and is susceptible to the
resistance mutation S122 while faldaprevir makes additional contacts in the S4
pocket and is not susceptible to this resistance mutation even though P2
extended moieties in both compounds are similar. Increased conserved active
site contacts throughout an inhibitor may allow the inhibitor to better
accommodate specific resistance mutations if they emerge. In addition, there are
many basic residues in the S6 pocket, such as R119, R123, R161, and K165,
which make conserved interactions with the conserved acidic D or E residue at
the P6 position of the substrate. Making additional electrostatic interactions with
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these residues may also increase the potency of inhibitors but may also be
challenging because this region is dynamic (46).
Another interesting strategy for designing a PI with high potency while
maintaining a flat resistance profile would be to use a bisTmacrocycle with both
P1TP3 and a P2TP4 macrocycles. This approach was used to design the inhibitor
MKT6325, which was in Phase I clinical trials that have been completed. This
inhibitor has better activity than grazoprevir and also has improved potency
compared to grazoprevir against drug resistance variants R155K (0.07 vs. 0.013
nM), A156T (5.3 vs. 0.42 nM), and D168Y (0.14 vs. 0.036 nm), so it would be
interesting to see how this inhibitor performs compared to other inhibitors in
clinical use and development (176T178).
This analysis has shown that differences in how inhibitors fit within the
substrate envelope and interact with residues in the active site are correlated
with how different patterns of drug resistance have emerged for these inhibitors.
Incorporation of the substrate envelope hypothesis into structure based drug
design would facilitate the development of robust inhibitors with greater potency
and a higher barrier to resistance.
3.5 Methods
3.5.1 Substrate Envelope and VIN and VOUT Calculations
We analyzed crystal structures of NS3/4A protease in complex with
inhibitors that have been FDA approved or are in Phase II or III clinical trials.
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These structures include the protease in complex with telaprevir (3SV6),
boceprevir (5EBQ), narlaprevir (3LON), faldaprevir (3P8N), simeprevir (3KEE),
asunaprevir (4WF8), danoprevir (3M5L), vaniprevir (3SU3), and grazoprevir
(3SUD) (179T182). The substrate envelope was calculated using crystal
structures of NS3/4A protease in complex with substrate cleavage products 4AT
4B (3M5M), 4BT5A (3M5N), and 5AT5B (3M5O) (43). The structure of the
substrate cleavage product 3T4A in complex with NS3/4A protease was modeled
from the fullTlength crystal structure as previously described (1CU1) (43, 183).
The PDB IDs for each of these structures is in parentheses. The models of
glecaprevir, paritaprevir, sovaprevir, and vedroprevir were generated based on
similar fragments of inhibitors from the existing crystal structures listed, and
models were minimized using Maestro in the Schrodinger Software Suite (108).
The substrate envelope was generated in PyMOL as previously described (43).
Details of the VIN and VOUT volume calculations have been described
previously and were performed using in house Fortran scripts (94). VOUT is the
volume of inhibitor that protrudes outside of the substrate envelope, and VIN is
the volume of inhibitor inside the substrate envelope. Briefly, to perform these
calculations, the active site is divided into a three dimensional grid, and each grid
cell is defined by the indices i,j,k. Then, an initial value of zero is assigned to
each grid cell. The variable gijk 1 is the total grid for the inhibitor and gijk 2 is the
total grid for the substrates. A grid cell value is increased by 1 when a substrate
or inhibitor nonThydrogen atom based on the OPLS2005 vdW radius occupies
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the grid cell. N1 and N2 are equal to the number of static crystal structure
calculations for the inhibitor (1) and substrates (4), respectively. The volume of
an individual inhibitor outside the substrate envelope, VOUT, is calculated using
the following equation, where the resulting sum of grid point values is normalized
by the product of N1 and N2, and the overall sum is multiplied by the volume of a
single grid cell d3.
!"#$ = '( )* − ,-./,*)* × ,-./,2)2344 5678 9:7;<=-,.,/ = '()* )* − ,-./,* × 117;=78?-,.,/
The volume of inhibitor inside the substrate envelope, VIN, is calculated
using the following equation.
!-@ = '( ,-./,*)*344 5678 9:7;<=-,.,/ × ,-./,2)2 = '()* ,-./,* × 117;=78?-,.,/
3.5.2 Van der Waals Contact Potential Energy
The van der Waals contact potential energies between ligands and the
protease were calculated in each structure using a simplified LennardTJones
potential function defined by the following equation, where rij is the distance
between NA atom i and ligand atom j, A is the energy well depth, and σ is the
collision diameter: ! B-. = 4A[ ( FB-. )2* − ( FB-. )H]
Van der Waals contact energies were calculated for all intermolecular
atom pairs within a 6 Å cutoff of the binding interface using an inThouse Fortran
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script. The nonbonded parameters were determined using the OPLS2005 force
field (112). Further details of this computation have been described previously
(94).
3.5.3 Hydrogen Bond Interactions
Hydrogen bonds were determined using Maestro. A hydrogen bond was
defined as having a donorTacceptor distance of a maximum of 3.5 Å and
involving only polar atoms nitrogen, oxygen, sulfur, and fluorine. The donor
minimum angle was 120 degrees and the acceptor minimum angle was 90
degrees, according to the default settings.
3.5.4 Plots and Figures
Microsoft Excel, Matlab, Prism, and PyMOL were used to create all plots
and figures (116, 118, 119).
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CHAPTER IV
4 IDENTIFICATION OF INFLUENZA A VIRUS CANDIDATE RESISTANCE
MUTATIONS TO BROADLY NEUTRALIZING ANTIBODY
4.1 Abstract
Influenza A virus (IAV), a major cause of morbidity and mortality, is
continually evolving in response to selective pressures. Universal influenza
vaccines that target multiple strains and stemTdirected, broadly neutralizing
antibodies are promising therapeutic strategies, but neutralization escape
mutants can develop. We used an integrated approach combining viral
passaging, deep sequencing methods, computational and biophysical analysis to
ascertain the impact of a broadly neutralizing antibody directed against the stem
of hemagglutinin (HA) on the generation of potential escape mutants. Human
influenza A/Brisbane/59/2007 (H1N1) was grown in MadinTDarby canine kidney
cells with escalating concentrations of the broadly neutralizing antibody F10 over
serial passages. Sequence analysis revealed a mutation profile in the IAV
genome that included three nonTsynonymous mutations in HA, as well as a
distinct mutation in neuraminidase that was previously identified to be associated
with antibody escape for A/Brisbane/59/2007. Structural analysis revealed that
the HA mutations are located away from the highly conserved antibody epitope
and may impact conformational changes important for fusion with the endosome
during the viral life cycle, suggesting a novel molecular mechanism of resistance
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where mutations away from the binding epitope are selected. Thus, whole
genome population sequencing is a powerful method for identifying viral genome
responses to antibody selective pressure to identify candidate resistance
mutations.
4.2 Introduction
Influenza A virus (IAV) causes a highly contagious acute respiratory
illness in humans that is responsible for significant morbidity and mortality.
Approximately 30,000 people die from influenza each year in the United States
(184). During the past century, three major influenza pandemics resulted in the
deaths of 50–100 million people (185). Individuals at the extremes of age and
those with certain underlying medical conditions are at particularly high risk for
serious complications. IAV evades the body’s immune system through small
changes in the viral genome that occur continuously over time through antigenic
drift. On occasion, antigenic shift occurs, in which the segmented genomes of at
least two distinct influenza viruses reassort to produce a novel strain to which
individuals are antigenically naïve. A pandemic strain can arise following
antigenic shift, particularly when the segment encoding hemagglutinin is derived
from a nonThuman influenza virus. Antigenic shift led to the pandemic flu of 1918T
1919, which affected 25% of the world population, as well as the recent 2009
H1N1 pandemic flu (186).
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IAV’s unique evolutionary mechanisms, including high mutation rate,
segment reassortment, and shifts between multiple host species, pose significant
challenges for controlling the disease and developing effective vaccinations.
Therefore, a detailed understanding of influenza virus genome sequence
evolution is imperative. The influenza virion consists of eight negativeTstrand
RNA segments which form proteinTRNA complexes enveloped in a lipid
membrane (187). These eight segments encode at least ten proteins known to
be essential for infectivity and replication. Within a given influenza strain,
sequence evolution proceeds by mutation, selection, and genetic drift, all of
which are affected by the environment, host, and drug treatment. High mutation
rates, together with rapid development of influenza epidemics, make tracing the
evolutionary history of the virus and discovering the principles governing IAV’s
evolution complex.
Influenza virus has two surface glycoproteins, hemagglutinin (HA) and
neuraminidase (NA). HA binds to sialic acid on host cells, a process that is
critical for initial attachment and infection. NA cleaves sialic acid from the host
cell membrane during the release of newly formed viral progeny, thus reducing
viral affinity for previously infected cells (37). Seventeen different subtypes of
influenza A HA (H1–H17) exist, which are divided into two distinct phylogenetic
groups, group 1 (H1, H2, H5, H6, H8, H9, H11–H13, H16 and H17) and group 2
(H3, H4, H7, H10, H14 and H15) (188, 189). Only H1, H2, and H3 are present in
human influenza strains. HA is synthesized as a single polypeptide (HA0) that is
116
cleaved by host proteases into HA1 and HA2 subunits. The HA trimer is
composed of an HA1 globular head (the receptor binding site) and a stem (or
“stalk”) region composed of HA2 and HA1 which has the fusion machinery (see
(190) for review). HA is the primary target of the humoral immune response
during infection or vaccination. However, influenza vaccines generally elicit strain
specific responses, thereby limiting their efficacy and necessitating administration
of new vaccines when a novel strain becomes dominant.
Broadly neutralizing antibodies (BnAbs) have conserved epitopes on HA
and can neutralize a wide spectrum of influenza viruses (12). BnAbs against
viruses such as hepatitis C and HIV have also been discovered (59, 191). In
influenza, the BnAb epitopes are involved with receptor binding as well as with
the fusion machinery and are functionally conserved and less prone to mutation.
BnAbs are potential therapeutic agents when used as passive immunotherapy
and can also be integrated into the design of universal vaccines, which could be
much more effective than current vaccines. BnAbs against the influenza
receptorTbinding site include CH65 (192), S139/1 (62, 193), and C05 (62).
In addition, several BnAbs directed against highly conserved epitopes on
the stem of HA have been characterized, including F10, C179, CR6261,
CR8020, and CR9114 (12, 194). The F10 antibody, derived from the IGHV1;69
germline by panning immobilized HA using phageTdisplay libraries generated
from healthy donors, broadly neutralizes all group 1 viruses (194). An
intraperitoneal injection of F10 one hour before challenge with a lethal dose of
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H1N1 or H5N1 viruses protected approximately 80T100% of mice. F10 was also
administered to mice 48 or 72 hours after inoculation with virus, and viral
replication in the lungs significantly decreased. In addition, the
A/Vietnam/1203/04 H5N1 strain was passaged three times in vitro in the
presence of F10 antibody, but no resistant viruses developed at that time (194).
Therefore, F10 is an important potential candidate for future therapeutic use.
Interestingly, CR9114 and CR6261 are also derived from the IGHV1;69 germline.
C179 was the first antibody discovered to neutralize more than one subtype of
influenza (58). CR6261 and F10 neutralize all group 1 viruses, and CR8020
neutralizes all group 2 viruses. Notably, CR9114 neutralizes all group 1 and
group 2 viruses, and the CR9114 epitope is conserved across influenza A and B
viruses (58). CR9114 neutralized H1TH12 and H14 viruses in a
microneutralization assay and protected mice from lethal challenge with certain
strains of influenza B viruses, making it one of the most effective broadly
neutralizing influenza antibodies identified to date (12, 58).
StemTdirected antibodies prevent fusion of the host and virus membranes
in the low pH of the endosome by locking HA in a preTfusion conformation and
preventing the extensive conformational changes in HA required for membrane
fusion, blocking entry of viral RNA into the infected cell. Despite the high
conservation of BnAb epitopes in the HA stem region, neutralization escape
mutations by stemTdirected BnAbs have occurred in and around these epitopes
(12, 58, 61, 63, 66, 67). Many of these mutations cause neutralization escape by
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directly reducing antibody binding affinity, but additional escape mechanisms that
impact HA function or viral fitness may also emerge. Understanding mechanisms
of escape and identifying novel escape mechanisms are critical steps for
evaluating BnAbs that may be incorporated into future therapies and vaccines.
The goal of this study was to identify potential IAV escape mutants for the
BnAb F10 through high throughput sequencing (HTS) analysis of samples
generated through in vitro trajectory experiments. Mutations in the influenza
genome have been structurally characterized to determine possible mechanisms
for resistance. In HA, no escape mutations emerged in the highly conserved
antibody binding epitope region, but potential resistance mutations that may
impact fusion were selected, suggesting a possible novel mechanism for
resistance. By screening candidate BnAbs through such new methods, we may
be able to identify which BnAbs are least likely to generate escape mutants and
thereby be most effective in the long term.
4.3 Results
4.3.1 Serial passage of influenza in the presence of F10 monoclonal
antibody
We tested F10, which broadly neutralizes all group 1 influenza HAs (194),
against influenza A/Brisbane/59/2007 (H1N1) virus in MDCK cells in our
experimental trajectories (Figure 4.1). F10 is a broadTspectrum antibody directed
against the stem of influenza HA (194) that was originally identified by panning
immobilized HA using phageTdisplay libraries. Rather than blocking cell
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attachment, this antibody binds to a highly conserved pocket in the stem region
of HA that contains the fusion peptide so that membrane fusion of IAV is blocked.
We passaged influenza virus A/Brisbane/59/2007 (H1N1) under escalating doses
of F10 antibody, starting at 1X the ED50, or 0.3 μg/mL, at passage 4 and
escalating to ≥5 μg/mL in MDCK cells to select for a resistant virus population in
two independent trajectories, designated Experiments 1 & 2. Each experiment
included a complete noTantibody control arm. In Experiment 2, we included an
additional control that included escalating amounts of irrelevant monoclonal
antibody 80R specific to severe acute respiratory syndrome coronavirus (195)
(Figure 4.1A). The variation in output viral titers over time is displayed in Figure
4.1B.
120
Figure 4.1 Experimental design and viral titers for F10 trajectories.
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Figure 4.1 Experimental design and viral titers for F10 trajectories. (A)
Schematic of Experiment 1 and Experiment 2 for F10 trajectories. Cyan boxes
indicate virus that was passaged without the presence of antibody, with the top
three passages as P1, P2, and P3, and additional passages as labeled. Red
boxes indicate virus that was passaged in the presence of F10 broadly
neutralizing antibody (Experiment 1). Orange boxes indicate virus that was
passaged in the presence of F10 broadly neutralizing antibody (Experiment 2).
Grey boxes indicate virus that was passaged in the presence of 80R control
antibody (Experiment 2). (B) Ratios of viral titers (output/input) plotted against
passage number. Experiment 1, upper panel. Experiment 2, lower panel.
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4.3.2 Sequence analysis reveals candidate F10 escape mutations
All viral samples were processed for HTS as previously described (196T
198). Analysis of HTS data from Experiments 1 & 2 using the WrightTFisher ABC
(WFABC) model identified viral mutations with a 99% posterior probability of
being under positive selection (Table 4.1) (196, 199). These candidate F10
escape mutations included three nonTsynonymous mutations in segment 4 (HA):
N203V, N460S, and S123G (H1 numbering system) and one nonTsynonymous
mutation in segment 6 (NA), E329K, which was previously identified as important
for antigenic drift (200). In addition, one nonTsynonymous mutation in segment 2
(PB1), A643T, one nonTsynonymous mutation in segment 3 (PA), L28P, and two
synonymous mutations in segments 4 and 5 were elicited. The allele frequencies
increased as a function of passage number, and none of these mutations was
elicited with the irrelevant control 80R antibody (Figure 4.2A). Selection
coefficients are shown in Figure 4.2B. Of note, segment 4 mutations A638G and
A639T generate a double mutant in perfect linkage to encode the HA N203V
amino acid substitution.
4.3.3 Structural mapping of candidate F10 hemagglutinin escape mutants
To further investigate the mutations in HA and identify possible structural
changes and escape mechanisms, we mapped the nonTsynonymous mutations
N203V, N460S, and S123G onto existing crystal structures. We leveraged the
knowledge on HA structure, conformational changes in HA that occur during
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fusion, and residues that are important for HA receptor binding. Notably, all three
mutations are located away from the F10 binding epitope. Hence, instead of
directly affecting F10 antibody binding, these distal mutations may impact the
function of HA by conformational changes important for fusion with the
endosome during the viral life cycle and by modulating receptor binding affinity
(Figure 4.3). Such detailed analysis of the location of these mutations in the HA
structure enabled us to generate hypotheses on how these mutations may
impact conformational changes that occur in both subunits of HA, HA1 and HA2.
4.3.4 Potential impact of specific mutations on hemagglutinin function
Residue 203 is located at the receptor binding site of HA and forms a
hydrogen bond with the human receptor analog LSTc in H2 HA (Figure 4.4)
(201). In the H3 subtype crystal structures, this residue also interacts with sialic
acids through hydrogen bonds (202, 203). In influenza A/Brisbane/59/2007
(H1N1) HA, the selected mutation N203V could result in the loss of this hydrogen
bond between the receptor and its binding site because the side chain changes
from a carboxamide to a nonpolar group. Residue N203 (or N190 by the H3
numbering system) has been implicated in conferring receptor binding specificity
(204), and mutations modulating receptor affinity are a known mechanism of
antibody escape. Interestingly, this residue is one of the 17 contact residues for
the BnAb C05 and is 99% conserved in human H1, H2, and H3 (62).
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Table 4.1 Top\ranking polymorphic sites (posterior probability s>0>99%)
Experiment 1 Segment Protein Nucleotidechange
Amino acid
change
3 PA T106C L28P
4 HA A398G S123G
4 HA G1147A Synonymous
4 HA A1410G N460S
5 NP T1148C Synonymous
6 NA G1004A E329K
Experiment 2 Segment Protein Nucleotidechange
Amino acid
change
2 PB1 G1950A A643T
4 HA A638G N203V4 HA A639T
6 NA G1004A E329K
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Figure 4.2 Significant mutations arising in influenza A virus under
selection with the broadly neutralizing antibody F10.
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Figure 4.2 Significant mutations arising in influenza A virus under
selection with the broadly neutralizing antibody F10. (A) Trajectories of
significant mutations elicited by viral passaging with F10, with 80R control
antibody, or without antibody in terms of allele frequency. Red = F10, Experiment
1q orange = F10, Experiment 2q grey = 80R controlq and cyan = no antibody
control. *Mutations individually marked as N203D and N203I are in perfect
linkage and yield N203V, as the wild type sequence is GGT AAC CAA (AAC =
positions 638/639/640), protein: GNQ. The mutant sequence is GGT GTC CAA
(GTC = positions 638/639/640), protein: GVQ (see second row, columns 1 and
2). (B) The posterior probability (s) distribution of selection coefficients for the
mutations. Left panel, Experiment 1. Right panel, Experiment 2. Specific
mutations are listed by influenza viral protein, nucleotide change, and amino acid
change. Syn = synonymous.
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Figure 4.3 Candidate escape mutations identified in the F10 trajectories
are mapped onto the structure of HA.
128
Figure 4.3 Candidate resistance mutations identified in the F10
trajectories are mapped onto the structure of HA. The F10 epitope on the HA
stem, in surface and stick representation, is colored in blue, cyan, and green
(PDB ID: 3FKU). Van der Waals contacts between HA and F10 are colored on
the surface of HA using a rainbow color spectrum, where residues with the
greatest van der Waals contacts are in green, intermediate contacts are in cyan,
and smallest contacts are in navy blue. The fusion peptide is in red stick
representation to the left of the F10 epitope, and candidate escape mutations are
labeled.
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Figure 4.4 The N203V mutation in HA is located in the HA receptor
binding site.
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Figure 4.4 The N203V mutation in HA is located in the HA receptor
binding site. (A) The head of HA is represented by a grey surface, and the
location of the mutation N203V is labeled with a circle and a yellow surface. The
human receptor analog LSTc is shown in gold sticks (PDB ID: 2WRG). (B)
N203V is located in the HA receptor binding site. In the crystal structure, this
residue forms a hydrogen bond with the human receptor analog LSTc. The
hydrogen bond is shown with a black dashed line connecting the side chain
oxygen atom of N203 with a nitrogen atom on LSTc.
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The other two nonTsynonymous HA mutations selected by the F10
antibody, N460S and S123G, are located at key positions that may influence the
conformational changes needed to facilitate membrane fusion. Influenza RNA
enters the host cell when the viral envelope and the endosomal membrane fuse.
The NTterminal fragment of the HA2 subunit, the fusion peptide, mediates fusion.
At neutral pH, the fusion peptide is buried in a negatively charged pocket in the
stem of HA, but at acidic pH, the fusion peptide dissociates from the HA stem
and inserts into the endosomal membrane to promote fusion between the viral
membrane and the endosomal membrane (190, 205, 206). Residue N460
hydrogen bonds with the backbone nitrogen of a glycine on the fusion peptide at
neutral pH, and the mutation N460S results in the loss of this stabilizing
hydrogen bond. Daniels et al. reported that mutations that destabilize the neutral
pH conformation of the fusion peptide can alter the conformational change in HA
that occurs at acidic pH (207). Furthermore, residue 460 hydrogen bonds with
glycine 4 (H3 numbering) on the NTterminus of the fusion peptide, and
substitution of a different residue that also results in the loss of a stabilizing
hydrogen bond with this glycine has been reported to impact the pH of
membrane fusion (208). The mutation N460S may also alter the F10 epitope on
the HA stem because residues 17T21 of the fusion peptide form the center of the
F10 epitope. Residue N460 is located adjacent to the fusion peptide in HA,
forming a hydrogen bond (Figure 4.5). The fusion peptide is critical for the
132
conformational changes in HA that occur at acidic pH, where the fusion peptide
dissociates from the stem of HA and inserts into the endosomal membrane.
The crystal structures of an early fusion intermediate of HA at neutral and
acidic pH show the conformational changes in HA1 that occur during early fusion
(Figure 4.6) (209). These structures reveal that residue S123 is located in a
hinge region of the HA1 subunit. HA1 acts as a clamp on HA2 and stabilizes the
metastable preTfusion state of HA (209). To remove this clamp during fusion,
HA1 undergoes conformational changes, and one of these conformational
changes occurs at a hinge region around S123. In this region, an alpha helix that
is present at neutral pH begins to unfold at acidic pH, causing additional
conformational changes in the adjacent antiparallel betaTsheet that connects to
the receptor binding subdomain (209). The mutation S123G introduces a flexible
glycine residue into this hinge region, which may promote the unfolding of this
alpha helix and consequently promote the early conformational changes in HA1
during membrane fusion.
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Figure 4.5 The N460S mutation in HA is located adjacent to the fusion
peptide in HA.
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Figure 4.5 The N460S mutation in HA is located adjacent to the fusion
peptide in HA. (A) The structure of the HA monomer at neutral pH is shown with
respect to the viral envelope and endosomal membrane (PDB ID: 3FKU). The
HA1 subunit, which forms the head of HA, is shown in blue, and the HA2 subunit,
which forms the stem of HA, is shown in grey. The fusion peptide is shown in red.
The fusion peptide is important for the conformational change that occurs in HA2
at acidic pH. (B) The location of the mutation N460S is circled on the structure of
HA at neutral pH with the epitope colored by van der Waals contacts and the
fusion peptide shown in red (PDB ID: 3FKU). (C) and (D) The stem is shown in
more detail, and the hydrogen bond between residue N460 and the fusion
peptide is shown with a black dashed line. (E) At acidic pH, the fusion peptide
dissociates from the stem of HA and inserts into the endosomal membrane (PDB
ID: 1HTM). (F) The structure of HA2 at acidic pH is shown, and residue N460 is
exposed to the surface and is in yellow (PDB ID: 1HTM). (G) and (H) show this
residue in more detail.
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Figure 4.6 S123G is located in a hinge region of conformational change in
an early fusion intermediate of HA1.
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Figure 4.6 S123G is located in a hinge region of conformational change in
an early fusion intermediate of HA1. (A) The structure of HA at neutral pH is
shown with residue S123 circled and surrounding residues 115T129 shown in
green (PDB ID: 3QQB). (B) The structure of an early fusion intermediate of HA at
acidic pH with residue S123 circled and surrounding residues 115T129 shown in
yellow (PDB ID: 3QQO). (C) A detailed view of S123 at neutral pH with
surrounding residues colored in green to shown the early conformational
changes that occur in HA1 during fusion. S123 is located in a hinge region of
conformational change in HA1, and the direction of the conformational changes
that occur at acidic pH is shown with red arrows (PDB ID: 3QQB). (D) The
resulting structure of the early fusion intermediate of HA is shown in yellow (PDB
ID: 3QQO).
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4.3.5 Neuraminidase mutant
In addition to mutations in HA, the development of NA E329K under
selection with F10, but not control antibody 80R, suggests an epistatic adaptation
of the virus to circumvent the broadly neutralizing antibody as an escape
mechanism. The E329K mutation in NA of influenza A/Brisbane/59/2007 was
described in the antigenic evolution of proteins in H1N1 viruses used in vaccine
formulations during the last 15 years through analysis of inhibition titers and
antigenic cartography (200). This single point mutation was found to be primarily
responsible for the lack of inhibition by polyclonal antibodies specific for an
earlier influenza vaccine antigen, impacting NA drift. Although antigenic change
and drift in NA is often due to antibody selection, antigenic change in NA may
also result from a functional change in HA (210). The E329K change is located
on a loop on the surface of NA, opposite from the tetramer interface, and the
glutamic acid to lysine substitution suggests that a change in a charged
interaction is involved in the development of this mutation (67). Amino acid
changes at residue 329 were also reported in earlier studies of NA in response to
selection with monoclonal antibodies (211T213).
4.3.6 PA, PB1, and synonymous mutants
One nonTsynonymous PB1 mutation significantly emerged in Experiment 2
and one nonTsynonymous PA mutation emerged in Experiment 1, as well as two
synonymous mutations in HA and NP in Experiment 1 only. The potential
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relevance of these mutations in the presence of F10 as a selective pressure
needs further evaluation. Synonymous mutations can affect viral fitness, such as
with RNA structure, optimum codon usage, translation efficiency, and mutational
robustness (214T216).
4.4 Discussion
We identified and characterized several candidate F10 escape mutations
for a vaccine strain of influenza virus, A/Brisbane/59/2007, by combining viral
passaging and HTS methods with computational and structural analysis. We
previously applied such methods to understand the temporal evolution of
oseltamivir resistance (197) and viral reassortment (198). Using a similar
approach, we defined three novel mutations in influenza HA that may impact viral
binding or fusion. In addition, our data highlight a mutation in NA (E329K)
previously identified to drive antigenic drift for this particular viral strain, further
validating our approach (200).
The three novel mutations in HA that we identified are located in regions
of HA that modulate receptor binding specificity or the fusion pH of HA (217).
Mutations at residue 203 (190 in H3 numbering) were reported to impact receptor
specificity for substrates with an αT2,3 or αT2,6 glycosidic linkage between the
terminal sialic acid and the adjacent carbohydrate (200, 218T221). For instance,
the mutation E190D in combination with G225D (H3 numbering) in H1 HA
increases specificity for αT2,6 linked sialic acids and reduces affinity for αT2,3
139
linked sialic acids (221). Such mutations that alter receptor binding affinity are
selected in the response to other neutralizing antibodies as well (222, 223).
In addition, both mutations at residue 460 and 123 are located in regions
of HA that modulate the pH of fusion (217). These regions include the HA1THA1
interface, the region in the stem surrounding the fusion peptide, and the HA1T
HA2 interface that includes the 110Thelix (H3 numbering). Residue 460 (residue
117 of HA2 in H3 numbering) is located in the stem region surrounding the fusion
peptide, and mutations at residues 111, 112, and 114 (H3 numbering) increase
the pH of fusion in H3, H5, and H7 subtypes (201, 217, 224, 225). Many other
mutations in the fusion peptide or the surrounding pocket have also been shown
to significantly affect the fusion activity of HA or the pH of membrane fusion (201,
217, 224T227). Residue 123 (residue 113 in H3 numbering) is located in the 110T
helix, which is involved in the reorganization of the HA1THA2 interface that
occurs during membrane fusion, and mutations at residues 104, 110, and 115 (in
H3 numbering) also impact the pH of fusion due to changes at the HA1THA2
interface (217, 228). Similarly, the three candidate F10 escape mutations
discovered in this study may also play an important role in modulating receptor
binding specificity and the pH of membrane fusion.
The stem region of HA is highly conserved, especially in the region of the
F10 epitope (Figure 4.7), suggesting an important role in membrane fusion (60).
Despite this conservation, previously reported mutations in HA which cause
neutralization escape by stemTdirected BnAbs have occurred in regions in and
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around the BnAb epitopes. For BnAb CR8043, the two escape mutations
reported, R25M and Q34R on HA2, are located on the HA stem near the center
of the CR8043 epitope (63). BnAb CR6261 neutralizes H1, H2, H5, H6, H8, and
H9 viruses, and after ten in vitro passages, an escape variant of H5N1 was
generated with a H111L mutation in HA2 (12, 66, 67). This residue is also buried
under the fusion peptide in the HA stem and is located under the CR6261
epitope. The BnAb C179 was the first BnAb reported to neutralize more than one
influenza subtype, and two escape mutations were also selected in the HA stem
region, T318K in HA1 and V52E in HA2, which are both extremely rare variants
(58). In addition, escape mutations against the BnAb CR8020, such as D19N and
G33E in HA2, also occur in the CR8020 epitope and are relatively rare variants,
especially in human isolates (61). Interestingly, the three candidate F10 escape
mutations that appeared in this study, N203V, N460S, and S123G, also occur at
low levels in the alignment of the group 1 HA sequences from the NCBI
database, at 2.4%, 1.1%, and 6.8%, respectively (229, 230). In addition, the wildT
type residues N460 and S123 are both highly conserved in group 1 HA, at 98%
and 91%, respectively.
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Figure 4.7 The F10 epitope on the stem region of HA is highly conserved.
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Figure 4.7 The F10 epitope on the stem region of HA is highly conserved.
The F10 epitope on the HA stem is colored based on the percentage of
sequence conservation in Group 1 HA. Colored sticks show the residues that
form the F10 epitope, and grey sticks show the residues of the F10 antibody that
make direct van der Waals contact with the F10 epitope. The percentage of
sequence conservation on the epitope is indicated by the color bar using a
rainbow color spectrum, where red indicates 90% sequence conservation, yellow
indicates 60% sequence conservation, green indicates 40% sequence
conservation, and so on. PDB ID: 3FKU.
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We conducted these experimental trajectories using influenza
A/Brisbane/59/2007 to characterize the effect of a BnAb on a contemporary
vaccine strain. However, thus far we have not been able to maintain a
continuously productive recombinant A/Brisbane/59/2007 virus using a plasmidT
based system. Performing similar trajectories with BnAb on a virus such as
pandemic influenza A/California/7/2009 (H1N1), followed by expression of
candidate escape mutants (using reverse genetic systems) and monitoring for
alterations in antibody ED50 measurements, would help identify which mutations
are the most daunting for resistance in circulating influenza strains (231, 232).
This will help define the impact of the polymerase mutations and perhaps
epigenetic effects of the synonymous mutations.
4.5 Conclusion
An inTdepth understanding of genomeTwide effects of BnAbs on IAV will
yield insights on which “universal” influenza vaccines may be the most effective
and least likely to induce escape mutants. Furthermore, additive and synergistic
effects of antiviral drugs and BnAb can be monitored to define and quantify the
impact of multiple selective pressures on the evolution of resistance over time.
Given that these will be “real world” pressures faced by IAV, these combination
studies may assist in determining which combinations may serve as optimal
strategies in future epidemics and pandemics.
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4.6 Methods
4.6.1 Cells, virus stocks, and chemicals.
MadinTDarby canine kidney (MDCK) cells were obtained from American
Type Culture Collection (Manassas, VA) and propagated in Eagle’s minimal
essential medium (MEM) with 10% fetal bovine serum (FBSq Hyclone, Logan,
UT) and 2 mM penicillin/streptomycin. Influenza virus A/Brisbane/59/2007
(H1N1), grown in chicken egg allantoic fluid, was obtained through the NIH
Biodefense and Emerging Infections Research Resources Repository, NIAID,
NIH (NRT12282q lot 58550257) and passaged three times in MDCK cells
(passages 1–3).
4.6.2 Viral titer determination by plaque assay
Viruses were quantified on MDCK cells to determine infectious titer
(plaque forming units per mL, or PFU/mL) as previously described (233). In brief,
six 10Tfold serial dilutions were performed on the viral samples followed by 1 h of
binding at 37°C on confluent MDCK cells in 12Twell plates. After washing off
unbound virus with phosphate buffered saline (PBS), the cells were overlaid with
agar (0.5%) in DMEMTF12 supplemented with penicillin/streptomycin, LT
glutamine, bovine serum albumin, HEPES, sodium bicarbonate, and 20 µg/mL
acetylated trypsin (Sigma, St. Louis, MO). After the agar solidified, the plates
were incubated for ~48 h at 37 °C. Cells were fixed and stained with primary
antibody antiTH1 (MAB8261, Millipore, Billerica, MA). Plaques were visualized
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with antiTmouse horseradish peroxidaseTconjugated secondary antibody (BD
Biosciences, San Jose, CA) and developed with peroxidase substrate kit (Vector
Laboratories, Burlingame, CA).
4.6.3 Determination of the ED50 for F10 antibody
The 50% effective dose (ED50) value was defined as the concentration of
antibody that reduced plaque number to 50% of no drug control. In brief, the ED50
was determined by seeding 2.5 x 105 MDCK cells/well in a 24Twell plate and
incubated overnight at 37 °C, 5% CO2. Virus was added to cells at a multiplicity
of infection (MOI) of 0.01 in 100 μL of influenza virus growth medium
[EMEM/10% FBS with 2 mM penicillin/streptomycin, 7.5% bovine serum albumin,
and 1 µg/mL TPCKTtreatedTtrypsin (Sigma)] plus serial dilutions of F10 antibody.
After incubation at 37 °C for 1 h, cells were washed once with PBSq 500 μL of
influenza virus growth medium with the appropriate concentration of antibody
was added and cells were again incubated at 37 °C for several days.
Supernatants were collected when >90% cytopathic effect (CPE) was achieved
for at least one antibody concentration. Supernatants were centrifuged for 15 min
at 300 × g at 4 °C and stored at T80 °C. The viral titer for each sample was
determined by plaque assay.
4.6.4 Viral culture
Viruses were serially passaged in MDCK cells (2.5 x 105 cells/well). The
MOI for passages was 0.01 except for late passages in the first experiment, for
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which output virus was briefly low and MOI was adjusted to accommodate.
Trajectories were prepared both in the presence and absence of escalating
doses of F10 antibody or equivalent amounts of the control monoclonal antibody
80R. In passage 4, the antibody concentration was 1X the ED50. For the next
passage, the concentration was increased to 4X the ED50, and then doubled for
each subsequent passage as long as >50% CPE was present. If <50% CPE was
present, the dose of antibody was escalated at a slower rate.
4.6.5 High\throughput sequencing
We developed a highTthroughput sample processing workflow, carried out
in 96Twell format, including RNA purification, reverse transcription, whole
genome PCR, followed by DNA barcoding and library preparation, as previously
described (197). Libraries were sequenced on the Illumina HiSeq2000 platform to
generate 100 nucleotide reads.
4.6.6 Bioinformatics analysis
An integrated bioinformatics pipeline was developed to trim and bin the
raw read data based on barcode, align reads to the reference IAV genome, and
quantify the level of nucleotide and amino acid variability within the viral
population, as previously described (196, 197). To streamline the processing of
large numbers of IAV samples, an SQL database with a web interface was
developed, integrating sample growth conditions with DNA barcoding
information. The database was directly accessed using the analysis pipeline,
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eliminating the potential of human error when correlating experimental conditions
with large scale IAV genomic data.
Short reads from the Illumina platform were filtered for quality scores >20
throughout the read and aligned to the strain’s reference genome using BLAST.
Over 95% of the selected reads could be mapped to the IAV reference genome
obtained from GenBank (accessions CY030232, CY031391, CY058484T
CY058486, CY058488T CY058489, CY058491). Only alignments longer than 80
nucleotides were retained. The median sequencing depth was 14,400. Amino
acid frequencies were calculated after aligning translated reads to the
corresponding positions in the reference proteins. Unfolded SNP frequencies
were generated using the IAV reference genome and used for the population
genetics analyses and the amino acid frequencies were used for the structural
analysis. The sequencing datasets generated in this study are available at
http://bib.umassmed.edu/influenza.
4.6.7 Population genetic analysis
To perform population genetic analysis and identify the SNPs under
selection from random drift, we applied a WrightTFisher ABC approach (see
http://jensenlab.epfl.ch/page-86730-en.html) to estimate effective population size
and selection coefficient based on the allele frequency trajectories through time
(196, 197, 199). We generated the trajectories of all SNPs once the newly
derived allele frequency rose to greater than 2% in any passage. We first
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estimated Ne, which determines the level of genetic drift, based on the
trajectories of the entire genome. Then we estimated the selection coefficient of
each SNP and the posterior probability given the genomeTwide estimated Ne. If
the posterior probability of the given trajectory with positive selection coefficient
was greater than 99%, we considered these sites to be significantly under
positive selection.
4.6.8 Structural analysis methods
The amino acid sequence of influenza A/Brisbane/59/2007 (H1N1) HA
was obtained from UniProt using the accession number B0VX46, which is
associated with the GenBank accession number CY030232. This HA sequence
was aligned to the amino acid sequences of published crystal structures to
determine the location of specific mutations on the structure of HA, and the
possible impact of these mutations was determined based on what has been
reported in the literature about HA structure, conformational changes in HA that
occur during fusion, and HA receptor binding. The published crystal structures
used in this analysis include a structure of F10 in complex with H5 HA (PDB ID:
3FKU), a structure of H1 HA bound to the human receptor analog sialylneolactoT
NTtetraose c (LSTc) (PDB ID: 2WRG), a structure of solubilized trimeric H3 HA at
the pH of membrane fusion (PDB ID: 1HTM), and structures of H2 HA at neutral
and acidic pH (PDB ID: 3QQB, 3QQO). The mutagenesis wizard in PyMOL was
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used to mutate residue 203 to an asparagine in two crystal structures to match
the A/Brisbane/59/2007 (H1N1) HA sequence (PDB ID: 3FKU, 2WRG) (116).
Van der Waals contacts between F10 and H5 HA were calculated using
an inThouse script that applies a simplified LennardTJones potential as described
previously (94). The van der Waals contact energy was calculated for all possible
HATF10 atom pairs within 6.0 Å of each other in the structure (PDB ID: 3FKU).
Sequence conservation in group 1 HA was calculated using a previously
published sequence alignment of all fullTlength nonTredundant influenza group 1
HA sequences downloaded from the National Center for Biotechnology
Information Influenza database in August 2011 (229, 230). To determine the
percent conservation at each position in the alignment, the alignment was viewed
using the Protein Family Alignment Annotation Tool editor (PFAAT) (234).
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CHAPTER V
5 STRUCTURAL BASIS OF AN INFLUENZA HEMAGGLUTININ STEM\
DIRECTED ANTIBODY RETAINING THE G6 IDIOTYPE
5.1 Abstract
StemTtargeting broadly neutralizing antibodies (sBnAbs) against
hemagglutinin can neutralize a wide range of influenza viruses and are promising
in developing strategies for broad protection against seasonal and pandemic
infections. Many sBnAbs utilize the IGHV1;69 germline gene, and the antiT
idiotypic antibody G6 has been used to study antibodies derived from the IGHV1;
69 germline gene because G6 preferentially binds to 51p1 FTallele V segments of
these antibodies. Typical potent IGHV1;69 sBnAbs include a rearranged
germline gene with distinctive VTsegment substitutions that optimize binding to
the conserved epitope on the HA stem. However, these substitutions have been
shown to either reduce or abrogate G6 binding with only a few sBnAbs retaining
the G6 idiotype. Here we report the crystal structure of D80, a G6Tbinding sBnAb,
both alone and in complex with the antiTidiotypic Ab G6. The structures reveal
only subtle changes in the sBnAb upon binding G6, suggesting a preTorganized
binding epitope, including a preTarranged CDR3 loop stabilized by extensive piT
stacking interactions that may be key for retaining the G6 idiotype while still being
able to potently target the HA stem region.
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5.2 Introduction
Seasonal influenza is a global health problem with millions of people
infected and thousands dead due to infection every year (79). Pandemic
influenza is a major threat and has occurred in the past when a new strain
against which there is little or no immunity emerged, such as the 1918 “Spanish”
flu, 1968 “Hong Kong” flu, and more recently the 2009 swine flu. Vaccines are
the primary method of prevention against influenza. However, as a result of
antigenic drift and a high mutation rate, vaccine strains need to be updated
annually as new strains become dominant, and some years, the vaccine is not
effective because circulating strains do not match the vaccine strains. In addition,
vaccines take time to manufacture and may not be ready if a pandemic occurs
(12). Although directTacting antivirals such as neuraminidase inhibitors exist, they
are only effective if administered early during infection, and emerging drug
resistance limits their use and efficacy (5). Hence, we need improved prevention
and therapeutic strategies against influenza that are effective and broadly
protective, and understanding and applying broadly neutralizing antibodies
(BnAbs) against influenza are promising for addressing some of these needs.
Influenza A is the most prevalent type of influenza, classified by two main
glycoproteins on the surface of the virus, hemagglutinin (HA) and neuraminidase
(NA). Various combinations of 16 HA and 9 NA subtypes define the strains of
influenza A, which are further divided into two phylogenetic groups based on HA.
HA binds to sialic acid on glycoproteins on the surface of cells to initiate viral
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infection. HA also mediates fusion between the viral and endosomal membranes
during the viral life cycle. Most antibodies (Abs) isolated against influenza and
utilized in seasonal vaccines target the head region of HA, which is highly
variable among various strains and easily mutates to escape Ab neutralization.
Influenza BnAbs have been discovered that neutralize a broad spectrum of
influenza viruses, and they target highly conserved regions of HA that are
important for function, such as the stem region (sBnAbs). sBnAbs that neutralize
all group 1, all group 2, or both groups of influenza A, and even crossTreactive
against influenza B have been reported (11, 12, 58, 60T62, 64, 66, 67, 192).
Therapeutic and prophylactic studies of these sBnAbs in mouse and ferret
models are promising toward developing a “universal” therapeutic for broad
protection against all influenza viruses.
Many influenza HA sBnAbs are derived from the immunoglobulin heavy
chain variable region germline gene 1T69 (IGHV1;69) on chromosome 14 (12).
These Abs target a conserved epitope on the stem region of HA and display
robustness against neutralization escape (12). Previous studies identified distinct
VTsegment amino acid substitutions within the rearranged germline gene that are
preferentially used to enable an Ab to become a potent sBnAb (235). As few as
two VTsegment mutations including I52S in CDR2 and a critical Tyr in CDR3 are
enough for an sBnAb to mature from the IGHV1;69 germline gene and bind to
HA (235). Almost all identified IGHV1;69 sBnAbs contain a hydrophobic residue
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at position 53 and belong to the 51p1 FTallele group, which encodes a critical
Phe54 in CDR2.
IGHV1;69 germlineTderived Abs from the 51p1 allele group are specifically
and uniquely recognized by the antiTidiotypic Ab G6 (236). AntiTidiotypic
antibodies bind to the variable region of another antibody, and can be used as a
diagnostic tool to monitor expression levels of Abs they recognize or as potential
immunotherapy (237). G6 is a murine antiTidiotypic antibody that was discovered
in a screen against rheumatoid factors and has been used to study many
different targets, including rheumatoid factors, fetal splenic tissue, germinal
centers in human tonsils, and B cell receptors in patients with B cell chronic
lymphocytic leukemia (BTCLL) (236, 238T244). G6 has been used as a diagnostic
tool for monitoring expression levels of IGHV1;69 antibodies from B cells (245,
246). Although antiTidiotypic antibodies have been studied for several years,
there are only a few structures of these antibodies in complex with their targets in
the protein structure database.
Due to G6’s potential therapeutic applications, G6 has been humanized
using a structureTbased CDR grafting approach, and some of the humanized G6
antibodies, especially HuG6.3, bind as tightly or better to their targets compared
to the parental murine G6 (239). Humanized G6 could potentially be used as a
“primogen” immunogen during influenza vaccination to promote proliferation of
naive IGHV1;69 B cells and memory IGHV1;69 BnAb B cells that could then
produce sBnAbs (12). However, we found that in most cases the same
154
substitutions in the VTsegment that allow mature potent sBnAbs to evolve from
the IGHV1;69 germline gene reduce or abrogate G6 binding. We identified only a
few IGHV1;69 BnAbs that retain binding to both G6 and HA.
5.2.1 An example of a stem\directed broadly neutralizing antibody that
neutralizes influenza and binds G6
D80 is an sBnAb that neutralizes all Group 1 influenza HAs and also binds
to G6. D80 was discovered after two rounds of panning with a “nonTimmune”
human phageTdisplay antibody library against HA (194, 195). D80 can neutralize
H5N1, and shares the same heavy chain as D8, which has been shown to be
effective therapeutically and prophylactically in mice infected with influenza (194).
D8 has subnanomolar binding affinity to HA and a very slow dissociation rate. In
addition, prophylaxis with 10 mg/kg of D8 IgG one hour before lethal challenge
with H5 and H1 viruses protected 80–100% of mice from death, and treatment
with 15 mg/kg of D8 IgG 24T72 h following lethal challenge with H5 viruses also
protected 80–100% of mice from death. D8 can bind to H2, H6, and H11
pseudotyped viruses.
In this study the crystal structures of one of these unique antibodies that
retain binding to both G6 and HA, D80 Fab both alone and bound to humanized
G6 is described. Both structures were refined to around 2.5 Å resolution and
allowed detailed comparative structural analysis to identify the determinants of
the G6 idiotype. There are no major conformational differences in the CDR loops
between the bound and unbound structures of D80, suggesting a preTorganized
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binding epitope. We discovered an extensive piTstacking interaction network
mainly involving the CDR3 loop that may contribute to the tight subnanomolar
binding that we observe between D80 and G6 (239) and allow retaining the G6
idiotype while still binding to HA. Our structures provide key insights that may be
scaffolds for the design of therapeutics or vaccines that utilize BnAbs and antiT
idiotypic antibodies such as G6.
5.3 Results
5.3.1 Elucidation of the G6 Idiotype: Preferential binding to germline\like
V\segments
Previous studies that interrogated the murine G6 (mG6) binding epitope
suggested that the binding epitope is located on the CDRTH2 loop of IGHV1;69
51p1 FTallele VTsegments, G6 does not bind to IGHV1;69 Abs of the LTallele
family that are primarily defined by Leu54, and binding does not seem to be
restricted by CDRTH3 composition and light chain type (236, 238, 247). Since
these studies analyzed only a limited number of antibodies, these observations
were expanded and validated by performing 1 round of panning with a 27 billionT
member naive human scFv (single chain variable region fragment) antibody
library against beads coupled with mG6 (Figure 5.1). Immunogenetic analysis of
the pool of scFvs that were both inTframe and where the VH and VL domains
could be deciphered (n = 133) indicated that 89% of the scFvs are composed of
IGHV1;69 VTsegments and all of these belong to the 51p1 FTallele group. In
accordance with the lack of any antibody recovered in the library from the LTallele
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family, when F54 is mutated to L54, G6 binding is lost. No preferential binding is
observed to particular DTsegments, JTsegments, light chains and CDRTH3 length,
in agreement with previous reports (236). However, preferential binding was
observed to nonTmutated germline configuration VTsegments (Figure 5.1G).
Most of the antibodies included no or only one or two substitutions relative to the
germline gene, sharing more than 95% identity in amino acid sequence. Hence,
almost all antibodies deviating more than 5% with respect to the germline gene
lost the G6 idiotype.
15
Figure 5.1 The G6 idiotype is defined by the CDR2 loop of the antibody heavy chain.
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Figure 5.1 The G6 idiotype is defined by the CDR2 loop of the antibody
heavy chain. Sequencing results were analyzed from 133 bacterial colonies
from a phage display panning experiment where beads coated with G6 were
incubated with a phage display library. A) Of the 133 colonies that were
sequenced, 89% were of the antibodies were derived from the IGHV1&69
germline gene. B) All of the antibodies from the phage display experiment that
were derived from the IGHV1&69 germline gene belong to the 51p1 FJallele
group. C, D, E) G6 binding does not seem to be influenced by C) any particular
light chain, D) DJsegment, or E) JJsegment. F) G6 binding also does not seem to
be influenced by the length of the CDR3 loop. G) G6 preferentially binds to
antibodies characterized by nonJmutated VJsegments similar to the IGHV1&69
germline gene. H) D80 is an sBnAb that binds to G6, but when the mutation F54L
is introduced to resemble LJallele IGHV1&69 antibodies, binding to G6 is lost,
confirming that the G6 idiotype is located in the CDR2 loop of the antibody heavy
chain.
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5.3.2 BCR CrossBLinking: F10 antibody maturation abrogates the G6
idiotype
The ability of the bivalent G6 (IgG) to bind to BJcells bearing IGHV1&69 FJ
alleles (239) suggests that G6 can lead to crossJlinking of the BJcell receptor
(BCR), which in turn can initiate BJcell proliferation. As influenza stem targeted
broadly neutralizing antibodies are mostly composed of IGHV1&69 FJalleles
(HV1J69JsBnAbs), theoretically, G6 can serve as a primogen that would bring to
the proliferation of HV1J69JsBnAbs memory BJcells and precursor HV1J69J
sBnAbs from the naive IGHV1&69 FJallele BJcell pool.
Therefore, the ability of mG6 and humanized G6.3 (hG6.3) to crossJlink BJ
cell receptors was tested by utilizing an artificial BCR display system. In this
system, BCR crossJlinking events were monitored by using an intracellular probe
that exhibits fluorescence when calcium ions are released as a result of BCR
crossJlinking induced signal transduction events. To simulate conditions in which
mG6 and hG6.3 target BJcells bearing HV1J69JsBnAbs, B cells were designed to
display the mature F10, or F10 variants in which the VJsegment was replaced by
a nonJmutated germline configuration IGHV1&69*01 VJsegment (VH1J69/F10), or
F10 variants with 1JtoJ4 amino acid substitutions back introduced (Figure 5.2).
Both mG6 and huG6.3 were able to crossJlink the F10 variant with the germlineJ
like VJsegment, but not the mature F10. In addition, backJmutations to the
germline gene increased crossJlinking in the presence of G6, but in contrast,
decreased crossJlinking in the presence of HA. Curiously, enhancement of the
G6 idiotype mirrored the decrease in HA binding as backJsubstitutions to the
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germline gene were introduced. In addition, the mutations I52S and I53M either
increase or do not impact B cell crossJlinking in the presence of G6.
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Figure 5.2 Murine G6 and humanized G6.3 crossBlink B cell receptors that
bear the G6 idiotype.
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Figure 5.2 Murine G6 and humanized G6.3 crossBlink B cell receptors that
bear the G6 idiotype. As mutations are introduced to increase B cell crossJ
linking to HA, however, B cell crossJlinking to G6 is decreased. A) Schematics
showing the constructs of the scFvs of B cell receptors used in this experiment,
illustrating the variable regions of the mature sBnAb F10 and the IGHV1&69
germline gene V segment F10 hybrid (VH1J69/F10). VH1J69/F10 chimeras with
specific mutations are shown in different colors. B) The locations of the
introduced mutations are mapped onto the structure of the antibody VH domain
and are shown in yellow. The remaining sections of the three VH CDR loops are
shown in green. C) Back mutations to the germline gene increased crossJlinking
to G6, but in contrast, decreased crossJlinking to HA. Mutations I52S and I53M
either increase or do not impact B cell crossJlinking to G6. D) DoseJdependent
binding curves generated for the VH1J69/F10 chimeras and for the respective
isotype controls.
16
Figure 5.3 The G6 idiotype appears on select influenza stem<directed broadly neutralizing antibodies.
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Figure 5.3 The G6 idiotype appears on select influenza stem<directed
broadly neutralizing antibodies. A) Various HV1/69/sBnAbs were tested for G6
binding using ELISA or Biacore. Shown are the CDR/H1, H2, H3 amino acid
sequences as well as the amino acid germline identity mean and STDEV of the
G6 reactive and nonreactive groups. B) Converting the V/segment of the non/G6
reactive HV1/69/sBnAbs F10, CR6261 and A66 restores the G6 binding epitope.
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5.3.3 Influenza stem<directed broadly neutralizing antibody binding to G6
versus HA
The lack of mature F10 binding to G6 led us to interrogate other HV1/69/
sBnAbs binding to G6. With a panel of 11 different HV1/69/sBnAbs, whether
maturation abrogated the idiotype was tested. The G6 binding epitope was
observed to be lost on most influenza BnAbs from the IGHV1/69 germline gene.
Of 11 different HV1/69/sBnAbs, only 3 were G6 reactive (Figure 5.3). These are:
D8 (same as D80 but with a different light chain), CR6331 and 70/1F02. These
three antibodies are defined by a low V/segment amino acid substitution
frequency, and these antibodies also have smaller CDR3 loops and a CDR3 loop
motif composed of three tyrosines at positions 97, 98 and 99.
To further confirm that the mature V/segment of HV1/69/sBnAbs prevents
G6 binding, the V/segments of F10, A66, and CR6261 were replaced with the
non/mutated IGHV1&69 germline gene and binding kinetics to G6 were analyzed.
In all three cases, G6 binding was rescued in the VH1/69/F10, VH1/69/A66 and
VH1/69/CR6261 chimeras, confirming the substitutions in the V segment of these
mature sBnAbs are responsible for the loss of the G6 idiotype. As seen with F10
above, gain of G6 binding was accompanied by a loss of binding to HA, as the
chimeras did not bind to the H5VN04 HA (235).
Therefore, although G6 binds to antibodies derived from the IGHV1&69
germline gene, maturation of antibodies into influenza HV1/69/sBnAbs results in
a loss of the G6 idiotype in most cases. The substitutions in HV1/69/sBnAbs that
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optimize binding to the conserved epitope on the HA stem either reduce or
abrogate G6 binding, with only a few sBnAbs retaining the G6 idiotype.
To investigate the structure of G6 and the critical binding interactions in
one of these few cases where an influenza sBnAb binds to both HA and G6, we
solved crystal structures of one of these antibodies: D80 in complex with G6 and
D80 unbound.
5.3.4 The crystal structures of the D80 Fab fragment and the D80<HuG6.3
Fab fragment complex
The crystal structures of the D80 Fab apo and bound to the HuG6.3 Fab were
solved. The D80 Fab fragment was solved at 2.7 Å resolution in a P 21 21 21
space group with 2 molecules in the asymmetric unit. The D80 Fab fragment
bound to the HuG6.3 Fab fragment was solved at 2.53 Å resolution in a C 1 2 1
space group with 1 molecule in the asymmetric unit (Table 5.1).
An overview of these structures is shown in Figure 5.4. The angle of
binding between the two Fabs is 149 degrees. The elbow angle, which is the
pseudo/dyad angle between the variable and constant domains, is 174 and 176
degrees in each asymmetric unit of the D80 apo structure. In the D80 bound
structure, the angle is 173 degrees, which is similar to the unliganded structure,
and in the G6 structure, this angle is 172 degrees. These elbow angles are
consistent with results for Fabs with kappa light chains and for unliganded versus
liganded forms of Fabs (248).
167
No major structural differences in the CDR loops were observed between
the bound and unbound structures of the D80 Fab, suggesting a pre/organized
binding epitope. To quantitatively measure the differences between the bound
and unbound structures of D80, the distances were calculated between all of the
alpha carbon atoms within each structure, the differences of these distances
between the bound and unbound structures were computed. These differences
were then graphed onto a contour plot, and the average differences were
mapped onto the structure as previously described (Figure 5.5) (249). This
method reduces bias that can be introduced by comparing structures using a
structural alignment. The distance difference plots highlight regions of differences
between bound and unbound structures of D80. (This calculation was performed
only for the heavy chain of D80 because the light chain makes peripheral weak
contacts with G6` discussed below). When looking at the VH domain of D80 in
both the bound and unbound structures, the most structural differences were
seen in the CDR1 loop, whereas the CDR2 and CDR3 loops had only a few
regions of ~ 2 Å difference displacement. There are also small differences
between the CH1 domains of the bound and unbound structures. In the
comparison of the two domains VH and CH1 relative to each other in the bound
and unbound structures (top left and bottom right of Figure 5.5A), there are
some differences that propagated throughout the plots because the angles
between the VH and CH1 domains are slightly different between the two
domains.
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Table 5.1 Crystallographic statistics for the D80<G6 complex crystal
structure and D80 unbound crystal structure.
Tab e 5.1: Data Co ect on and Ref nement Stat st cs
Structure D80 Fab Fragment D80 G6 Fab Fragment Comp ex
PDB Code 5JQD 5JO4
Reso ut on Range 46.12 2.59 (2.68 2.59) 49.61 2.53 (2.62 2.53)
Space Group P 21 21 21 C 1 2 1
Un t Ce 89.06 91.58 106.76 90 90 90 143.16 50.78 139.74 90 90.9 90
Tota Ref ect ons 132762 (9946) 148763 (14956)
Un que Ref ect ons 26405 (2602) 33988 (3370)
Mu t p c ty 5.0 (3.8) 4.4 (4.4)
Comp eteness (%) 0.95 (0.95) 0.97 (1.00)
Mean I/S gma (I) 11.16 (2.42) 14.35 (1.99)
W son B Factor 46.81 39.51
R merge 0.09 (0.52) 0.08 (0.81)
R meas 0.10 (0.61) 0.10 (0.92)
CC1/2 0.996 (0.746) 0.998 (0.718)
CC* 0.999 (0.925) 0.999 (0.914)
Ref ect ons Used n Ref nement 26404 (2602) 33148 (3110)
Ref ect ons Used for R Free 1273 (127) 1968 (192)
R work 0.2152 (0.2891) 0.1966 (0.2766)
R free 0.2438 (0.2981) 0.2478 (0.3480)
CC(work) 0.93 (0.75) 0.95 (0.83)
CC(free) 0.96 (0.69) 0.91 (0.65)
Number of Non Hydrogen Atoms 6431 6757
Macromo ecu es 6338 6530
L gands 0 5
Prote n Res dues 851 866
RMS(Bonds) 0.005 0.010
RMS(Ang es) 0.76 1.36
Ramachandran Favored (%) 97 91
Ramachandran A owed (%) 3.2 7
Ramachandran Out ers (%) 0.24 1.8
Rotamer Out ers (%) 3.5 5.3
C ash score 7.11 10.23
Average B Factor 48.57 56.05
Macromo ecu es 48.70 56.48
L gands N/A 63.23
So vent 40.05 43.21
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Figure 5.4 Crystal structures of a stem<directed broadly neutralizing
antibody that bears the G6 idiotype: D80 in complex with G6.
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Figure 5.4 Crystal structures of a stem<directed broadly neutralizing
antibody that bears the G6 idiotype: D80 in complex with G6. A) Overview of
the crystal structure of the D80 Fab fragment bound to the HuG6.3 Fab fragment.
Each immunological domain on the Fab is labeled. D80 is in light green and G6
is in purple. The elbow angles in the G6 and D80 structures are 172 and 173
degrees, respectively. B) The binding angle between the two Fab fragments is
149 degrees. C) Overview of the crystal structure of the unbound D80 Fab
fragment is shown in dark green. One molecule from the asymmetric unit is
shown. The elbow angle is 174 and 176 degrees in each molecule of the
asymmetric unit, respectively.
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Figure 5.5 The bound and unbound structures of the D80 Fab fragment
do not show significant differences.
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Figure 5.5 The bound and unbound structures of the D80 Fab fragment
do not show significant differences. A) A double difference plot of the heavy
chain alpha carbons of the D80 fragment was calculated between the bound and
unbound structures of D80. The areas on the plot that represent the three CDR
loops in the VH domain of D80 are in boxes. B) A structural alignment of the
bound VH domain of D80 (in dark green) and the unbound VH domain of D80 (in
light green). C) The average double difference values for each residue were
mapped onto the unbound structure of D80 and colored on a rainbow scale,
where the greatest differences are shown in red and the least differences are
shown in dark blue.
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5.3.5 Intermolecular binding interface
Van der Waals contact energies of the residues participating in the binding
interaction were calculated using a simplified Lennard/Jones potential and
mapped onto the structures of D80 and G6 (Figure 5.6) (94). The two Fabs
interact with each other through their variable domains, and the CDR loops of the
VH region of the D80 Fab directly interact with their complementary CDR loops in
the VH and VL domains of the G6 Fab. The VL region of D80 has only
peripheral contacts with the G6 Fab. The heavy chain variable region of D80 is
most important for binding, and CDRs 2 and 3 make the greatest contact with
G6, especially residues M53, F54, G55, T56, N58 in CDR2 and Y98 and Y99 in
CDR3. These residues insert into a pocket formed by the CDR loops of the
heavy and variable chain regions of G6. The residues on G6 that make the most
contact with D80 include Y99H and W31H from the heavy chain of G6, and F94L,
Y91L, and N32L from the light chain of G6. The pocket in G6 is not entirely filled
by D80, but could play a role in the diversity of antibody binding to G6. Using the
POVME pocket volume analyzer (250, 251), the pocket was analyzed, and there
is a remaining pocket volume of 32 Å3 (Figure 5.7). In general, water molecules
cannot be visualized reliably at ~ 3.0 Å resolution, and the complex structure was
solved at 2.52 Å resolution. However, we did see 1/2 waters buried in the
interface between D80 and G6. In addition, hydrophobic residues and protein
backbone atoms line this pocket. G6 binds to a large family of antibodies that are
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derived from the 51p1 alleles of the IGHV1&69 germline gene, so this pocket may
be important for accommodating these different antibodies.
In addition to van der Waals interactions, hydrogen bonding and pi/
stacking interactions were analyzed in the interface between D80 and HuG6.3
(Figure 5.8). In CDR1 of D80, hydrogen bonds exist between the side chain
atoms of T28, S30, and Y32 with W31H and D55H of G6 (Figure 5.8A). In CDR2
of D80, more extensive hydrogen bond interactions exist between side chain
atoms of T52, T56, and N58 of D80 with N32L, S92L, and Q93L of G6. Y99H of G6
is also involved in a pi/stacking interaction with the backbone carbon of G55 in
D80 (Figure 5.8B). In CDR3, there are no direct intermolecular hydrogen bond
interactions, but van der Waals packing interactions with F94L and Q93L were
observed (Figure 5.8C). In addition, an extensive pi stacking interaction network
exists that involves the CDR2 and CDR3 loops of D80 with F94L and W31H in the
pocket of G6, which are also residues in G6 that are involved in extensive van
der Waals contacts with D80 (Figure 5.8D). This pi/stacking interaction network
is conserved between the unbound and bound structures of D80, and may
contribute to the tight subnanomolar binding that observed between D80 and G6
(239).
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Figure 5.6 Overview of the binding epitopes and intermolecular
interactions between D80 and G6.
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Figure 5.6 Overview of the binding epitopes and intermolecular
interactions between D80 and G6. A) Overview of the D80/G6 complex crystal
structure shown in surface representation. The D80 Fab fragment is in light
green, and the G6 Fab fragment is in purple. B) The D80/G6 complex crystal
structure splayed open to view the residues in the binding site that interact with
each other. The residues in the binding site are colored on a rainbow scale by
the Van der Waals energy contacts, where residues with the greatest contacts
are shown in red and the least contacts are shown in dark blue. The VH of D80 is
shown in green and the variable region of G6 is shown in purple. The constant
domains are shown in gray. C) A zoomed in view of the splayed open structure of
G6 with interaction residues labeled, and E) a histogram of the per residue van
der Waals contact energies for G6. D) A zoomed in view of the splayed open
structure of D80 with interaction residues and CDR loops labeled, and F) a
histogram of the per residue van der Waals contact energies for D80.
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Figure 5.7 Characterizing the pocket in the binding site of G6.
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Figure 5.7 Characterizing the pocket in the binding site of G6. A) The
pocket within the binding site of G6 that remains upon binding D80 is shown in
orange with G6 shown in purple and D80 shown in light green. B) The residues
that line the pocket in G6 are shown in purple and the pocket is shown in orange.
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Figure 5.8 Hydrogen bond and pi<stacking interactions between D80 and
G6.
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Figure 5.8 Hydrogen bond and pi<stacking interactions between D80 and
G6. A) Hydrogen bonding interactions between the CDR1 loop of D80 (shown in
green sticks) and G6 (shown in purple). B) Main figure: Hydrogen bonding
interactions between the CDR2 loop of D80 (shown in green sticks) and G6
(shown in purple). B) Left inset figure: Y99H of G6 is involved in a pi/stacking
interaction with the backbone carbon of G55 in D80. C) Hydrogen bonding
interactions between the CDR3 loop of D80 (shown in green sticks) and G6
(shown in purple). D) An extensive pi/stacking interaction network that involves
the CDR2 and CDR3 loops of D80 (shown in green sticks) and F94L and W31H of
G6 (shown in purple sticks).
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5.4 Discussion
The crystal structure of D80 bound to G6 highlights some structural
features that may be required for an sBnAb to bind to both G6 and HA. In
addition to D80, the sBnAbs 70/1F02 and CR6331 also bind to both G6 and HA.
One feature that these three Abs have in common is that they all have shorter
CDR3 loops compared to the other eight sBnAbs that were tested for binding to
G6. Hence, a long CDR3 loop may preclude binding to G6. In addition, these Abs
have a triple tyrosine motif in the CDR3 loop, and the CDR2 loop contains
flexible residues such as alanine and glycine in positions 52a and 57, whereas
many other Abs that do not bind G6 contain proline at these positions. The triple
tyrosine motif in D80 is involved in an extensive pi/stacking interaction network
that may pre/organize the binding epitope and promote tight binding to G6 and
HA, and related tyrosine pi/stacking interactions may also be involved in 70/1F02
and CR6331 binding to both G6 and HA.
The IGHV1&69 germline gene encodes two hydrophobic residues on
CDR2 that are important for binding to hydrophobic pockets, such as the stem
region on HA and the pocket in G6, and residue F54 has also been shown to be
critical for binding to G6 (236). As sBnAbs mature and accumulate mutations, the
CDR2 loops often acquire prolines or other rigid residues, which may abrogate
binding to G6.
Theoretically, G6 could be used as a “primogen” immunogen during
influenza vaccination to promote proliferation of naïve IGHV1&69 B cells and
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memory IGHV1&69 sBnAb B cells that could then produce sBnAbs (12). sBnAbs
are not often elicited naturally in humans because the globular head of HA is
immunodominant, even though stem epitopes have been shown to be accessible
to sBnAbs (194, 235, 252/254). The germline precursors of IGHV1&69 sBnAbs,
such as CR6261 (which does not bind G6 as the mature antibody), do not bind
soluble HA but do engage HA when the antibody is expressed as a cell surface
IgM and trigger B/cell receptor associated tyrosine kinase signaling (12, 255). G6
could play a role as a potential substrate for affinity maturation of IGHV1&69 B
cells and promote proliferation of germline precursors of IGHV1&69 B cells that
could then mature and produce sBnAbs (255). G6 may also help to G6 binds
best to IGHV1&69 antibodies that are in the germline configuration.
Some other strategies that have been used to develop therapeutics with
sBnAbs include priming with a DNA vaccine followed by boosting with a seasonal
vaccine and the development of “headless” HA immunogens that have been
designed to promote an antibody response to the HA stem (12, 256/261). There
is a report of a successful anti/idiotypic antibody vaccine that was developed in
cats for feline infectious peritonitis virus (262). In that case, the anti/idiotypic
antibody was used as an “image” of the antigen that could induce immune/
mediated responses similar to those produced by the original antigen, and anti/
idiotypic antibodies have also been used in the development of other vaccines
(262/265).
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In conclusion, we elucidated the determinants of the G6 idiotype and
solved the crystal structure of D80, a G6/binding sBnAb, both alone and in
complex with the anti/idiotypic Ab G6. This work provides key insights that may
guide the design of future therapeutics or vaccines that utilize BnAbs and anti/
idiotypic antibodies such as G6.
5.5 Methods
5.5.1 Panning the naïve human scFv<phagemid library against beads
coupled with G6
Magnetic M/280 Tosylactivated dynabeads were coupled with an isotype
control mouse Ab and with mG6 according to the manufacturer’s protocol. The
phagemid library mixture was subtracted of non/specific and mouse/IgG binders
by performing two rounds of subtractions with the isotype control beads after
which the phagemid suspension was added to G6 coupled beads. Following six
washes with TBS/Tween/20, the phagemids were eluted with 100 mM of TEA
and neutralized with PBS. The eluted phagemid suspension was used to infect
TG1 cells from which single clones were send to sequencing.
5.5.2 B cell cross<linking assay and binding kinetics assay
B cell receptor cross/linking assays were performed as described in the
study of Andrew McGuire, et al (266). Biacore assays were performed using CM5
chips that were immobilized with anti/mouse Ab according to manufacturer’s
protocol. G6 was captured at a level of ~320 RUs and scFvs or IgG were flowed
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over the chip. The single cycle kinetics function was employed with association
set for 120 sec and dissociation for 800 sec.
5.5.3 Protein expression, purification, and crystallization
For crystallographic purposes, Fab fragments were expressed in insect
cells using a baculovirus expression system. Fab fragments were purified using a
polyhistidine tag with nickel/affinity chromatography and subsequent size
exclusion chromatography. For unbound D80 crystallization, the D80 Fab
fragment crystals were grown at 20 degrees Celsius by hanging/drop vapor
diffusion in a solution using 20% PEG 4000, 0.2 M CaCl2, and 0.1 M Tris pH 8.4.
D80 crystallized in a P 21 21 21 space group with 2 molecules in the asymmetric
unit and unit cell dimensions of a = 89.0, b = 91.6, and c = 106.8 Å. For D80/G6
complex crystallization, the D80/G6 Fab fragment complex crystals were grown
at 20 degrees Celsius by hanging/drop vapor diffusion in a solution using 0.1 M
NH4SO4 and 12% PEG 3350. The D80/G6 complex was crystallized in a C 1 2 1
space group with 1 molecule in the asymmetric unit and unit cell dimensions of a
= 143.2, b = 50.8, and c = 139.7 Å.
5.5.4 Diffraction data collection and structure solution
Diffraction data was collected at cryogenic temperatures using
synchrotron radiation at the GM/CA/CAT 23/ID/B beam line at the Argonne
National Laboratory (Advanced Photon Source, Chicago, IL). Data was indexed
and scaled using xia2 and HKL3000 (267/273). Molecular replacement solutions
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were determined using M/RAGE in PHENIX (274, 275). Cycles of rigid body,
restrained, and TLS refinement with subsequent model building were performed
using phenix.refine in PHENIX and Coot, respectively (274, 276).
5.5.5 Structural data analysis
Molecular graphics images and elbow angles were calculated using
PyMOL (116). Double difference plot calculations and van der Waals calculations
were performed using in house scripts as described previously (94, 249). Pocket
volume analysis was performed using the POVME pocket volume analysis tool
(250, 251). Hydrogen bonds were detected using the PyMOL polar contacts tool,
where h bond cutoff center was set to 3.6 Å and h bond cutoff edge was set
to 3.2 Å (116). Pi/stacking interactions or pi/atom interactions were detected in
Maestro and defined using the default values as follows: A face/to/face pi
stacking interaction is defined as an angle between ring planes of less than 30
degrees and a distance between ring centroids of less than 4.4 Å. An edge/to/
face pi stacking interaction is defined as an angle between ring planes that is
between 60 and 120 degrees, and a distance between ring centroids that is less
than 5.5 Å (108). A pi/atom interaction is defined as a distance between an atom
and a ring centroid of less than 6.6 Å, and the angle between the ring plane and
the line between the cation center and the ring centroid does not deviate from the
perpendicular by more than 30 degrees.
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CHAPTER 6
6 DISCUSSION
6.1 Impact of uncertainty in coordinates on molecular dynamics
simulation analysis
One concern with the molecular dynamics simulations examined in this
thesis is that the precision of the simulations has not been addressed, specifically
how the uncertainty in the crystal structure coordinates relates to the precision of
the quantities calculated from the simulations. To begin to address this concern,
Table 6.1 presents some known parameters from the simulations that can
provide initial insight into this uncertainty, including some crystallographic
statistics from the starting models and the correlation of the average alpha
carbon root mean squared fluctuation (RMSF) from the simulations to the
average alpha carbon temperature factors from the crystal structures.
Figure 2.2 also shows how the average RMSF and average
crystallographic temperature factors compare in both the N1 and N2 NA
molecular dynamics simulations. An important question for the energies
calculated from molecular dynamics trajectories is what energy differences would
be considered significant, how would this significance be determined, and do
energies calculated from the observed structural differences taking into account
the expected coordinate uncertainty exceed this value in a significant way. For
this thesis, the van der Waals energy calculation was performed every 200
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picoseconds and averaged over 400 nanoseconds. To calculate the standard
error of the average for each residue in each simulation, the data was “chunked”
using block averaging and significant differences were calculated. Increasing the
sampling of the calculation from 200 picoseconds to every 10 picoseconds would
also further validate these calculations. However, these calculations do not
specifically address how the coordinate uncertainty in one static crystal structure
would impact the van der Waals energy calculation and how this error might be
propagated throughout a molecular dynamics simulation. Thoroughly addressing
this specific question especially for the van der Waals energy calculation would
be important for validating this work and also validating future and past work that
examines differences in van der Waals energy calculations from molecular
dynamics simulations.
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Table 6.1 Starting crystal structures for molecular dynamics simulations
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6.2 Assessing equilibration of molecular dynamics simulations
Additional concerns about the molecular dynamics simulations examined
in this thesis are concerns that the simulations are equilibrated and that
quantities calculated from the trajectories should be calculated from the
equilibrated aspects of the trajectory only. Traditionally, equilibration is based on
the convergence of a root mean squared deviation (RMSD) plot that is visually
inspected, and equilibration is determined intuitively, but this method is subjective
and controversial (277). To begin to address the concern of equilibration in the
molecular dynamics simulations examined in this thesis, the total potential
energy during each simulation was graphed for all simulations in Figures 6.1 and
6.2 to show that the total potential energy of each system is equilibrated over
time. In addition, Figure 6.3 shows the overall RMSD of each chain from each
trajectory over the course of the simulation. The overall RMSD is approximately 1
Å for each chain.
The total potential energy for all systems remains constant throughout the
simulation, and based on the current RMSD plots, aside from Figure 6.3A and
6.3B, most of the plots demonstrate a relatively low overall RMSD around 1 Å
that remains relatively constant, so this information provides initial insight into
how the simulations are behaving. To further evaluate and confirm that the
system has equilibrated, especially for the simulations analyzed in Figure 6.3A
and 6.3B, it would be important to investigate what portions of the protein are
influencing the increase in RMSD from 1 to 1.5 Å and confirm that these regions
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of the protein would not have an impact on the results presented in the thesis. In
addition, recalculating the values presented in the thesis by using only
equilibrated portions of the trajectory instead of the full trajectories and examining
how each van der Waals energy for each residue varies over the course of each
trajectory would provide further validation, but we do not anticipate that these
additional calculations would impact the final results.
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Figure 6.1 Potential Energy Over the Trajectory for N1 NA Molecular
Dynamics Simulations.
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Figure 6.1 Potential Energy Over the Trajectory for N1 NA Molecular
Dynamics Simulations.
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Figure 6.2 Potential Energy Over the Trajectory for N2 NA Molecular
Dynamics Simulations.
TO abbreviation = Truncated Octahedron (shape of water box)
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Figure 6.2 Potential Energy Over the Trajectory for N2 NA Molecular
Dynamics Simulations.
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Figure 6.3 Per Chain Root Mean Squared Deviation for Molecular
Dynamics Simulations.
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Figure 6.3 Per Chain Root Mean Squared Deviation for Molecular
Dynamics Simulations.
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6.3 Dynamic substrate envelopes compared to static substrate
envelopes
Another question about the dynamic substrate envelope is whether
dynamic substrate envelopes are better than static substrate envelopes for NA.
Previous work by Ozen, et al has shown that the dynamic substrate envelope
was better than that static substrate envelope for HIV protease and HCV NS3/4A
protease (94, 95). Local and global dynamics are important for function for many
enzymes, so incorporating additional information from protein dynamics can
provide a more accurate representation of the volume occupied by the substrate
in the active site. However, in both HIV protease and HCV NS3/4A protease, the
dynamic substrate envelope reflects many of the same characteristics of the
static substrate envelope, and we expect that this pattern would be maintained
with NA. However, the static substrate envelope represents a step/function like
assessment of interactions in the active site whereas the dynamic substrate
envelope represents a probabilistic distribution function, which inherently
contains more information. However, to thoroughly confirm that the dynamic
substrate envelope reflects many of the essential characteristics of the static
substrate envelope, the static substrate envelopes for each system can be
determined quantitatively to compare interactions directly with the results from
the dynamic substrate envelopes.
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6.4 Generalization of N1 and N2 NA sequences examined in molecular
dynamics simulations compared to all N1 and N2 NA sequences.
The sequences in the crystal structures of N1 and N2 that were examined
in this study are representative of N1 and N2 sequences in general. We chose
prototypic N1 and N2 sequences for this study based on three criteria: 1)
existence of high quality high resolution crystal structures for MD simulations 2)
presence of a “typical” 150/loop in the active site based on previous reports for
N1 and N2, and 3) high percent identity to N1 and N2 consensus sequences
based on multiple sequence alignments (72, 106). All of the crystal structures
used in this study are of the globular head domain. Alignments were performed
using the multiple sequence alignment tools available on the Influenza Research
Database (www.fludb.org) and accessed on February 18, 2016. The strain of N2
NA used is A/Tanzania/205/2010 H3N2 NA. This strain has 94% sequence
identity and 96% sequence similarity to a consensus sequence determined from
an alignment of 8,745 complete and unique sequences. The strain of N1 NA
used is A/Brevig Mission/1/1918 H1N1 NA. This strain has 92% sequence
identity and 96% sequence similarity to a consensus sequence determined from
an alignment of 7,370 complete and unique N1 NA sequences. The high
sequence similarity and identity of the crystal structures compared to the
consensus sequence from the multiple sequence alignments shows that the
crystal structures examined in the study are representative of N1 and N2
sequences in general.
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6.5 Role of electrostatics in analysis of drug resistance residues in
influenza neuraminidase
To strengthen the analysis of the molecular dynamics simulations of
influenza neuraminidase, the role of electrostatics for the drug resistance
residues that were examined should be determined. The key questions to answer
are whether charge/charge interactions might play a role in differential binding of
substrates (typically uncharged) versus inhibitors (typically charged). To address
this concern more quantitatively, the Coulombic contribution to interaction
energies can be calculated using pre/existing tools available from Schrodinger
that were developed to analyze Desmond trajectories, including the Simulation
Interaction Analysis tool and additional analysis scripts. Using these tools, the
Coulombic contribution to interaction energies can be directly compared to van
der Waals interaction energies, and both quantities can be calculated using the
same tools. The Salt Bridges Plugin in VMD can also be used to identify salt
bridges that occur over the course of a trajectory and measure the duration of the
interactions.
Electrostatics play an important role in the high binding affinity of
neuraminidase inhibitors compared to substrates (278, 279). Von Itzstein, et al
used structure based drug design to develop the neuraminidase inhibitor
zanamivir, and they discovered that there is a negatively charged pocket in the
neuraminidase active site lined by residue E119, which is one of the drug
resistance residues discussed in this study (278). The binding affinity of the
transition state analog of sialic acid, DANA (2,3/didehydro/2/deoxy/N/
200
acetylneuraminic acid), to neuraminidase is 4 μM, but when the C4 hydroxyl on
DANA was replaced with an amine, they discovered the binding affinity improved
to 0.04 μM. When this moiety was replaced with guanidinium, the binding affinity
improved to between 0.08/0.7 nM (278, 279). Crystal structures of these
inhibitors were solved in complex with influenza A/Tokyo/3/67 neuraminidase,
and they showed that the amine forms a salt bridge with E119, and one of the
terminal nitrogen atoms on the guanidinium is 3.5 Å from the side chain
carboxylate of E119 and likely also within the electrostatic influence of E119
(278). Furthermore, E119 does not form these interactions with sialic acid, which
was also noted previously by von Itzstein, et al (278). To address electrostatics in
the analysis described in this study of comparing substrate and inhibitor
interactions in both N1 and N2 subtypes, the electrostatic contribution to
interactions should be analyzed more quantitatively and compared to the
calculated van der Waals interactions to address the contribution of both van der
Waals and Coulombic energy to the differences in molecular interactions seen
between substrates and inhibitors in N1 and N2 neuraminidase.
6.6 Incorporating the substrate envelope hypothesis and protein
dynamics into drug design
Clinically, a common strategy for treating diseases and decreasing
susceptibility to drug resistance is to use combination drug therapy to create a
high genetic barrier to the development of resistance. With this strategy, different
drugs inhibit distinct targets simultaneously, decreasing the likelihood of (both or)
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all targets evolving to select resistance mutations at the same time. However,
developing individual drugs to avoid drug resistance is still important so that
robust drugs are available when needed. Drug development can take over 12
years and cost over $300 million dollars to bring a single drug from the research
laboratory to a patient, so investing effort to design drugs that are less
susceptible to drug resistance from the beginning can be very valuable (280).
Currently, there are clinical situations where some diseases have become
refractory to nearly all treatments as a result of drug resistance mutations, such
as carbapenem/resistant enterobacteriaceae (CRE) and vancomycin resistant
enterococcus (VRE), which have become resistant to “drugs of last resort” (281,
282).
Structure based drug design (SBDD) should incorporate strategies for
reducing susceptibility to drug resistance, such as the substrate envelope
hypothesis. In addition, while current SBDD incorporates ligand flexibility,
aspects of target flexibility are not as well integrated. A common strategy in
SBDD is to design relatively rigid ligands with increased van der Waals contacts
and hydrogen bonds in the binding site, which was used in the design of HIV
protease inhibitors, but these conformationally constrained ligands may not be
able to adapt to drug resistance mutations and dynamic changes in the binding
site (46). Including aspects of protein dynamics and the substrate envelope
hypothesis into SBDD would support the development of more effective and
robust drugs that are less susceptible to drug resistance (283/285).
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Some general principles for SBDD have been developed based on
lessons learned through evaluation of the substrate envelope hypothesis in HIV/1
and HCV proteases and the results presented in this thesis on influenza NA (43,
44, 46, 176, 286). To minimize susceptibility to drug resistance, drugs should be
designed to remain within the substrate envelope and refrain from making
extensive contacts with residues outside of the substrate envelope that are not
important for substrate binding. In addition, taking advantage of unused regions
of the substrate envelope to increase inhibitor contacts can improve potency. It
may be necessary for a drug to protrude from the substrate envelope to improve
the pharmacokinetic properties of a drug or to facilitate chemical synthesis. If a
drug must protrude outside of the substrate envelope, the protrusions should be
either in the direction of solvent or evolutionarily conserved residues if possible,
such as catalytic residues or structural framework residues, to reduce the
potential for the development of drug resistance mutations.
Inhibitors are often designed to form multiple intermolecular hydrogen
bonds to increase potency, and these hydrogen bonds should also be optimized
to target evolutionarily conserved residues (46, 176, 286). To minimize
susceptibility to drug resistance mutations, inhibitors can be designed to
establish hydrogen bonds with backbone atoms, since these hydrogen bonds
may be impacted less by mutations compared to hydrogen bonds with side chain
atoms. Inhibitors can also be designed to fill interactions that are made by
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conserved water molecules that form hydrogen bonds with conserved side chain
or backbone atoms in the binding site (176).
In addition, inhibitors should be designed to maintain a balance between
flexibility and potency (46, 176, 286). Natural substrates are often more flexible
than inhibitors, which can allow them to accommodate changes in the active site,
such as drug resistance mutations or changes due to different protein
conformations. Inhibitors that mimic the flexibility of natural substrates may
decrease the susceptibility to drug resistance, but inhibitors that are too flexible
may not be very potent, so a balance between inhibitor flexibility and potency
must be maintained. For example, in influenza NA, the glycerol moiety on
zanamivir matches the flexibility of the glycerol moiety on sialic acid, and
zanamivir is not susceptible to drug resistance mutations at this location.
However, oseltamivir has a pentyl/ether hydrophobic group at this location, and it
is highly susceptible to the drug resistance mutation H274Y at this location. In
HCV protease inhibitors, macrocycles, which are chains of carbons that join two
distant moieties in an inhibitor together, can also be used to position inhibitors in
an optimal conformation in the active site to enhance inhibitor potency while also
allowing the inhibitor enough flexibility to accommodate drug resistance
mutations (176, 287).
Protein dynamics can be incorporated into dynamic substrate envelopes
for drug targets, which would provide additional guidance for developing drugs
that are less affected by drug resistance (46). These calculations are a
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systematic way of providing insight into the flexibility of substrates and the
conformations of drug targets that are most prevalent and accessible to
inhibitors. This analysis provides a more accurate representation of the substrate
envelope compared to static crystal structures because it defines a probabilistic
consensus volume distribution of which portions of the binding site are most
occupied. This volume distribution can be compared to the volume distribution of
inhibitors inside and outside of the dynamic substrate envelope and also the
volume remaining in the envelope. These volumes can then be optimized to
mimic natural substrates and minimize unnecessary protrusions from the
dynamic substrate envelope (46).
6.7 Understanding additional drug resistance mutations in influenza
neuraminidase N1 and N2 subtypes
In influenza NA, dynamic substrate envelopes explain different patterns of
drug resistance in N1 and N2 subtypes for residues that directly contact inhibitors
in the active site, such as E119 in N2 and I222 and S246 in N1. In addition,
dynamic substrate envelopes provide insight into the main drug resistance
mutation H274Y in N1 because this residue is directly in contact with E276 in the
active site, which is makes van der Waals contacts specifically with oseltamivir.
Results from these MD simulations show how many of the residues in the active
site that are correlated with reduced susceptibility to NA inhibitors are more
important for inhibitor binding compared to substrate binding. However, the
substrate envelope hypothesis is not as effective for explaining mechanisms of
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drug resistance for mutations that are not directly in the active site, multiple drug
resistant variants, secondary permissive mutations, and mutations that involve
changes in electrostatic interactions.
For instance, R292K is a drug resistance mutation in N2 that affects
zanamivir, oseltamivir, and peramivir. This residue is important for both inhibitor
and substrate contacts, and the currently understood mechanism of resistance is
that R292K prevents rotation of residue E276, which leads to drug resistance in
N2 (84). However, E276 seems to be important for both substrate and inhibitor
binding in N2, and interactions with E276 are not specific for oseltamivir unlike in
the N1 subtype. In addition, both inhibitors and substrates form hydrogen bonds
with R292 in N2. Understanding the drug resistance mechanism of this residue
and other more complex drug resistance mutations would require more in depth
study, including molecular dynamics simulations of NA drug resistant variants to
understand how the effects of specific mutations are propagated to the active
site.
The existing crystal structures of NA are of the globular head domain, but
the full neuraminidase enzyme consists of a cytoplasmic N/terminal tail, a
transmembrane domain of approximately 30 amino acids, and a protein stalk
connecting the transmembrane and globular head domains, which has
approximately 40 amino acids. These domains of the enzyme have not yet been
visualized at atomic resolution, but at least one drug resistance mutation has
occurred in the stalk region, N70S in N1 (84). Although the globular head domain
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is still active without the transmembrane or stalk domains, mutations in these
domains, such as N70S, have been shown to impact NA activity and cause
resistance. The globular head domain has also coevolved with the
transmembrane domain (288). Therefore, further investigation into the structures
of these domains in NA are needed to have a complete understanding of NA and
how mutations in these additional domains may impact substrate cleavage,
inhibitor binding, and the development of drug resistance mutations.
6.8 Understanding molecular recognition and antibody neutralization
escape in influenza broadly neutralizing antibodies
Broadly neutralizing antibodies (BnAbs) against influenza have invigorated
the influenza field with their potential to develop into universal therapies and
vaccines that are protective against a broad spectrum of strains and subtypes
(12). However, antibody neutralization escape mutations have emerged, and
increasing our understanding of molecular recognition and the development of
resistance mutations in these BnAbs is important for designing antibodies with
reduced susceptibility to resistance. For instance, antibody neutralization escape
mutations in stem directed BnAbs have emerged directly in the binding epitope
and have been reported for C179, CR8020, and CR6261 (12, 58, 61, 64/67).
Through our investigation of influenza evolution during viral passaging
experiments in the presence of F10 as a selective pressure, we discovered that
antibody neutralization escape mutations can occur outside of the binding
epitope in locations that may shift the protein dynamics of HA and impact the
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conformational changes in HA that occur during fusion. While several structural
studies have been reported of BnAbs alone and in complex with HA (11, 12, 58,
60/62, 192), few studies have characterized antibody resistant HA variants.
Further investigations are also needed to understand mechanisms of resistance
at a molecular level, including both direct mechanisms, which occur at the
binding epitope, and indirect mechanisms, which occur outside of the binding
epitope.
In addition to using x/ray crystallography to study structures of BnAbs in
complex with HA, cryo/electron microscopy (cryo/EM) is a technique that is
gaining popularity and would also be useful in studying these structures. The
main advantage of cryo/EM is that a molecule or system of interest does not
need to be crystallized, but some limitations of cryo/EM are that systems need to
be at least ~200 kDa or greater in size, and visualizing structures at resolutions
approaching 2 Å, which is required for drug design, have only recently been
accomplished (289). However, the size of HA in complex with 3 Fab fragments is
approximately 330 kDa, and negative/stain EM has been used to study HA in
complex with Fab fragments, so cryo/EM should be beneficial in the future in
conjunction with x/ray crystallography (290).
Stem/directed BnAbs all bind to the conserved stem region of HA but in
slightly different regions, and consequently these BnAbs have slightly different
binding epitopes and neutralization profiles. Increasing our understanding of the
different binding epitopes of BnAbs on the stem of HA, such as which residues
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are most important for binding in each epitope, which residues are most
conserved, where resistance mutations are most likely to develop, and how
different resistance mutations would impact antibody binding, would be beneficial
for engineering antibodies that are less susceptible to resistance and also are as
broadly neutralizing as possible.
For instance, both F10 and D80 neutralize group 1 HA, but they are not
effective in neutralizing group 2 HA or influenza B HA. However, antibodies have
been discovered that are more broadly neutralizing. FI6v3 is a universal influenza
A antibody, CR8033 and CR8071 are both universal influenza B antibodies, and
CR9114 neutralizes all influenza A and B HA (11, 12, 291). Like in D80 and F10,
the heavy chain of CR9114 is derived from the VH1/69 germline gene, and
CR9114 likely shares a similar epitope to F10 and CR6261, but subtle
differences in the binding site on HA compared to D80 and F10 allow CR9114 to
also bind influenza A group 2 HA and influenza B HA (11, 12). Increased
flexibility in the CDR2 of the heavy chain allows CR9114 to accommodate
differences in binding epitopes between group 1 HA and other HAs. Although
CR9114 has been well studied, there are only three high/resolution structures of
CR9114 in complex with HA. To have a better understanding of molecular
recognition in CR9114 and other BnAbs and to identify potential resistance
mutations, x/ray crystallography or cryo/EM should be attempted to determine
additional structures of BnAbs in complex with different HA variants and potential
antibody resistant variants. If resistance mutations develop, these structures
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would inform the design of better antibodies that neutralize all influenza HA while
avoiding resistance. Targeting regions that are evolutionarily conserved and
important for function in HA may prevent resistance, but we have shown that
escape mutations can still emerge in conserved regions of HA. In addition, we
have shown that protein dynamics can play an important role in mechanisms of
escape. Incorporating this knowledge into future antibody design may be
challenging.
6.9 Impact of crystal contacts on D80 Fab fragment antigen binding site.
There are two molecules in the asymmetric unit for the D80 Fab fragment
crystal structure, and on examination, the crystal contacts do not appear to
impact the conclusion that the pre/epitope is pre/organized. For one molecule in
the asymmetric unit, the crystal contacts are with the C/terminal portion of the
constant domain of the light chain of D80, which is on the opposite end of the
D80 Fab fragment from the antigen binding site on the heavy chain variable
domain of D80. For the second molecule in the asymmetric unit, many of the
crystal contacts are also with the C/terminal portion of the constant domain of the
light chain of D80. There are also additional contacts with the beta/sheet body of
the heavy chain in the variable domain of on D80, but there are no contacts with
the antigen binding site on D80. To more clearly illustrate the crystal contacts in
the structure of D80, a list of the exact crystal contacts can also be delineated
and additional illustrative figures can be created.
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6.10 Understanding binding of D80 to HA
Although the structure of D80 bound to HA has not yet been determined,
there is some binding data available about how D80 binds to HA. In addition, the
crystal structures of many different stem/directed broadly neutralizing antibody
(BnAb) fragments bound to HA have been determined. In particular, a single
chain Fv fragment of the BnAb F10, which is derived from the same germline
gene VH1/69 as D80, has been crystallized in complex with H5 HA, and this
crystal structure shows that F10 binds a highly conserved epitope on the stem
region of HA, as shown in Chapter IV. Binding of both D80 and F10 to HA have
been tested together in several experiments (both antibodies were discovered in
the same laboratory), and these experiments show that D80 and F10 share an
overlapping epitope on the stem region of HA. The binding epitope on HA is in a
pocket on the HA stem formed by the HA2 protomer fusion peptide with residues
from the HA1 protomer on one side and the αA helix of HA2 on the other side. In
one experiment, binding of various stem directed BnAbs was compared using a
competition ELISA (enzyme/linked immunosorbent assay) between phage
BnAbs and soluble BnAbs on plates coated with H5 HA (194). The phage BnAbs
(1012 pfu) were mixed with 5 µg/mL of soluble BnAbs and added to the HA
coated plates, which were then washed, and then followed up by HRP/anti/M13
(horseradish peroxidase conjugated to anti/M13 monoclonal antibody) for
detecting phage/displayed antibodies by ELISA. The results of this experiment,
shown in Figure 6.4, suggest that these BnAbs share an overlapping epitope. In
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another experiment, binding of three stem directed BnAbs, F10, A66, and D8,
which shares the same heavy chain as D80 but a different light chain, was tested
against 14 different HA variants with mutations in the binding epitope (194). All of
these antibodies bound similarly to the variants, and these results, shown in
Figure 6.5D, also suggest that these antibodies share an overlapping epitope.
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Figure 6.4 Competition ELISA assay between phage<bound broadly
neutralizing antibodies and soluble broadly neutralizing antibodies.
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Figure 6.4 Competition ELISA assay between phage<bound broadly
neutralizing antibodies and soluble broadly neutralizing antibodies.
Adapted from Figure S3 of Sui, et al (194).
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Figure 6.5 Analysis of crystal structure of H5 HA and F10 single chain Fv
fragment and HA binding epitope.
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Figure 6.5 Analysis of crystal structure of H5 HA and F10 single chain Fv
fragment and HA binding epitope. Adapted from Figure 4 of Sui, et al (194). A)
Structure of the H5 HA trimer bound to a single chain Fv fragment of F10. HA1,
HA2, the αA of HA2, the fusion peptide, and VH and VL of F10 are shown in
yellow, blue, magenta, red, and gold, respectively. B) The binding epitope of F10
on H5 HA. H5 HA is shown in surface representation. C) Surface of the
conserved stem region on HA where F10 binds. HA1 and HA2 are in yellow and
blue. Residues involved in binding are in red, and residues in the epitope that do
not impact binding are in cyan. D) Binding of three stem/directed broadly
neutralizing antibodies, D8, F10, and A66 to variants of H5 HA with mutations in
the binding epitope.
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To also understand if the crystal structure of D80 bound to G6 may
provide some insight into how D80 binds to HA, the binding epitopes of D80 on
G6 and F10 on HA were compared. Although the epitope on HA is a shallow
binding surface while the epitope on G6 is a deep pocket, one important similarity
between the two epitopes is that there is a tryptophan in both G6 and HA (W31H
in G6 and W21 in the fusion peptide of HA2) that make extensive contacts with
M54 of the antibody. However, there are significant differences in the CDR loop
sequences of D80 compared to F10, and these differences may affect how D80
binds to HA compared to F10. For instance, F10 has two prolines in the heavy
chain CDR2 that may limit the conformation of the CDR2 loop, and the CDR3
loop in F10 is also four residues longer than the CDR3 loop in D80, so
understanding how the binding epitope may accommodate this longer loop and
how the different CDR2 loops may fit in the binding site are important for
understanding exactly how D80 binds to HA and how it compares to D80 binding
to G6. Furthermore, several stem/directed BnAbs are derived from the VH1/69
germline gene, and while the un/mutated germline gene retains binding to G6,
most BnAbs lose binding affinity to G6 as they gain binding affinity to HA, such
as F10. Only three BnAbs are known to retain binding to both G6 and HA: D80,
CR6331, and 70/1F02 (Figure 5.3). Although all of this information provides
some initial insight into how D80 may bind to HA, further experiments are needed
to clearly understand how D80 binds to HA, how it compares to other known
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crystal structures of VH1/69 BnAbs bound to HA, and how this information
relates to D80 binding to G6.
6.11 Using broadly neutralizing antibodies in influenza therapy
Research involving influenza BnAbs has mostly focused on various
strategies for incorporating BnAbs into influenza therapy and inducing BnAbs
through vaccines (12, 292). Priming with a DNA vaccine and boosting using a
seasonal vaccine has successfully induced stem/directed BnAbs in ferrets and
mice (12, 260). One challenge with eliciting stem/directed BnAbs through
vaccines is that the stem region of HA is immunosubdominant, so these
antibodies are not as easily induced as antibodies against the head region of HA.
Some potential reasons why the head region is immunodominant is that the HA
stem is not as accessible as the HA head region on the surface of the influenza
virus, pre/existing immunological memory can bias the antibody response
towards more head region antibodies, and HA stem reactive B cells are rare and
can be polyreactive, limiting their development (293). However, further study is
needed to definitively confirm these hypotheses in humans. HA immunogens that
are “headless” have been designed to promote an antibody response to the
stem. Recently, a vaccine using this strategy was developed that induces BnAbs
against influenza A group 1 viruses, is protective in mice, and reduces fever in
nonhuman primates (290). To overcome the influence of the immunodominant
head region, HA immunogens have been designed with glycan shielding on the
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head region (294). HA is glycosylated by host enzymes, and these glycans do
not produce an immune response because they are recognized as “self”
structures. Glycan shielding can be used to reduce an immune response and has
been shown to reduce the immune response to the HIV envelope protein (295).
Structure/based rational immunogen design can also be used to focus an
antibody response. Antibodyomics is an emerging field of study where
sequencing transcripts from B cells are analyzed to understand how antibodies
mature in response to immunogens (296). Many BnAbs such as D80, F10, and
CR9114 are derived from the VH1/69 germline gene, and each of these
antibodies developed with a typical level of affinity maturation, so understanding
how these antibodies evolved would inform immunogen design. In addition, it
may be possible to focus an antibody response by using an immunogen that can
bind specifically to the germline gene, such as humanized G6 (12, 239). Although
we solved the structure of humanized G6 bound to the BnAb D80, the structure
of D80 bound to HA is still unknown. Understanding how D80 and other
antibodies are able to bind both G6 and HA would be important for understanding
the mechanism of how G6 may be an effective immunogen. Some laboratories
are currently using an iterative approach for immunogen design that includes
structure based drug design and computational techniques for vaccine design in
HIV/1 and other viruses, and this type of approach may also be useful in the
design of immunogens that produce a broad response to influenza infection.
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6.12 Concluding remarks
In conclusion, we used the substrate envelope hypothesis to provide
insight into different patterns of drug resistance in influenza NA and HCV NS3/4A
protease, and we used structural analyses to understand mechanisms of
potential antibody neutralization escape mutations in influenza against the BnAb
F10. In addition, we solved crystal structures of the Fab fragment of BnAb D80
alone and in complex with the Fab fragment of the anti/idiotypic antibody G6,
which binds antibodies from the VH1/69 germline gene. I hope that this work will
provide helpful guidelines for the design of future antiviral therapies that are more
effective and less susceptible to resistance and antibody neutralization escape
mutations.
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APPENDIX CHAPTER I
7 APPENDIX CHAPTER I
7.1 Molecular Dynamics Protocol
7.1.1 Protein Preparation Wizard Protocol
This utility processes the structures by assigning bond orders, adding
hydrogens, creating zero/order bonds to metals, creating disulfide bonds, and
filling in missing side chains using Prime. Next, tautomerization states were
optimized using Epik, and hydrogen bond networks and protonation states were
determined and optimized using PROPKA pH 7.0, with the options of using
exhaustive sampling of water orientations and minimizing hydrogens of altered
species. Finally, hydrogens were minimized using the Impact Refinement Module
and the OPLS2005 force field.
7.1.2 Molecular Dynamics Minimization Protocol
For the initial minimization step, solute heavy atoms were restrained using
a 1000 kcal mol 1 Å 2 force constant and a hybrid method of steepest descent for
up to 10 steps and of the limited/memory Broyden/Fletcher/Goldfarb/Shanno
(LBFGS) algorithm for up to 2000 steps, with a convergence threshold of 50 kcal
mol 1 Å 2. Next, the system was minimized in 7 stages with a harmonic restraint
on all backbone atoms that was gradually reduced from 1000 to 1 kcal mol 1 Å 2
with 5000 steps for each stage using the hybrid steepest descent LBFGS method
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(250 steps steepest descent and 4750 steps LBFGS). Lastly, a minimization
without any restraints was performed, for a total of over ~40,000 minimization
steps.
7.1.3 Molecular Dynamics Protocol
For the first short MD stage, a 10 ps MD simulation was performed in an
NVT ensemble using a Berendsen thermostat at 10 K with a force constant of 50
kcal mol 1 Å 2 on heavy atoms and velocity resampling every 1 ps. MD steps
were integrated using 1 fs timesteps for bonded and non/bonded near
interactions (van der Waals, short/range electrostatic interactions) within a 9 Å
cutoff and 3 fs timesteps for long/range interactions (electrostatic interactions). A
fast temperature relaxation constant of 0.1 was used. For the second and third
short equilibration MD stages, a 10 ps MD simulation was performed in an NPT
ensemble using a Berendsen thermostat and barostat at 10 K and 300 K,
respectively. A pressure of 1 atm was used, the harmonic restraint was retained,
and the velocity was resampled every 1 ps. A fast temperature relaxation
constant of 0.1 and a slow pressure relaxation constant of 50.0 were used. MD
steps were integrated using 2 fs timesteps for bonded and non/bonded
interactions within a 9 Å cutoff and 6 fs timesteps for long/range interactions. For
the final short equilibration stage, a 10 ps MD simulation was performed in an
NPT ensemble using a Berendsen thermostat and barostat at 300 K with a
pressure of 1 atm. A fast temperature relaxation constant of 0.1 and a normal
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pressure relaxation constant of 2.0 were used. The harmonic restraint was
decreased to 10 kcal mol 1 Å 2 on heavy atoms.
For the production stage, MD simulations were performed for 100 ns and
1 atm in the NPT ensemble using a Nose/Hoover thermostat and a Martyna/
Tuckerman/Klein (MTK) barostat. Long/range electrostatics were calculated
using the Particle Mesh Ewald method with a cutoff radius of 9 Å. The M/SHAKE
algorithm was used to implement constraints that eliminate the highest frequency
vibrational motions so that longer timesteps can be used (2 fs instead of 1 fs).
Timesteps are scheduled using a parameter called RESPA (reference system
propagator algorithm). MD steps were integrated using 2 fs timesteps for bonded
and non/bonded near interactions (van der Waals, short/range electrostatic
interactions) within a 9 Å cutoff and 6 fs timesteps for long/range interactions
(electrostatic interactions). For each system, the trajectories of each monomer
were concatenated to provide 400 ns of sampling.
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8.1 Determination of D80 Fab Fragment Resolution Cutoff
We worked on solving the crystal structure of the D80 Fab fragment for
approximately a year and a half. As a result of some difficulty optimizing
cryoprotectant conditions for the D80 crystals, even though we had sent more
than a dozen crystals to the synchrotron on two separate occasions, we were
only able to collect one decent quality diffraction dataset for these crystals. The
square edge of the data collected was to 2.7 Å, but the corners of the frames
contained data out to 2.52 Å. Overall, I chose to deposit the structure of D80 that
was processed and refined using data to 2.59 Å instead of 2.7 Å. 
Although x/ray crystallography methodology has improved over time,
specific criteria for the selection of resolution cutoff for a crystallographic data set
is still debated and the relationship between data quality and model quality is not
well understood. Traditionally, Rmerge values, completeness, multiplicity, and
signal to noise ratios are used to determine data quality and resolution cutoff.
Rmerge values indicate how well multiple measurements of a reflection throughout
a dataset agree. The traditional criteria were that the data should have an overall
Rmerge value of less than 0.1, high resolution Rmerge values less than 0.8 and a
high resolution signal to noise ratio (I/σ) around 2. However, these types of
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cutoffs can be too conservative and useful data can be discarded, as has been
shown previously (297).
Karplus, et al instead recommend the use of Pearson’s correlation
coefficient (CC) to more accurately assess data quality and model agreement on
the same scale and to decrease the omission of useful data that can be used to
create better models (297). CC1/2 is the correlation coefficient between two
random halves of the unmerged data. Another measurement, CC*, estimates the
correlation of the averaged dataset with the estimated true signal without noise
by assuming that errors in the two half datasets are random and of similar size.
In addition, the values CCwork and CCfree are the correlations of the experimental
intensities with the intensities calculated from the refined model. A CCwork greater
than CC* indicates overfitting and a CCfree less than CC* (observed at low
resolution) implies that overfitting has not occurred and the model does not
account for all of the signal from the data. At high resolution, a CCfree close to
CC* indicates that the model is limited by data quality.
Using these criteria and by examining refinements of the data with
different resolution limits, following the method described by Karplus, et al, I
evaluated three different models of the D80 Fab fragment (297). I processed and
refined the data at 2.7, 2.59, and 2.52 Å resolution, and I calculated
crystallographic statistics, including overall Rwork and Rfree values at lower
resolution limits than what was used during refinement. To perform these
calculations, I used the commands in Phenix described on page 5 of the
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supplemental material of Karplus, et al (297). Table 8.1 shows the overall
Rwork/Rfree for the D80 Fab fragment dataset, analogous to Table S2 from
Karplus, et al (297). Table 8.2 shows a similar representation for CC1/2, CC*,
CCwork, and CCfree.
Overall, I chose to deposit the structure of D80 that was processed and
refined using data to 2.59 Å instead of 2.7 Å that I originally proposed in the
thesis. Tables 8.3, 8.4, and 8.5 show the results of the paired refinement. For the
refinement at 2.7 Å, an unmerged data file was not created at the time of data
processing, and I did not re/process the data to get the unmerged data file at 2.7
Å, so some crystallographic statistics are missing from Table 8.2. Using the data
to 2.59 Å improved the model, but the data out to 2.52 Å did not seem to improve
the model.
226
Table 8.1 Overall Rwork/Rfree for D80 Refinement
High/resolution limit for refinement (Å)
High/resolution limit
for R value calculation
(Å)
2.7 Å 2.59 Å 2.52 Å
2.7 Å 0.2194 /
0.2632
0.2163 /
0.2592
0.2342 /
0.2612
2.59 Å / 0.2212 /
0.2629
0.2403 /
0.2680
2.52 Å / / 0.2447 /
0.2730
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Table 8.2 CC*, CC1/2, CCwork, and CCfree for D80 Refinement
High/resolution limit for refinement (Å)
High/resolution limit
for R value calculation
(Å)
2.7 Å 2.59 Å 2.52 Å
2.7 Å /
0.996 (0.868)
0.999 (0.964)
0.919 (0.782)
0.950 (0.812)
0.993 (0.74)
0.998 (0.922)
0.916 (0.687)
0.877 (0.657)
2.59 Å / 0.996 (0.746)
0.999 (0.925)
0.921 (0.661)
0.950 (0.584)
0.993 (0.543)
0.998 (0.839)
0.918 (0.604)
0.877 (0.538)
2.52 Å / / 0.992 (0.429)
0.998 (0.775)
0.919 (0.516)
0.877 (0.344)
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Table 8.3 High resolution limit for refinement set at 2.7 Å
Original Structure Presented in Thesis` No Unmerged Data File`
Data Indexed and Scaled Using HKL3000 and Structure Refined Using Phenix
Structure D80 Fab Fragment
Resolution Range 46.12 – 2.70 (2.80/2.70)
Space Group P 21 21 21
Unit Cell 89.06 91.58 106.76 90 90 90
Total Reflections 116269
Unique Reflections 23313 (2316)
Multiplicity 5.0 (4.9)
Completeness (%) 0.95 (0.92)
Mean I/Sigma (I) 17.7 (3.8)
Wilson B/Factor 47.05
R/merge 0.083
Reflections Used in Refinement 23312 (2316)
Reflections Used for R/Free 1126 (113)
R/work 0.2194 (0.2819)
R/free 0.2632 (0.3689)
Number of Non/Hydrogen Atoms 6395
Macromolecules 6330
Ligands N/A
Protein Residues 851
RMS(Bonds) 0.016
RMS(Angles) 1.43
Ramachandran Favored (%) 97
Ramachandran Allowed (%) 2.5
Ramachandran Outliers (%) 0.24
Rotamer Outliers (%) 3.6
Clash score 6.72
Average B/Factor 48.50
Macromolecules 48.64
Ligands N/A
Solvent 35.40
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Table 8.4 High resolution limit for refinement set at 2.59 Å
Data indexed and scaled using HKL3000 and structure refined using Phenix
Limit for R Value Calculation
(Å)
2.59 2.7
PDB Code 5JQD N/A
Resolution Range 46.12 – 2.59 (2.68 – 2.59) 46.12 – 2.7 (2.797 – 2.7)
Space Group P 21 21 21 P 21 21 21
Unit Cell 89.06 91.58 106.76 90 90 90 89.06 91.58 106.76 90 90 90
Total Reflections 132762 (9946) 120917 (12012)
Unique Reflections 26405 (2602) 23382 (2343)
Multiplicity 5.0 (3.8) 5.2 (5.1)
Completeness (%) 0.95 (0.95) 0.95 (0.97)
Mean I/Sigma (I) 11.16 (2.42) 12.27 (3.62)
Wilson B/Factor 46.81 47.06
R/merge 0.09 (0.52) 0.09 (0.42)
R/meas 0.10 (0.61) 0.10 (0.46)
CC1/2 0.996 (0.746) 0.996 (0.868)
CC* 0.999 (0.925) 0.999 (0.964)
Reflections Used in
Refinement
26404 (2602) 23381 (2343)
Reflections Used for R/Free 1273 (127) 1129 (114)
R/work 0.2152 (0.2891) 0.2163 (0.2863)
R/free 0.2438 (0.2981) 0.2592 (0.3465)
CC(work) 0.93 (0.75) 0.919 (0.782)
CC(free) 0.96 (0.69) 0.950 (0.812)
Number of Non/Hydrogen
Atoms
6431 6403
Macromolecules 6338 6338
Ligands 0 0
Protein Residues 851 851
RMS(Bonds) 0.005 0.003
RMS(Angles) 0.76 0.74
Ramachandran Favored (%) 97 97
Ramachandran Allowed (%) 3.2 3.4
Ramachandran Outliers (%) 0.24 0.12
Rotamer Outliers (%) 3.5 2.5
Clash score 7.11 2.51
Average B/Factor 48.57 50.28
Macromolecules 48.70 50.38
Ligands N/A N/A
Solvent 40.05 40.76
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Table 8.5 High resolution limit for refinement set at 2.52 Å
Data indexed and scaled using XIA2 and structure refined using Phenix
Limit for R Value
Calculation (Å)
2.52 2.59 2.7
Resolution Range 69.53 – 2.52
(2.61 – 2.52)
69.53 – 2.59
(2.683 – 2.59)
69.53 – 2.7
(2.797 – 2.7)
Space Group P 21 21 21 P 21 21 21 P 21 21 21
Unit Cell 89.11 91.59 106.81
90 90 90
89.11 91.59 106.81
90 90 90
89.11 91.59
106.81 90 90 90
Total Reflections 137016 (8633) 130503 (9576) 118980 (11567)
Unique Reflections 28583 (2727) 26470 (2610) 23399 (2330)
Multiplicity 4.8 (3.2) 4.9 (3.7) 5.1 (5.0)
Completeness (%) 0.94 (0.91) 0.94 (0.95) 0.95 (0.97)
Mean I/Sigma (I) 10.14 (2.45) 10.76 (3.04) 11.76 (4.33)
Wilson B/Factor 29.64 31.09 33.13
R/merge 0.1314 (0.6204) 0.127 (0.553) 0.1186 (0.464)
R/meas 0.1473 (0.7332) 0.142 (0.6418) 0.1322 (0.5189)
CC1/2 0.992 (0.429) 0.993 (0.543) 0.993 (0.74)
CC* 0.998 (0.775) 0.998 (0.839) 0.998 (0.922)
Reflections Used in
Refinement
28332 (2622) 26300 (2547) 23302 (2299)
Reflections Used for R/
Free
1981 (189) 1838 (179) 1629 (166)
R/work 0.2447 (0.3523) 0.2403 (0.3360) 0.2342 (0.3032)
R/free 0..2730 (0.3914) 0.2680 (0.3695) 0.2612 (0.3268)
CC(work) 0.919 (0.516) 0.918 (0.604) 0.916 (0.687)
CC(free) 0.877 (0.344) 0.877 (0.538) 0.877 (0.657)
Number of Non/Hydrogen
Atoms
6525 6525 6525
Macromolecules 6285 6285 6285
Ligands N/A N/A N/A
Protein Residues 849 849 849
RMS(Bonds) 0.002 0.004 0.002
RMS(Angles) 0.66 0.98 0.66
Ramachandran Favored
(%)
94 94 94
Ramachandran Allowed
(%)
5.2 5.2 5.2
Ramachandran Outliers
(%)
0.72 0.72 0.72
Rotamer Outliers (%) 1.5 1.5 1.5
Clash score 7.02 7.02 7.02
Average B/Factor 38.71 38.71 38.71
Macromolecules 39.02 39.02 39.02
Ligands N/A N/A N/A
Solvent 30.65 30.65 30.65
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9.1 Hepatitis C NS3/4A Protease Inhibitor Ki Determination Assay: Data
and Modeling
Using an assay described elsewhere for determining the inhibitor constant
(Ki) for HCV NS3/4A protease, I determined the Ki values of 7 novel HCV
protease inhibitors synthesized in the Schiffer laboratory with wild/type HCV
NS3/4A protease genotype 1a (175). These inhibitors included AH/58, AH/79,
AH/82, EK/31, JA/30, JA/43, and JA/44. Djade Soumana expressed and purified
the protein, and I performed the assay and analyzed the data. The results of this
work is shown in Figure 9.1. In addition, I used the Schrodinger Software Suite to
model additional 6 novel inhibitors synthesized in the Schiffer laboratory bound to
HCV NS3/4A protease, and I performed 10 nanosecond molecular dynamics
simulations of these models using Desmond. These inhibitors included AH/54,
AH/58, JA/43, AH/82, AH/87, and an isopropyl analog of AH/87. The results of
this work is shown in Figure 9.2. The chemical structures of these inhibitors is
shown in Figure 9.3.
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Figure 9.1 Ki values of seven novel HCV NS3/4A protease inhibitors with
wild<type genotype 1a HCV NS3/4A protease.
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Figure 9.1 Ki values of seven novel HCV NS3/4A protease inhibitors with
wild<type genotype 1a HCV NS3/4A protease.
23
Figure 9.2 Molecular dynamics simulation results for models of HCV NS3/4A protease bound to novel
inhibitors.
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Figure 9.2 Molecular dynamics simulation results for models of HCV
NS3/4A protease bound to novel inhibitors. Each column of results
corresponds to the analysis from each model of HCV NS3/4A protease bound to
a different inhibitor. From left to right, the inhibitors that were analyzed were AHF
54 with a protonated amide nitrogen adjacent to the P1’ sulfonamide (AHF54
State 1), AHF54 with a deprotonated amide nitrogen adjacent to the P1’
sulfonamide (AHF54 State 2), AHF58, JAF43, AHF82, AHF87, and an isopropyl
analog of AHF87. The top row shows the alpha carbon RMSD over the course of
the minimization, equilibration, and molecular dynamics simulation of each
model. The second row from the top shows the average ligand RMSF over the
course of the molecular dynamics simulation. The third row from the top shows
the ligand RMSD over the course of the minimization, equilibration, and
molecular dynamics simulation of each model. The fourth row from the top shows
the average alpha carbon RMSF over the course of the molecular dynamics
simulation, and the bottom row shows snapshots of the model over the course of
the molecular dynamics simulation.
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Figure 9.3 Chemical structures of novel HCV NS3/4A protease inhibitors.
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Figure 9.3 Chemical structures of novel HCV NS3/4A protease inhibitors.
Aspects of the inhibitors in the P2’ and P4 regions that are variable are shown in
red and blue, respectively.
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10.1 Influenza Neuraminidase Baculovirus Insect Cell Expression and
Purification
Using an insect cell expression system with baculovirus expression
technology, I successfully expressed and purified N1 NA. The NA construct was
prepared based on published methods (106, 107, 298, 299). cDNA
corresponding to the NA ectodomain, residues 82 to 467, was cloned into
baculovirus transfer vector pFastBac1 (BacOtoOBacTM kit from Invitrogen) with a
GP67 signal peptide, a 6XOhistidine tag, a tetramerization domain, and a
thrombin cleavage site at the NOterminal end of NA. Suspension cultures of insect
cell Sf9 and Hi5 cells were cultured in SfO900 II SFM serum free media (GIBCO)
and HyQ SFXOInsect media (HyClone), respectively. Transfection was performed
using Sf9 cells, and expression was performed using Hi5 cells. Recombinant
baculovirus was prepared according to the manufacturer’s protocol (Invitrogen).
Protein was expressed in Hi5 suspension cultures for 3 days at 28°C and 120
rpm with a MOI of 5, and preparation was performed on a 1 L scale. Hi5 cells
were removed by centrifugation, and soluble NA was recovered from cell
supernatant by Ni2+ affinity chromatography. The eluted protein was analyzed
using SDSOPAGE (Figure 10.1) and a Western blot using an antiOHis tag antibody
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(Figure 10.2). The activity of this protein was also assessed using a cleavage
assay described in Appendix V.
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Figure 10.1 Expression and purification of N1 NA using a nickelONTA
column analyzed using SDSOPAGE.
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Figure 10.1 Expression and purification of N1 NA using a nickelONTA
column analyzed using SDSOPAGE. The abbreviations represent low molecular
weight ladder (L1), Kaleidoscope ladder (L2), control NA from the Biodefense
and Emerging Infections Research Resources Repository (C1), control HCV
NS3/4A protease (C2), virus supernatant (SU), flow through (FT), wash (W),
elution followed by TCA precipitation (E1), and elution follow by dialysis and
concentration (C2).
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Figure 10.2 Expression and purification of N1 NA using a nickelONTA
column analyzed by Western blot using an antiOHisOtag antibody.
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Figure 10.2 Expression and purification of N1 NA using a nickelONTA
column analyzed by Western blot using an antiOHisOtag antibody. The
abbreviations represent low molecular weight ladder (L1), Kaleidoscope ladder
(L2), control NA from the Biodefense and Emerging Infections Research
Resources Repository (C1), control HCV NS3/4A protease (C2), virus
supernatant (SU), flow through (FT), wash (W), elution followed by TCA
precipitation (E1), and elution follow by dialysis and concentration (C2).
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11.1 Influenza Neuraminidase 1D NMR Cleavage Assay
With assistance from Akbar Ali in the Schiffer lab, I implemented a
previously published oneOdimensional (1D) proton NMR assay performed over
time to detect the formation of free sialic acid during a neuraminidase cleavage
reaction (300, 301). Proton NMR can be used to monitor sialic acid release from
glycans since the protons on free sialic acid have different chemical shifts
compared to the protons on sialic acid bound to glycans. Figure 11.1 shows a
previously published example of this experiment using sialyllactose, a
trisaccharide (301).
To understand the results that would be expected from this experiment,
the changes in the proton NMR signal must be described. First, the signal from
the full substrate can be measured at time zero before cleavage occurs. The
signals from the protons on the sialic acid of the substrate are between 2.7 and
2.8 ppm, and that signal corresponds to the signal from the equatorial hydrogen
on C3 of sialic acid. There is also a strong peak around 2 ppm that corresponds
to the signal from the methyl hydrogens on the NOacetyl group of sialic acid.
Finally, there is a signal around 1.7 ppm that corresponds to the signal from the
axial hydrogen on C3 of sialic acid.
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Then, neuraminidase can be added to the substrate solution, and how
these proton signals evolve over time can be observed. Over the course of the
experiment, the signal from the NOacetyl group shifts and the signal splits. In
addition, signals from the equatorial and axial C3 hydrogens of free sialic acid
emerge at 2.2 ppm and 1.8 ppm, respectively, and become stronger over time.
I was able to replicate this experiment with commercial bacterial
neuraminidase from Clostridium perfringens produced by New England Biolabs.
Two 1D proton NMR scans are shown in Figure 11.2A, one at time zero with
substrate only and one at 36 hours after neuraminidase was added to the
substrate solution and the substrate was allowed to incubate and be cleaved by
neuraminidase for 36 hours. This assay was performed with a pentasaccharide
LSTOc substrate. With this compound, the NOacetyl peak is split initially, and it
splits more over the course of the reaction. In addition, the peaks from the free
sialic acid hydrogens at 2.2 ppm and 1.8 ppm emerge and are very clear signals.
Figure 11.2B shows a second analogous experiment where two scans
were taken at time zero and time 90 minutes, and a full glycoprotein was used as
the substrate, αO1 acid glycoprotein. The signal is not as prominent as with the
pentasaccharide or the trisaccharide, but over time the signal from the free sialic
acid emerges.
Finally, this experiment was performed with neuraminidase that was
expressed and purified in the laboratory and was described in Appendix IV, and
the results of this experiment are shown in Figure 11.3B and compared to the
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results from Figure 11.2B (Figures 11.2B and 11.3A are equivalent). The
cleavage results using the inOhouse neuraminidase are not as clear as the results
from the experiments with the commercial bacterial neuraminidase, but the signal
from the NOacetyl peak appears to split, and this data suggests that the protein
shown in Appendix IV is folded and active.
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Figure 11.1 A previously published example of using proton NMR to detect
neuraminidase substrate cleavage using sialyllactose, a trisaccharide
(301).
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Figure 11.1 A previously published example of using proton NMR to detect
neuraminidase substrate cleavage using sialyllactose, a trisaccharide (300,
301)
24
Figure 11.2 1D proton NMR neuraminidase cleavage assay performed with commercially available
neuraminidase (NA) from New England Biolabs.
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Figure 11.2 1D proton NMR neuraminidase cleavage assay performed with
commercially available neuraminidase (NA) from New England Biolabs. A)
This experiment was performed with the pentasaccharide substrate LST<c. B)
This experiment was performed with the glycoprotein substrate α<1 acid
glycoprotein.
25
Figure 11.3 1D proton NMR neuraminidase cleavage assay performed with the substrate α?1 acid
glycoprotein and two different neuraminidases (NA).
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Figure 11.3 1D proton NMR neuraminidase cleavage assay performed with
the substrate α?1 acid glycoprotein and two different neuraminidases (NA).
A) This experiment was performed with commercially available neuraminidase
from New England Biolabs. B) This experiment was performed with influenza
neuraminidase produced in house and described in Appendix IV.
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